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Abstract 
This thesis is concerned with the design of organometallic half sandwich complexes which 
can catalyse the conversion of oxidised coenzyme nicotinamide adenine dinucleotide to its 
reduced form. The coenzyme pair NAD+/NADH is involved in many biological processes, 
such as regulation of the redox balance, and DNA repair. Disturbance of the NAD+/NADH 
ratio can lead to cell death. In particular, cancer cells are under constant oxidative stress and 
therefore might be more susceptible to changes in the NAD+/NADH levels. 
A series of neutral Ru(II) complexes of the type [(η6-arene)Ru(N,N’)(L)] (arene =  
p-cymene (p-cym), hexamethylbenzene (hmb), biphenyl (bip), benzene (bn); N,N’ =  
N-(2-aminoethyl)-4-(trifluoromethyl)benzenesulfonamide (TfEn), N-(2-aminoethyl)-
toluensulfonamide (TsEn), or N-(2-aminoethyl)-4-methylensulfonamide (MsEn)) were 
synthesized and fully characterized. The complexes were shown by 1H-NMR to catalyse 
region-selectively the transfer hydrogenation of NAD+ to 1,4-NADH. Comparison of the 
turnover frequencies (TOF) for the complexes show a trend in which a decrease in catalytic 
activity with the arene ligand follows the order bn > bip > p-cym > hmb and TfEn > TsEn > 
MsEn. Complex [(η6-bn)Ru(TfEn)Cl] (12) was found to be the most active with a TOF of 
10.4 h-1. The catalytic cycle for the transfer hydrogenation reaction was studied for complex 
[(p-cym)Ru(TsEn)Cl] (2).  
The monotosylate ethylenediamine Ru(II) complexes were used to carry out, for the first 
time, transfer hydrogenation reactions in cellulo (A2780 ovarian cancer cells) using formate 
as a hydride source. The antiproliferative activity of six complexes on co-administration with 
non-toxic doses of sodium formate were studied. A significant potentiation of the 
antiproliferative activity by formate was observed. The concentrations of NAD+ and NADH 
in cells showed an important reduction in the NAD+/NADH ratio. This study demonstrates 
that it may be possible to use catalytic transfer hydrogenation as a strategy for multi-targeted 
redox mechanisms of action for anticancer drugs. 
 vi 
 
In order to compare the anticancer mechanism of the monotosylate ethylenediamine Ru(II) 
complexes with the corresponding ethylenediamine (en) complexes, DNA binding studies 
were carried out. The complexes were shown to bind to nucleobases only moderately strongly 
and no direct coordination to calf thymus DNA was observed. The complexes can destabilize 
DNA, but they display low affinity towards DNA, which suggests that DNA is probably not 
involved in the mechanism of these family of compounds. 
Interaction of complex [(p-cym)Ru(TsEn)] (2) with glutathione (GSH) was also studied. 
The complex undergoes ligand substitution. Two Ru(II) dimers were formed as the main 
products of the reaction: ([((p-cym)Ru)2(µ-GS)3] and [((p-cym)Ru)2(µ-GS)2]). These dimers 
share structural similitudes with other reported Ru(II) arene anticancer drugs, which suggests 
that they could be  responsible for the moderate antiproliferactive activity of complex 2. 
A series of CpxRh(III) (CpX = CpXPhPh, CpXPh or Cp*) complexes containing en or TfEn 
were synthesised and fully characterised. The complexes were shown to catalyse 
regioselectively the transfer hydrogenation of NAD+ to 1,4-NADH with higher TOF than 
their Ru(II) analogues. Rh(III)-en compounds were shown to be more active than the Rh(III)-
TfEn analogues. The nature of the Cpx ring was shown to influence significantly the catalytic 
activity of the complexes following the trend: CpXPhPh > CpXPh > Cp*. Complex 
[(CpXPhPh)Rh(en)Cl]+ (19) was the most active, with a TOF of 24.2 h-1. The catalytic cycle 
for the transfer hydrogenation reaction was studied using complex [(Cp*)Rh(en)Cl]+ (17) and 
compared to that of the Ru(II) analogues, and was found to be similar. Antiproliferative 
activity of the complexes in combination with formate, in A2780 cells, was investigated, but 
the potentiation due to the transfer hydrogenation was much lower than that obtained with 
Ru(II) compounds. 
 
 vii 
 
Abbreviations 
9-EtG 9-Ethylguanine 
9-MetA 9-Methyladenine 
Å Angstrom 
bip Biphenyl 
bipy Bipyridine 
bn Benzene 
ͦ C Degree celsius 
ca. Circa 
CD Circular dichroism 
Cp Cyclopentadienyl 
Cp* Pentamethylcyclopentadienyl 
CpxPh 3-Phenyl-1,2,4,5-tetramethyl-1,3-cyclopentandienyl 
CpxPhPh 3-Biphenyl-1,2,4,5-tetramethyl-1,3-cyclopentandienyl 
CT Calf Timus 
d Doublet 
dd Doublet of doublets 
ddw doublly distilled water 
 viii 
 
DFT Density functional theory 
DMSO Dimethyl sulfoxide  
DNA Deoxyribonucleic acid  
EDTA Ethylenediaminetetraacetic acid 
en Ethylenediamine 
ESI-MS Electrospray ionisation mass spectrometry 
FDA Food and drug administration (U.S.) 
GSH Glutathione 
GSSG Glutathione disulfide 
h Hour  
hmb Hexamethylbenzene 
HPLC High performance liquid chromatography 
HR-MS High resolution mass spectrometry 
IC50 50 % inhibitory concentration 
ICP-MS Inductively coupled plasma mass spectrometry 
ie. In essence 
J Coupling constant 
k Kinetic constant 
 ix 
 
K Kelvin 
Ka Association constant 
Kcat Catalyst constant 
KIE Kinetic isotope effect 
KM Michaelis-Menten constant 
L-BSO L-Buthionine sulfoximine 
LC-MS Liquid chromatography-mass spectrometry 
LD Linear dicroism 
m Multiplet 
min Minutes 
MsEn N-(2-Aminoethyl)methylensulfonamide 
m/z Mass-to-charge ratio 
NAC N-acetyl-L-cysteine 
NAD+ Nicotinamide adenine dinucleotide 
NADH Nicotinamide adenine dinucleotide reduced  
NbEn N-(2-Aminoethyl)-4-nitrobenzenesulfonamide 
o-terp ortho-terphenyl 
PBS Phosphate buffer saline 
 x 
 
p-cym para-cymene 
PDT Photodynamic therapy 
Ph Phenyl 
phen Phenanthroline 
ppm Parts per million 
q Quadruplet 
redox Reduction-oxidation 
RNS Reactive nitrogen species 
ROS Reactive oxygen species 
s Second 
s Singlet 
sept Septuplet 
SOD Superoxide dismutase  
SRB Sulforhodamine B 
t Time 
 t triplet 
T Temperature 
TFA Trifluoroacetic acid 
 xi 
 
TfEn N-(2-Aminoethyl)-4-(trifluoromethyl)benzenesulfonamide 
TH Transfer hydrogenation 
Tm Melting temperature 
TON Turnover number 
TOF Turnover frequency 
TOFmax Maximum turnover frequency 
TsEn N-(2-Aminoethyl)-4-toluensulfonamide 
TsDPEN (1S,2S)-N-(p-toluensulfonyl)-1,2-diphenylethylenediamine 
TsCYDN (1S,2S)-N-(p-toluensulfonyl)-1,2-diaminocyclohexane  
V velocity  
v/v volume for volume 
δ Chemical shift 
λ Wavelength 
  
 xii 
 
Complexes 
[(bip)Ru(en)Cl]+ (RM175) 
[(p-cym)Ru(MsEn)Cl] (1) 
[(p-cym)Ru(TsEn)Cl] (2) 
[(p-cym)Ru(TfEn)Cl] (3) 
[(hmb)Ru(MsEn)Cl] (4) 
[(hmb)Ru(TsEn)Cl] (5) 
[(hmb)Ru(TfEn)Cl] (6)  
[(bip)Ru(MsEn)Cl] (7) 
[(bip)Ru(TsEn)Cl] (8) 
[(bip)Ru(TfEn)Cl] (9) 
[(bn)Ru(MsEn)Cl] (10) 
[(bn)Ru(TsEn)Cl] (11) 
[(bn)Ru(TfEn)Cl] (12) 
[(o-terp)Ru(MsEn)Cl] (13) 
[(o-terp)Ru(TsEn)Cl] (14) 
[(o-terp)Ru(TfEn)Cl] (15) 
[(p-cym)Ru(NbEn)Cl] (16) 
 xiii 
 
[(Cp*)Rh(en)Cl]+ (17) 
[(CpXPh)Rh(en)Cl]+ (18) 
[(CpXPhPh)Rh(en)Cl]+ (19) 
[(Cp*)Rh(TfEn)Cl] (20) 
 
Chapter 1 
1 
 
 
Chapter 1 
 
 
Introduction 
 
Chapter 1 
2 
 
1. Introduction 
This thesis is concerned with the design of catalytic drugs which can reduce 
nicotinamide adenine dinucleotide by transfer hydrogenation using Noyori-type catalysts. In 
this chapter, a brief introduction will be given to metals in medicine, followed by catalytic 
metallodrugs and transfer hydrogenation reactions, catalysis and mechanism, focusing on 
water-soluble Noyori-type complexes. Finally, the introduction will focus on NAD+ and its 
functions, as well as the different chemical
 
strategies to reduce NAD+. 
 
1.1. Metals in medicine 
It is generally accepted that many metals are toxic to humans. However, it is wise to 
remember the words of Paracelsus,”Alle Ding' sind Gift, und nichts ohn' Gift; allein die 
Dosis macht, daß ein Ding kein Gift ist“ (All things are poison, and nothing is without 
poison; only the dose permits something not to be poisonous). For example, sugar, salt or 
water are essential nutrients, but when taken in excess either of them can result in disease as 
hyperactivity, hypertension or intoxication.1 Consequently, and despite the fact that metals 
can be extremely toxic at high concentrations, some are essential for life. Currently 24 
elements are thought to be essential for life, 14 of them being metals (Na, Mg, K, Ca, V, Mn, 
Fe, Co, Ni, Cu, Zn, Se, Mo and Sn). 2 
For many years, the use of metals in medicine has been a taboo. Nevertheless, we can 
find countless examples of metals and metal complexes that have been used in medicine since 
ancient times. In the 3000 BC the Egyptians used copper to sterilize water; around 1500 BC 
various iron remedies were used in Egypt and zinc was used to heal wounds; three thousand 
five hundred years ago gold was used in a variety of medicines in Arabia and during the 
renaissance era mercurous chloride was administered as a diuretic in Europe.2 More recently, 
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arsenic based drugs (salvarsan, for syphilis treatment), gold based drugs (K[Au(CN)2] for 
tuberculosis treatment, and Auranofin for arthritis), and more recently, platinum drugs like 
cisplatin (which is now widely used in cancer treatment) were developed and 
commercialized,.2 All ofthese examples provide evidence of the potential of metal-based 
drugs in modern medicine. These examples, also demonstrate the possibility of structurally 
tuning the metallodrugs to modulate their properties. The structure can be altered by changing 
the ligands that surround the metal, or by changing the coordination number/oxidation state 
of the metal. In this way, we can begin to overcome the toxicity, and control the reactivity 
and selectivity of the metal complex towards specific targets or diseases.3 
1.1.1. Platinum-based anti-cancer drugs 
The history of modern metal-based chemotherapy begins in 1965 with the discovery of 
the antiproliferative and cytotoxic activity of cisplatin by B. Rosenberg.4, 5 The medical 
success of cisplatin opened the doors to a large research area focused on understanding the its 
mechanism of action. It is currently accepted that cisplatin cytotoxicity is mainly, due to 
interactions with DNA.6-8 
Even though cisplatin has been a clinical success, the drug has severe drawbacks. 
• Severe side effects are due to high toxicity. The most common side-effects 
include nephrotoxicity (kidney damage), neurotoxicity (nerve damage), nausea 
and vomiting, ototoxicity (hearing loss), electrolyte disturbance, myelotoxicity 
(bone marrow suppression)and haemolytic anaemia.9, 10 
• Development of cisplatin-resistant by some cancer cell lines.11 
• Only a limited range of tumours is sensitive to cisplatin intervention. 
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Figure 1.1. Structures of platinum anticancer drugs: cisplatin, carboplatin, oxaliplatin, 
nedaplatin, lobaplatin, heptaplatin, picoplatin and the Pt(IV) drug, satraplatin. 
Many efforts have been focussed on the structure-activity relationships of platinum 
amino complexes in order to overcome toxicity and resistance. More than 3,000 platinum 
complexes have been studied for anticancer applications. However, only few of these have 
reached clinical trials, and currently only six platinum-based drugs have been approved and 
are in use (cisplatin, carboplatin, oxaliplatin, nedaplatin (Japan), heptaplatin (Korea) and 
Lobaplatin (China), (Figure 1.1)).12-14 There are currently five platinum-based drugs in 
various stages of clinical trials, with two being close to approval (satraplatin and 
picoplatin).12-14  
Chapter 1 
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More recently research on the platinum-based anticancer drugs has been focussed on 
the synthesis of platinum(IV) analogues.15, 16 Changing the oxidation state of the platinum 
centre, from +2 to +4, was a strategy developed in order to generate more stable and water-
soluble complexes which could be administered orally. Furthermore, the platinum(VI) drugs 
are inactive, and only become active once they have been reduced to platinum(II). This 
reduction can either occur once the complex has been activated through an external source 
such as light, or by intracellular reduction pathways.17 This could be a useful strategy to 
reduce the toxicity and side effects associated with platinum (II) drugs. 
1.1.2. Ruthenium-based anti-cancer drugs 
Ruthenium complexes have been shown to be amongst the most promising metal-based 
compounds for use in cancer treatment, partly because of the slower ligand exchange rate 
compared to platinum and the wide availability of oxidation states.18 Furthermore, many 
ruthenium compounds have shown low toxicity, which could be due to the capability of 
ruthenium to mimic iron in binding biological molecules. 18 
In his initial reports, Rosenberg observed that disruption of DNA replication was 
achieved not only by cisplatin, but also by [(NH3)4RuCl(OH)]Cl.5 In 1976, the first studies on 
amino-Ru(III) complexes, analogous to the successful cisplatin, were reported.19 Studies with 
complex [fac-[(NH3)3RuCl3] in E. coli suggested that the cellular target of Ru(III) complexes 
was probably DNA. The research was, since then, focussed on the mode of action and the 
interactions of the amine-Ru(III) complexes with DNA. Clarke et al. demonstrated the ability 
of this type of complex to bind to nucleobases and inhibit DNA synthesis, as well as protein 
synthesis to a lesser extend.20, 21 In their work, Clarke et al. also reported that inert Ru(III) is 
reduced in cells by glutathione or other reducing agents to form more reactive Ru(II) species. 
20-24
 The hypothesis was based on the fact that the Ru(II) π-acceptor property is lower than in 
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the case of Ru(III), leading to more labile bonds with π-donating ligands such as chlorides, 
facilitating hydrolysis.20-24 
 
Figure 1.2. Structures of NAMI-A, KP1019, RM175 and RAPTA-C. 
Currently, there are two Ru(III) coordination complexes undergoing clinical trials, 
NAMI-A and KP1019/NKP1339 (Figure 1.2). KP1019/NKP1339 was shown to have good 
activity against a wide variety of cancer cells including some platinum resistant cell lines 
(NCT01415297).25, 26 On the other hand, NAMI-A does not show high anticancer activity, 
but displays high selectivity for solid tumour metastatic cells and low toxicity at 
pharmacologically active doses.27, 28 
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Proceeding the work of Clarke et al, a large number of Ru(II) complexes were 
developed. Initially, they were shown to have stability problems due to fast ligand 
substitution.29 The first stable and active Ru(II) complex reported was [RuII(azpy)2Cl2], (azpy 
= 2-phenylazopyridine) by Reedijk et al.30, 31 Unfortunately, despite the in cellulo activity, the 
complex was not tested in vivo due to low solubility. 29 Later, a series of organometiallic 
compounds containing η6-arene moiety, which occupies three coordination sites, showed very 
promising results.32 Currently, the ruthenium(II) drugs which displayed the most promising 
anticancer activity are the half-sandwich organometallic complexes, in particular RM175. 
Another promising anticancer drug is the Ru(II) half sandwich compound RAPTA-C, which 
is not very active but demonstrated interesting anti-metastatic  properties. (Figure 1.2). 28,32  
1.1.3. Other metal-based anti-cancer drugs 
Compounds of nearly all the metals of the periodic table have been investigated as 
chemotherapeutical anticancer agents, although, few of those have shown promising in vivo 
activities or entered clinical trials. Some of the most promising metals are arsenic, iron, tin, 
copper, gallium, titanium, gold, manganese, vanadium, bismuth and osmium. 33-36 
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Table 1.1. Some metal complexes which show the most promising anticancer activity. The 
table does not include Ru or Pt complexes. 
Metal Drug  
Arsenic Trisenox Approved for acute promyelocytic leukaemia 
Currently in clinical trials for lung cancer and others 
Darinaparsin Currently in clinical trials for solid tumours 
Approbed in some countries for the treatment of T-cell 
lymphoma. 
GSAO Currently in clinical trials for solid tumours 
Iron Ferrocenes 
and 
derivatives 
See section 1.1.4.1. 
Titanium 
 
Budotitane First non-platinum metal-based coordination compound 
entering clinical trials. 
Abandoned 
Titanocene 
dichloride 
See section 1.1.4.1 
Gold Auranofin Currently undergoing clinical trials for chronic 
lymphocytic leukaemia, small lymphocytic lymphoma and 
prolymphocytic leukaemia 
Gallium Gallium 
maltolate 
Currently in clinical trials for liver cancer and lymphoma. 
Gallium 
nitrate 
Currently in clinical use for the treatment of cancer-
associated hypocalcaemia 
NKP-2235 
 
Clinical trials for cancers with high incidence of bone 
metastases 
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1.1.4. Organometallic anti-cancer complexes 
In general, the variety of oxidation states of metals allows the synthesis of complexes 
with a great diversity of structures, containing up to six different ligands (in octahedral 
complexes). The rational design of those ligands provides control over the reactivity and 
properties of the complexes. Organometallic complexes are a family of metal compounds 
containing at least one metal-carbon bond. Organometallic complexes in particular, can 
stabilize low oxidation states of the metal, and have recently shown promising results as 
anticancer agents. 
1.1.4.1. Metallocenes  
Metallocenes or sandwich complexes are organometallic complexes which contain two 
π-bonded cyclopentadienyl groups (Cp) bound to the metal centre. There are two main 
structures: a classical metallocene, where the metal atom at the centre of two parallel Cp 
rings, and a bent structure where the metal centre is bound to two Cp rings  and two halogens 
forming a tetrahedral type structure (Figure 1.3). The cytotoxicity of many metallocenes has 
been studied. However, the most promising results have been obtained with ferrocenes and 
titanocenes. 
 
Figure 1.3. General structure of metallocenes.  
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Ferrocene and derivatives 
Iron is an abundant metal in biology, it can be found in traces in nearly all living 
organisms. Due to the natural occurrence of iron in the body, the relative non-toxicity of the 
iron ions in high quantities and the capability of the body to metabolize it, the use of iron in 
medicine has been studied intensively. Furthermore, the iron transport system of the body 
represents an advantage for the distribution and accumulation of iron-based drugs. 
 
Figure 1.4. Structure of ferrocene, ferrocerone and ferrocifen. 
Ferrocene (Figure 1.4) is the first organometallic compound for which antiproliferative 
activity was reported.37 Initial reports by Köpf et al. confirm that anti-proliferative activity is 
associated with the ferroceneium salts and that neutral ferrocene is relatively non-toxic.37 The 
mechanism of action of these compounds was also studied, showing that ferrocene 
derivatives can induce DNA damage, via generation of hydroxyl radicals.38 However, other 
targets have been proposed and the mechanism of ferrocene and its derivatives is still 
uncertain.39 Ferrocene is readily hydroxylated in the liver and excreted in the urine.40 The 
newly formed hydroxyferrocene, is unstable, and easily decomposes liberating iron ions 
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which can be utilized by the body. On this basis, ferrocerone (Figure 1.4), a ferrocene cation, 
has been used for the treatment of anemia in Russia.41 Ferrocerone is the first organometallic 
compound commercialized for medicinal purposes. Numerous ferrocene derivatives have 
been tested for anti-proliferative purposes. 
One of the most successful approaches for the development of anti-cancer ferrocene 
type drugs has been the addition of organic drugs to the Cp moiety, such as anti-cancer 
commercialized drugs (tamoxifen, or resveratrol), flavonoids (aurones, flavones or 
chalcones), hormones (testosterone), natural products (curcuma or illudins). Currently, the 
most promising compounds are ferrocifens.41, 42 Ferrocifen is a tamoxifen-containing 
ferrocene compound that has been synthesized for the treatment of hormone dependent breast 
cancer, (Figure 1.4). The complex has shown significant anti-proliferative activity towards 
non-hormone dependent as well as hormone dependent breast cancers.43, 44 These compounds 
are believed to have a dual mode of action, through the tamoxifen moiety binding to 
estrogens receptors of hormone dependent breast cancer cells, and through the formation of 
cytotoxic glutathione and nuchleobases ferrocifen compounds. 43, 44 
Titanocenes  
In the family of bent metallocenes, the titanium(IV) compounds (titanocenes) have 
displayed higher cytotoxicity.45 Titanocene dichloride (Figure 1.5) was the first titanium 
organometallic complex to enter clinical trials. Titanocene dichloride showed very promising 
results in animal testing, but the poor response displayed in humans led to the termination of 
the clinical trials. Furthermore, this compound also showed problems due to solubility and 
stability under biological conditions. Titanocenes containing different halides, with either 
mono- and bi-dentate ligands were also synthesized and tested for their anti-proliferative 
activity, leading to results similar to titanocene dichloride.46 Lotz et al. published a series of 
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titanocenes containing one or two heteroaromatic molecules instead of chlorine 
(benzothiophene or dibenzothiophene, Figure 1.5) .  
In order to overcome the solubility issue, a series of ionic titanocenes ([Cp2TiXL]+ and 
[Cp2TiL2]2+) containing neutral L ligands were also synthesized, however the activities were 
lower than those obtained for the neutral compounds.46  
Similarly in the case of ferrocenes, compounds with functionalized Cp rings have been 
studied, with the aim to overcome the drawbacks of [(Cp)2TiCl2]. McGowan et al. 
synthesized a series of ionic titanocenes containing amino pendant arms attached to the Cp 
ring, which increased their solubility (Figure 1.5). These compounds showed an increased 
cytotoxicity compared to the neutral titanocene dichloride. Furthermore, some of the 
compounds synthesised were shown to be cytotoxic towards cisplatin resistant cell lines.47, 48  
Tacke et al. has also developed a versatile synthetic route to functionalized-Cp 
titanocenes via the fulvene route.49 With this method, a series of ansa-titanocenes 
(titanocenes containing an interanular bridge between the Cp rings, Figure 1.5), with 
increased stability, have been synthetized, which have a greater cytotoxic activity when 
compared to titanocene dichloride. However, they are still 100 fold less active than cisplatin. 
Another series of titanocenes containing benzyl-substituted and heteroaryl-substituted Cp, 
were also synthesized (Figure 1.5) showing an important increase in the antiproliferative 
activity, some compounds displaying IC50 values in a similar range to cisplatin.49 
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Figure 1.5. Structures of some titanocenes 
1.1.4.2. Half-sandwich organometallic complexes 
Half-sandwich or piano stool complexes are organometallic complexes that contain a 
cyclic polyhapto ligand bound to a metal centre and three other ligands either mono-, bi- or 
tridentate (Figure 1.6). The properties and behaviour of the complexes can be optimized by 
changing any of the ligands.18, 50-52 
 
Figure 1.6. Typical structure of half-sandwich complexes [(η6-arene)Ru(X)(Y)(Z)]n+ and 
[(η5-Cp ring)Rh(X)(Y)(Z)]n+ where X, Y and Z can be mono-, bi- or tridentate ligands 
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Function of the aromatic ring 
The arene unit in complexes of the type [(η6-arene)M((X)(Y)(Z)]n+ can stabilize a low 
oxidation state of metals such as Ru(II) and Os(II), while the Cp aromatic rings are more 
suited to stabilize metals in a higher oxidation state such as Rh(III) or Ir(III). The nature of 
the arene or Cp ring is also an important factor to take into account; more electron-rich arenes 
or Cp rings will stabilise the complex better. 
The arene and or the Cp ring does not only have an effect on the stability of the 
complex, but also plays an important role by adding a hydrophobic moiety that will facilitate 
the cellular uptake.52, 53 
It has also been observed that the cytotoxicity of some half sandwich Ru(II) complexes 
is closely related to the size of the arene. Complexes that target DNA, for example, display 
better anti-proliferative activity when containing extended arenes. The increase in the 
cytotoxicity is assumed to arise from the ability of the arenes to intercalate DNA.51, 54-56 
Function of the X, Y and Z ligands 
The ligands X, Y and Z give metal complexes a wide versatility, for example, we can 
synthesize complexes containing three monodentate ligands (RAPTA-C), a monodentate 
ligand and a bidentate ligand (RM175), or in some cases complexes with a tridentate ligand. 
By changing those X, Y and Z ligands, the chemical reactivity, the physical properties, the 
stability, the affinity for determined targets or even the mechanism of action of the complex 
can be tuned. Linking the X,Y ligand in a chelating ligand, seems to be advantageous for 
anticancer activity.52 
In general, a monodentate ligand provides the metal complex with potential binding 
sites via ligand substitution. Changes on those monodentate ligands will, mainly, influence 
the rate of ligand exchange and the stability of the complex.51, 54 In a few cases, however, the 
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monodentate ligand does not play the role of a leaving group, but is part of an inert general 
structure with a similar roles as the bidentate ligands.57 
The bidentate ligand of a half sandwich organometalic complex provides the compound 
with stability. Furthermore, the nature of the chelating ligand allows the fine tuning of the 
electronic structure and reactivity of the complex. The nature of the chelating ligand can 
influence the rate and extent of hydrolysis or ligand substitution. The extent of DNA binding 
or the selectivity for different nucleobases can also be controlled by modifying the chelating 
ligand.58-61 For example, comparing the complexes of the type [(η6-arene]Ru(en)Cl]+ and 
[(η6-arene)Ru(acac)Cl] (en = ethylenediamine, acac = acetoacetonate), the complex 
containing the N,N′ chelating ligand shows a higher affinity for N7 guanine, whereas the 
complexes containing acac have a preference for N7 adenine nucleobases.56, 62 Finally, the 
chelating ligand can also influence the target and the mechanism of action of the drug.63  
Anti-cancer complexes 
In this area of organometallic complexes, ruthenium(II) complexes have been 
promising. However, osmium, rhodium and iridium complexes are currently being 
intensively studied.63-66 Nowadays, there is an immense library of half sandwich 
organometallic compounds displaying promising results. However, for the purpose of this 
introduction, only a few representative compounds will be discussed. 
Initially, half-sandwich ruthenium complexes were synthesized with the aim of 
targeting DNA. Many Ru(II) compounds were shown to interact with DNA, although the 
binding, in various cases, was shown to be weaker than with platinum drugs.41, 52, 67-69 On the 
contrary, various Ru complexes have shown a strong affinity for protein binding, and it is 
currently believed that some complexes like RAPTA have preference for proteins instead of 
DNA.70-74 
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[(bip)Ru(en)Cl]+ (RM175) is an inactive drug in its chlorido form. At low chloride 
concentrations (cell nucleus) the complex hydrolyses to form [(bip)Ru(en)H2O]2+. The active 
aqua complex binds strongly to DNA, binding preferentially to N7 of guanine. The binding of 
this type of complex generates unwinding of the DNA helix which results in the inhibition of 
DNA replication. RM175 possesses an interesting biological mode of action since in addition 
to the ruthenium-guanine binding, it also interacts with DNA through the intercalation of the 
extended arene (biphenyl) between nucleobases, the so-called dual mode interaction. Such a 
double interaction results in a DNA with extra degree of distortion.52, 53, 62, 74-78 It has also 
been shown that RM175 reacts with glutathione (GSH) to form S-coordinated GSH-Ru(II) 
adducts. However, this thiolato adduct is then oxidised to the sulfenato adduct, which 
weakens the ruthenium–sulfur bond. Then, substitution of the sulfenato group by N7 guanine 
occurs. GSH does not act as a detoxification system for this type of complex. 77, 78 
RAPTA complexes are believed to bind DNA.68 However, in vivo studies demonstrated 
that those compounds were not active against healthy cells or primary tumours, but to 
metastatic cells.79 Those results suggested that DNA is not the primary target for this 
complex. It is currently believed that the mechanisms of action involve protein binding and 
enzyme inactivation.70-72, 80 Currently, it is believed that RAPTA-C treatment leads to the 
increase of p53 (tumour suppressor protein) and apoptosis.81 
Similarly in the case of ferrocenes, complexes containing biomolecules or active 
organic compounds have also been synthesized.82 For example, Ru(II) arene compounds 
containing paullone (organic drug capable of inhibiting cyclin-dependent kinase) type 
chelating ligands displayed high cytotoxicity, as well as, inhibition of cyclin-dependent 
kinases (regulate cell division and apoptosis).83, 84 RAPTA analogues containing ethacrynic 
acid have been synthesized to inhibit glutathione transferase. Two of those complexes have 
shown higher affinity for the enzyme than the ethacrynic acid itself.85 Ru(II) compounds 
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containing chloroquine (anti-parasitic) have been shown to be active against malaria, and 
some cancer cell lines.86 Cp*Ru(II) complexes containing staurosporin (kinase inhibitor that 
competitively binds to the ATP binding site) have also been synthesised and shown to 
selectively inhibit specific kinases.87, 88 Sulphonamide containing compounds, capable of 
inhibiting carbonic anhydrases have also been reported.89 
Sheldrick et al. reported a series of Cp* Ir(III) and Rh(III) compounds containing 
polypyridyl chelating ligands. These compounds were shown to intercalate DNA, and over 
time, covalently bind and deform the DNA. However, DNA does not seem to be the main 
target for these type of complexes. IC50 values achieved with some of the complexes were as 
low as that of cisplatin, and in some cases an order of magnitude lower.90, 91 
A library of Ir(III) compounds of the type [(Cpx)Ir(XY)Cl] (Cpx = 
petamethylcyclopentadienyl (Cp*), 3-Phenyl-1,2,4,5-tetramethyl-1,3-cyclopentandiene 
(CpxPh) or 3-biphenyl-1,2,4,5-tetramethyl-1,3-cyclopentandiene (CpxPhPh); XY = N,N′; N,O 
or O,O′ ligands) was synthesised. 58 Cp* compounds were the less active complexes from the 
series, while CpxPhPh were 1 to 2 orders of magnitude more active, achieving µM and sub 
µM IC50 values in some cases. The anti-proliferative activity of these Cp series was correlated 
with hydrophobicity and DNA-binding.58 A series of phenylpyridyl Ir(III) Cp complexes also 
displayed significant cytotoxic activity towards A2780 cancer cell lines. The high activity of 
those complexes was attributed to the high nucleobase binding ability.92, 93 
McGowan et al. reported a series of Ir(III) compounds containing picolinamide ligands, 
ketoiminates or naphtoquinone chelating ligands. The ketoiminate complexes exhibited high 
activity against some cancer cell lines, comparable to cisplatin.94 More recently, the same 
group reported Rh(III) and Ir(III) picolinamide complexes which inhibited thioredoxin 
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reductase I (an enzyme that can reduce thioredoxin) and displayed high cytotoxicity against 
HT-29, MCF-7 and A2780 cancer cell lines.66 
In the search for new mechanisms of action, a series of compounds has also been 
studied with the aim of targeting the redox system, and induce cell death by oxidative 
stress.95 Some examples are the azopyridine ruthenium(II) complexes. The chlorido 
analogues are able to catalytically oxidize glutathione to form glutathione disulfide in cells. 
The iodide adducts, however, do not hydrolyze or react with GSH but still increased levels of 
ROS.96,107 Amouri et al. presented a series of Cp*-Ir compounds containing 2-methyl-1,4-
napthoquinone derivatives which are believed to target cytochrome P450 reductase triggering 
the formation of ROS. 97 
 
1.2. Catalytic drugs 
For many years the development of metal-based drugs was focussed on cytotoxic 
compounds which can react stoichiometrically with some biologically relevant molecules. 
Therefore, the concentration of the complex necessary to display cytotoxic activity is 
relatively high. The downfall of using high concentrations of metal drugs relies on their lack 
of specificity towards their targets. Metal-based drugs might show significant preference 
towards some targets, but they might also be reactive towards other biomolecules. The same 
principle applies to the selectivity towards cells. Some drugs might preferentially target 
malignant cells, however, at a higher concentration also healthy cells will be affected.  
In recent years, a number of compounds with catalytic properties, have been 
synthesized and tested in vitro or in vivo, showing promising results.98-101 This novel 
approach decreases the metallodrug concentration necessary to achieve the desired 
antitumoural effect. Nevertheless, catalytic drugs require specific substrates and conditions, 
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which might translate with reduce side reactions and general toxicity. So far the applications 
of catalytic drugs have been mainly focused on the regulation of redox levels in cells, 
depletion or transformation of specific biomolecules, functional group transformations and in 
situ synthesis of compounds. However, catalytic drugs are still a recent research area and 
many other applications can be found. Here some of the most promising metal-based catalytic 
drugs are discussed. 
Redox regulation 
Porphyrins are well known photosynthesizers which can be used in photodynamic 
therapy (PDT) when coordinated to transition metals and lantanides. PDT consists on the 
administration of non-cytotoxic compound which can be excited by light irradiation, at a 
specific wavelength. The excited compound promotes the formation of singlet oxygen (1O2). 
Singlet oxygen, like other reactive oxygen species (ROS), is known to cause damage by 
oxidative stress when in high concentrations.102 PDT has also been achieved with non-
porphyrin containing complexes.103 
Some Mn(II) and Fe(III) porphyrins have also been shown to catalyse decomposition of 
peroxinitriles and act as scavengers for other reactive oxygen species (ROS) and reactive 
nitrogen species (RNS).104, 105 
Manganese(II) compounds have been studied as mimics of superoxide dismutase 
enzymes. These enzymes, and the Mn(II) mimics, are capable of dismutating superoxide to 
oxygen and hydrogen peroxide. Superoxides are strong oxidizing agents that can cause 
cellular damage by oxidative stress.105, 106 This strategy allows control of the levels of 
oxidative species, and can be used to treat many illnesses caused by oxidative stress damage. 
The most successful Mn(II) SOD mimic is M40403 (Figure 1.7), which was in Phase II 
clinical trials (NCT00101621, NCT 00033956). 
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Figure 1.7. Structure of Mn40403. 
Depletion or transformation of bimolecules 
Sadler et al. have developed a series of Ru(II) complexes with potential catalytic 
activity which can be utilised for cancer therapy. For example,  
[(bip)Ru(2(p-N,N-diethylaminophenylazo)pyridine)I], has been shown to catalyse the 
oxidation of glutathione (GSH) to glutathione disulphide (GSSG).107 This process depletes 
the GSH pool and disrupts the redox balance of the cell. [(bip)Ru(en)Cl]+  
(en = ethylenediamine) has also been shown to react with GSH at pH 7 in the presence of 
oxygen to give the sulfenato-GSH adduct.77, 78 
More recently, The possibility of performing transfer hydrogenation reactions in vitro 
has been published. Initially, [(bip)Ru(en)Cl]+ was used to regenerate NADH from NAD+ 
using sodium formate as a hydride source (see section 1.2.2.). 108 Later, a series of Ru(II) and 
Ir(III) complexes of the type [(η6-arene)Ru(bpm)Cl]+, [(Cpx)Ir(phen)OH2]2+ and 
[(Cpx)Ir(PhPy)Py]+ (bpm = bipyrimidine, phen = phenantroline, PhPy = 2-phenylpyridine,  
Py = pyridine), which can use NADH as a hydride donor, were studied.109,110  
The development of catalytic drugs for the hydrolytic cleavage of peptide/proteins has 
been investigated for several years. However, few of those catalysts can be used as 
therapeutic agents. In 2000, Suh et al. reported the first Co(III) compound capable of 
catalysing the cleavage of peptide deformylase at physiologically relevant conditions, which 
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might be attractive as antibiotic agents.111 In 2002, a Co(III) compound capable of catalysing 
the cleavage of myoglobin was developed, however the compound was not fit for therapeutic 
applications.112, 113 More recently, the same group has reported the synthesis and catalytic 
applications of a series of Co(III) complexes capable of performing hydrolytic cleavage of 
amyloids at 310 K and pH 7.4.114-116 Amyloids are insoluble aggregations of peptides or 
proteins, and are present in some conditions such as Alzheimer’s disease, Parkinson’s disease 
and Type II diabetes.117, 118 
 
 
Figure 1.8. Structures of [(η6-arene)Ru(en)Cl]+ (A), [(η6-arene)Ru(2(p-N,N-
diethylaminophenylazo) pyridine)I] (B), [(η6-arene)Ru(bpm)Cl] (C), [(Cpx)Ir(phen)OH2]2+ 
(D) and [(Cpx)Ir(Phpy)py]+ (E). R′ = p-cym, bip, hmb, bn, indane or others arenes.  
R = methyl, phenyl or biphenyl. 
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Cowan et. al. have developed copper and nickel compounds containing the ATCUN 
moiety (Figure 1.9) which can be coupled to enzyme recognizing peptides.98 In such a 
strategy, the compound binds to the enzyme sequence and catalyses its degradation in the 
presence of H2O2 and ascorbic acid. In a similar approach, binding and degradation of RNA, 
have been used by Cowan and co-workers as a method to target Stern Loop IIb in  
hepatitis C.119 
 
Figure 1.9. Structures of [Cu(ATCUN-R)] (A) and [Co(cyclen-R)(OH)2]. R = peptides, 
biotine and other molecules which can be recognised by specific targets. 
Functional group transformations 
[(Cp*)Ru(COD)Cl], is a Ru(II) complex which has been shown to catalyse the cleavage 
of allylcarbamates, to give the corresponding primary amine.120 In a similar manner, the 
complex [(Cp*)Ru(η6-pyrene)]PF6 can catalyse the same reaction after irradiation with light 
(λ = 330, or UV light) and further release of the pyrene moiety. Both reactions require the 
presence of thiols, preferably aromatic. This reaction allows the activation of fluorescent or 
cytotoxic compounds containing protected amines, which in their protected form are 
inactive.121 
Organic azides have been shown to be inert towards any cell components and can be 
hydrolysed to amines. This property makes azides ideal candidates for the delivery of active 
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amine containing flouorophores or cytotoxic compounds into living organism.122 After 
hydrolysis of the azide, the amine can display its fluorescence or activity. A series of metal 
porphyrine has been studied by Meggers et al,. which can catalyse the hydrolysis of azides. 
The complex [Fe(TPP)Cl] (TPP = 5,10,15,20-tetraphenylporphyrine) displayed the best 
catalytic activity. This strategy has been shown in vivo for the activation of an azide caged 
rhodamine 110 which after reaction with an Fe(III) compound becomes rhodamine 110 and 
displays fluorescence.123 
 
Figure 1.10. Structures of [(Cp*)Ru(COD)Cl] (A), [(Cp*)Ru(η6-pyrene)]+ (B) and 
[Fe(TPP)Cl] (C) 
In situ synthesis  
Click chemistry, or azide-alkinyl cycloadditions, has been studied as an in vitro 
synthetic method for C-C bond formation. However the process requires the presence of 
cytotoxic Cu(I) as a catalyst.124 
Bradley et al. carried out Suzuki-Miyaura cross-coupling reactions and allylcarbamate 
cleavage inside HeLa cells using Pd(0) nanoparticles.125 Suzuki-Miyaura cross coupling 
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reactions, using the palladium(II) catalyst [Pd(OAc)2(ADHP)2] (ADHP = 2-amino-4,6-
dihydroxypyrimidine), have also been performed to label I-containing modified proteins with 
fluorescent tags bearing boronic acid.126-128 In 2012, Davis et al. demonstrated the application 
of such catalytic reaction on the membrane surface of E. coli.127, 128 
Sonogashira reactions, using [Pd(OAc)2(N,N-dimethylADHP)2], were also achieved. 
Homopropargylglycine modified ubiquinone and peptides were labelled with a fluorescent 
tag.129 
1.2.1. [(η6-arene)Ru(en)Cl]+ 
Ruthenium(II) arene complexes of the type [(η6-arene)Ru(en)Cl]PF6 where the arene is 
hexamethylbenzene, p-cymene, indane and en is ethylenediamine have been shown to 
catalyse the regioselective reduction of NAD+, using formate as a hydride source, via a 
transfer hydrogenation process. The catalytic reactions can be carried out in water at 
physiological relevant conditions (pH* 7.2, 310 K). Complex [(hmb)Ru(en)Cl]PF6 displayed 
the higher catalytic activity with a turnover frequency (TOF) of 0.85 h-1. The complex shows 
typical Michaelis-Menten type kinetics behaviour. The Michaelis constant (KM) calculated 
was 58 mM and a maximum TOF (TOFmax) was 1.46 h-1. 
Human lung A549 cancer cells were treated with concentrated sodium formate 
solutions and exposed to the complex [(hmb)Ru(en)Cl]PF6. However, no significant effect on 
cell growth in the presence of these ruthenium complexes, and formate, was observed.108 In 
order to catalyze the reduction of NAD+ in vivo, more active catalysts are required. 
1.2.2. The role of formate 
In order to perform transfer hydrogenation reactions to reduce NAD+ in cellulo and  
in vivo, a hydride source must be co-administrated with the catalyst. For that purpose, 
formate has been selected amongst other hydride sources for various reasons: formate salts 
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are mild hydride adducts with very good water solubility, which allow good absorption and 
distribution of complexes in the body. Many formate salts are easily available and very 
cheap. Finally, mammalian cells display high tolerance for formate.  
Formic acid and formate salts are natural constituents of many foods. They are 
intermediary metabolites in normal metabolism, for example formate is generated in the 
catabolism of several amino acids like glycine or tryptophan, and they are precursor in the 
biosynthesis of several body constituents. Under normal conditions the concentration of 
formate in human blood serum is between 0.02-0.25 mM. Furthermore formate is a product 
from the metabolism of methanol, which is ingested in low quantities through fruit juices and 
fermented beverages. High doses of methanol have been shown to be toxic in humans and 
primates, including blindness, kidney damage, acidosis and death. Excessive concentrations 
of formate (10-20 mM in human blood plasma) have also been shown to be toxic. However, 
clinical reports suggest that irreversible damage occurs when concentration of formate in 
plasma is 7 mM or higher for at least 24 h. In general, the tolerance of the body to large 
amounts of formate is relatively high.130 
Calcium formate, for example have been patented (US 5248818 A) and is currently 
used as a calcium supplement.130 Sodium and calcium formate salts have also been approved 
by the FDA as additives in preserved food.131 
 
1.3. Transfer hydrogenation reactions 
Transfer hydrogenation reactions are usually defined as the reduction process by which 
a metal complex catalyses the transfer of a hydride ion from a donor to a molecule containing 
a multiple bond. Double bonds such as C=C, C=N and C=O can be successfully reduced 
affording high yields with excellent enantioselectivity. Transfer hydrogenation reactions have 
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been studied extensively during the last few years as an alternative to hydrogenation and 
hydroboration reactions. In general, transfer hydrogenation reactions provide an inexpensive 
method for the reduction of substrates under mild conditions, without the toxicity and 
flammable nature of borane or hydrogen. 
The study of transfer hydrogenation reactions has primarily focused on the reduction of 
ketones and imines. Initially, metal catalysts containing phosphine,132-136 pyridine,132, 137, 138 
oxazole,139, 140 diamines,141, 142 diimines143 or carbonate144 as the chelating ligands have been 
studied. The discovery of the catalytic properties of half-sandwich organometiallic 
complexes, containing either β-amino-alcohols or mono-tosylated diamines, has been a new 
paradigm.145 These two types of complexes allowed transfer hydrogenation reactions to be 
performed under mild conditions, and with turnover frequencies (TOF) of up to c.a. 30 x to 
70 x times higher than with previous catalysts.145 Turnover frequency is the number of 
catalytic cycles per catalytic site per unit of time for a fixed set of reaction conditions. Higher 
turnover frequencies indicate a better catalytic activity. 145 
Complexes containing β-amino alcohols chelating ligands are amongst the most 
successful catalysts for transfer hydrogenation reactions, leading to high yield and 
enantioselectivity. However, transfer hydrogenation reactions are performed using secondary 
alcohols as hydride donor, and in organic solvents. 146-151 The reactions were not successful in 
aqueous media until recently. Catalytic reactions using formic acid/triethylamine in water 
have been achieved under basic pH or using sodium formate.152-155  
The catalysts containing mono-tosylate diamine chelating ligands have been shown to 
carry out the asymmetric reduction of ketones and imines with high yield in organic solvents, 
using secondary alcohols as hydride donors. However, the complexes were less active than 
those containing β-amino alcohols as chelating ligands.145 Interestingly, transfer 
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hydrogenation reactions in aqueous media were achieved successfully, and with higher 
conversions and enantioselectivities than catalysts containing β-amino alcohols. 154  
1.3.1. Mono-tosylate diamine chelating ligands: Noyori-type catalysts 
In 1995 Noyori et al. discovered the transfer hydrogenation properties of the ruthenium 
catalyst containing (1S,2S)-N-(p-toluensulfonyl)-1,2-diphenylethylenediamine (TsDPEN) 
(Figure 1.11).156 In the first report, Noyori’s catalyst was prepared in situ by reacting the 
[RuCl2(η6-mesitylen)]2 dimer with the TsDPEN ligand immediately before the reaction, 
without further purification.156 The complex was synthesized in isopropanol at 80 ͦ C for  
20 min. The catalysis was activated in the presence of KOH base. The reduction of 
acetophenone was achieved with 95 % yield and 97 % enantiomeric excess after 15 h. The 
catalytic activity of Ru(II) complexes containing R-DPEN chelating ligand were, later, 
studied using different η6-arenes, with [(p-cym)Ru(TsDPEN)Cl] displaying more promising 
results. 
 
Figure 1.11. Structures of Ru(II) complexes containing Noyori’s catalyst, TsCYDN and a 
tethered compound from Wills et al. 
Transfer hydrogenation reactions with Noyori’s catalysts are generally carried out in 
organic solvents, and using isopropanol/KOH or formic acid/triethylamine as a hydride 
source. 
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The reduction of ketones with the p-cym Ru(II) compounds containing TsDPEN was 
achieved at room temperature and in the presence of air, with high conversions and 
enantioselectivities. In many cases , the conversion time was shorter than with other catalysts 
except for β-amino alcohol containing complexes.145 Cp*Rh(III) and Cp*Ir(III) analogues 
containing the TsDPEN ligand have also been studied, but the yield and enantioselectivity for 
the reduction of acetophenone (30 ͦ C, solvent and hydrogen source Isopropanol/t-BuOK), 
was shown to be lower than in the case of Ru(II).157 Reduction of imines was also achieved 
successfully with Noyori’s catalysts. The Rh(III) analogues were shown to be more active 
than Ru(II) analogues, but, in general, with lower enantioselectivities (20 ͦ C, hydrogen source 
triethylamine/formic acid).158-161 The ruthenium catalysts have also been used for the 
reduction of double C=C bonds.158,162  
Xiao et al. reported in 2004 a significant increase in activity with  
[(p-cym)Ru(TsDPEN)Cl] in water using formate as a hydride source.163  
After the publication of Noyori’s work with the TsDPEN ligand, many studies were 
performed to develop Noyori-type modified ligands to achieve better activities and 
enantioselctivities. Complexes containing the mono-tosylated diaminocyclohexane 
(TsCYDN) ligand, synthesized by Knochel et al. and co-workers, were found to be amongst 
the most successful (Figure 1.11).164 High enantioselectivity and conversion was achieved in 
reduction of ketones, using either isopropanol/KOH or acid formic/triethylamine as the 
hydride source.164 When performing the reactions in isopropanol, Ru(II)-TsCYDN complexes 
gave higher conversion and enantioselectivities than the Rh(III) or Ir(III) analogues.157 
However, when the reaction was performed in water using formate or formic 
acid/triethylamine, Rh(III) TsCYDN catalyst was more active than the Ru(II) and Ir(III) 
analogues. Furthermore, higher conversion and enantioselectivity was obtained using Rh(III) 
analogues.165 
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Ikariya et al. have recently published Ru(II), Ir(III) and Rh(III) TsCYDN catalysts in 
combination with silver salts and H2 for the reduction of imines. The reaction was performed 
at 30 ͦ C and isopropanol as a solvent. The Ir(III) catalyst gave the best results with a 99 % 
conversion and 70 % enantioselectivity.166 
Another interesting family of Noyori-type catalysts, which achieved great success in 
asymmetric transfer hydrogenation of ketones, are the tethered complexes synthesized by 
Wills et al., especially (S,S)-teth-TsDPEN-RuCl and (R,R)-teth-TsDPEN-RuCl (Figure 1.11). 
In this type of complexes the TsDPEN is bound to the η6- or η5-arene group.167-171 These 
catalysts have a rigid structure, which improves the enantioselectivity, both in ketone and 
imine reduction. A rigid structure blocks the rotation of the arenes, which allows the addition 
of bulky groups on the arene. This enhances the enantioselectivity of the complex as one site 
of the complex will be hindered. Furthermore, the tethered ligand provides the complex with 
extra stability towards metal-ligand dissociation.167-171 
Mechanism of Noyori-Ru(III) complexes 
Studies on the mechanism of action of TsDPEN complexes, have been performed since 
the first publication of the Ru(II) complex in 1995 by Noyori et al. In their initial reports, 
Noyori described the isolation of the chlorido complex, the 16-electron species and the 
hydride species.172 The NH2 protons, from the TsDPEN chelating ligand, are acidic. Under 
basic conditions (for example KOH, used for transfer hydrogenation reaction), the complex 
[(η6-arene)Ru(TsDPEN)Cl] is deprotonated and HCl is released to afford a 16-electron 
species (active catalyst). The 16-electron species, reacts with isopropanol (hydride source) to 
form a hydride adduct via a concerted process (β-elimination), with simultaneous transfer of a 
hydride and a proton.172 This process was confirmed by Casey et al. via a kinetic isotopic 
effect, investigating the variation of the reaction rate when using isopropanol or deuterated-
isopropanol ((CH3)2CHOD, (CH3)2CDOH and (CH3)2CDOD).173 The reduction of the 
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substrate, involves a second concerted process.172,174 The 6 member ring transition state is 
formed due to a hydrogen bond between the carbonyl of the substrate, and the NH2 from the 
chelating ligand (TsDPEN). Figure 1.12. It was also reported that the hydrogen on the amino 
group of the ligand TsDPEN, is essential for the catalytic reaction.174, 175  
 
Figure 1.12. Proposed mechanism for the reduction of ketones and imines using  
[(p-cym)Ru(TsDPEN)Cl] catalyst and isopropanol/KOH as a hydride source.173 
When using formic acid/triethylamine as a hydride source, a similar mechanism has 
been reported by Ikarya et al.176 
 
Figure 1.13. Formation of ruthenium hydride using formic acid/triethylamine.176 
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Recently, Wills et al. have reported the formation of hydride complexes and the 
reduction of a cyclic imine (91 % conversion, 18 % enantiomeric excess in 5 days) when 
using a dimethylated version of TsDPEN (Figure 1.13). For the imine reduction, the use of  
N-methylated tethered complexes resulted in a decrease in activity compared to the reaction 
with non-methylated catalysts. However, the reaction achieved more than 95 % conversion 
within 20 h. The same reactions using the N-methylated TsDPEN complex to reduce 
acetophenone, gave conversions of 1.7 % after 6 days, and a 6 % conversion after 18 h when 
using the N-methylated tethered compound.177,178 (Figure 1.14)  
 
Figure 1.14. Reduction of cyclic imine. 
Traditionally, transfer hydrogenation reactions have been carried out in isopropanol, 
organic solvents or in an azeotropic mixture of formic acid and triethylamine. Until 2004 very 
little attention was focused on transfer hydrogenation reactions in water. Xiao et al. reported 
a significant increase in the activity when using [(p-cym)Ru(TsDPEN)Cl] complex in water, 
and using formate as a hydride source.163 While the reduction of acetophenone in water 
achieved full conversion in 1 h, the same reaction in formic acid/triethylamine achieved full 
conversion after 12 h. 163 It has been hypothesised that the presence of water can stabilize the 
intermediates by hydrogen bond formation with the substrate. 
Mechanistic studies of the reaction in water were also performed by Xiao and  
co-workers.179 At basic pH, the catalytic cycle follows a similar mechanism than that 
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described in non-aqueous media. Interestingly, at low pH, the amide is protonated, and the 
catalytic activity of the complex decreases. This effect is due to a partial ligand-metal 
dissociation (Figure 1.15).  
 
Figure 1.15. Effect of the pH on the diamine complexes. R1 = p-cym, bn, hmb, bip or other 
arenes. R2 = sulfonate group 
Water-soluble Noyori-type catalysts 
Water-soluble compounds have received much attention since the presence of water has 
been shown to facilitate the transfer hydrogenation reactions. Furthermore, water is a more 
environmentally friendly and less toxic solvent.180,181,182 
A series of modified ligands containing water-soluble groups has been developed. The 
first examples by Bubert et al., who added a hydrophilic sulfonate group in the para- and 
ortho- positions of the N-arylsulfonyl fragment of the TsDPEN and TsCYDN (Figure 1.16). 
The reaction was performed in isopropanol/water at 22 ͦC. The transfer hydrogenation rate 
was low, but the enantioselectivity of the reaction was excellent. The Ir(III) complexes were 
the most successful catalysts, followed by the Rh(III) and, finally, the Ru(II) complexes. It 
was also shown that a higher percentage of water in the reaction mixture increased the 
reaction rate.183 The addition of sulfonic acid or sulfonate groups to the complexes in order to 
increase the water solubility has also been used by Deng et al.184 Two sulfonate groups were 
added to the ortho- positions of the Ph in the backbone of the ligand, Figure 1.16. The Ru(II) 
complex was shown to achieve 99 % conversion with high enantioselectivity (84-95 %) after 
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24 h in water at 40 ͦC, using sodium formate as a hydride source and 0.04 mol equiv. of a 
surfactant. However, the use of Rh(III) or Ir(III) resulted in low conversions and 
enantioselectivities.184 High conversion and enantioselectivity for the reduction of cyclic 
imines was also achieved with these complexes, in water at 28 ͦC, using sodium formate as a 
hydride source and 0.5 mol equiv. of CTAB (cetyltrimethylammonium bromide, 
surfactant).185 In 2011, Gebbink et al. synthesized a compound containing a TsDPEN 
chelating ligand and a sulfonate-containing η6-arene.186 This complex is capable of reducing 
acetophenone, with a 99 % conversion and 97 % enantiomeric excess, in water at 40 ͦC, and 
using sodium formate as a hydride donor. The catalyst was shown to be recyclable, but there 
is an important loss of activity after the third run.186 
Another way to increase water solubility was the addition of amino groups by  
Deng et al. (Figure 1.16) Although the catalytic activity of the Ru(II) catalyst was not 
remarkable using HCOONa, the Rh(III) analogue furnished high conversion with excellent 
enantioselectivities in a great variety of ketones.187 
Zhou et al. published the synthesis and catalytic activities of a series of water-soluble 
complexes containing imidazolium, triethylammonium and pyridinium attached to the 
TsDPEN moiety. Figure 1.16.188, 189 These complexes achieved 100 % conversion in 2-3 h 
with enantioselctivities of up to 93 % when the reaction was performed in water at 40 ͦ C and 
using sodium formate as a hydride source. Interestingly, the pyridinium complexes were 
recyclable, up to 6 times, with a minimum loss of conversion and enantioselectivity. 189 
Süss-Fink et al. reported the catalytic activity of a series of ruthenium complexes 
containing TsCYDN ligand and different η6-arenes.190 The p-cym analogue was shown to be 
the most active (TOF = 46.5 h-1) with 92 % conversion and 81 % enantiomeric excess when 
reducing acetophenone in water/formate, pH 9 and 60 ͦ C. Water-soluble  
Chapter 1 
34 
 
2-S-(p-toluenesulfonylamino) methylpyrrolidine (Figure 1.16) complexes were found to 
catalyse the transfer hydrogenation of α-aryl ketones and α-aryl imines in aqueous solution 
using formate as the hydrogen source. However, Ru(II)-TsCYDN complexes gave higher 
reaction rates and enantioselectivities.191  
 
Figure 1.16. Some water-soluble modified Noyori-type ligands. 
In his research on tethered complexes, Wills et al. reported the synthesis and catalytic 
activity of some water-soluble analogues. The Rh(III) complex containing  
2-(2,3,4,5-tetramethylcyclopentadienyl)-benzyl (1R,2R)-toluenesulfonyl-cyclohexyldiamine 
was the most successful achieving full conversion and 96 % enantiomeric exess in the 
reduction of acetophenone after 3 h, in water at 28 ͦ C, and using sodium formate as a 
hydrogen source. 171 
In the search for recyclable immobilized catalyst, polyethyleneglycol(PEG)-TsDPEN 
Ru(II) complexes were synthesized. However, this was only recyclable when the catalytic 
reaction was performed in water. The complex was water-soluble and catalysed the reduction 
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of ketones with high yields and enantioselectivities at 22 or 40 ͦ C and using sodium formate 
as a hydride donor.192  
 
Figure 1.17. Structures of monosulfonamide ethileneamine ligands.  
Water-soluble monosulfonamide ethyleneamine complexes have also been synthesized. 
Figure 1.17. These kinds of complexes have been used for the catalytic reduction of 
aldehydes,193 α,β-unsaturated ketones194 or α,β-unsaturated esters.195 The absence of phenyl 
groups in the diamine backbone, makes the complexes more soluble. However, the ligands 
also lose their chirality and cannot be used for asymmetric transfer hydrogenation. The Ir(III) 
analogues were shown to be the most active for the reduction of aldehydes, in water, at 65 ͦ C 
using sodium formate (Table 1.2). 
Some interesting work on the monosulfonamide ethyleneamine complexes has been 
performed by Ward et al. Biotin labelled ligands interact with streptavidin and avidin and act 
as metalloenzymes (Figure 1.17). This kind of complex has achieved good 
enantioselectivities (> 90 %) with ketone substrates.196, 197 
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Table 1.2. Turnover frequencies and conversions of some Ru(II), Rh(III) and Ir(III) 
monosulfonamide ethyleneamine catalysts for the reduction of benzaldehyde. The reactions 
were performed in water at 65 ͦ C using sodium formate as a hydride source. 193 
Catalyst Conversion (%) TOF (h-1) 
Ru(II)-MsEn 1.2 12 
Rh(III)-MsEn 74 900 
Ir(III)-MsEn 99 1800 
Ru(II)-TsEn 99 1000 
Rh(III)-TsEn 99 6000 
Ir(III)-TsEn 99 12000 
Ir(III)-TfEn 98 132000 
 
Many other modifications of Noyori-type catalysts have been studied, for example 
catalysts attached to solid supports, raisins and dendrimers.198, 199 However, they are beyond 
the scope of this thesis. 
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1.4. Nicotinamide adenine dinucleotide (NAD+/NADH) 
Nicotinamide adenine dinucleotide (NAD(H)), is a coenzyme found in living cells. The 
compound consists of two nucleotides joined via diphosphate groups. One nucleotide 
contains an adenine base and the other nicotinamide. Nicotinamide adenine dinucleotide 
exists in two different forms, oxidized (NAD+) and reduced (NADH). The total concentration 
of NAD+ and NADH in most cells is in the range of 10-3 M to 10-6 M. The ratio between the 
two varies from 1 to 700. The coenzyme is predominantly found in the nucleus, mitochondria 
and cytosol. 200, 201 
 
Figure 1.18.  Structures of nicotinamide adenine dinucleotide (NAD+) and nicotinamide 
adenine dinucleotide reduced (NADH). 
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1.4.1. Functions 
One of the important functions of NAD+ is to control the redox state of the cell, NAD+ 
is also involved in energy production and modulation processes of the cell. Furthermore, 
NAD+ and NADH are used as substrates in many enzymatic reactions (mono-ADP-
ribosylation, poly-ADP-ribosylation, ADP-ribose cyclisation and formation of O-acetyl-
ADP-ribose). NAD+ and NADH have also been shown to function as signalling agents, both 
intra- and extracellular.  
Modulating metabolic energy 
Molecules like NADH, ATP or FADH store and transport electrons that are required in 
other metabolic pathways. 
In the specific case of NADH: 
 
NAD+ and NADH are involved in many important energy metabolism-related 
reactions, such as glycolysis, Krebs cycle, the lactate dehydrogenase-catalyzed lactate-
pyruvate conversions, mitochondrial oxidative phosphorylation, mitochondrial tricarboxylic 
acid (TCA) cycle, regulating Sir2 family proteins.201, 202 
Controlling redox state of the cell 
The NAD+/NADH couple has a major role in controlling the redox state of the cell:  
• NAD+/NADH has a reduction potential which allows the reduction or oxidation of 
species necessary in other metabolic processes. 203 
• The NAD+/NADH couple contributes in the overall reducing potential of the cell. 
NADH can act as an antioxidant. 
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• NAD+ can act as an inhibitor of some metabolic processes which generate ROS. 
• Even though the antioxidant function of NAD+/NADH by itself is minor, NAD+ is 
necessary for the generation of NADP+
. 
To a lesser extent NADH can also be converted 
into NADPH by enzymes
. 
  
 NADP(H) is a substrate of various enzymes which reduce themselves of ROS, 
furthermore the main antioxidant action of NADP+/NADPH is the regulation and 
regeneration of GSH from GSSG. 
 GSH is one of the main antioxidants in cells and one of the most abundant. 
[GSH]cytosol = 1-11 mM, [GSH]mitochondria = 5-11 mM and [GSH]nucleus = 1-11 mM. 204 
Small changes in the GSH/GSSG ratio will affect greatly the reduction potential of the 
cell. 204 
Excess of NADH, NADPH or GSH might trigger reductive stress. For example, excess 
of NADH will result in the generation of ROS by some enzymes which oxidise the excess 
NADH (xanthine oxidase) or the release of iron from ferritin. Excess of NADPH could also 
contribute to the generation of ROS by the activity of NADPH oxidases.200, 203, 205 
 
Figure 1.19. Summary of the processes for redox state regulation which involve 
NAD+/NADH. 
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Substrate in enzymatic reactions 
NAD+ can act as a substrate for some enzymatic reactions, in which NAD+ is 
hydrolysed to obtain an ADP-ribose group and later transferred to proteins, amino-acids or 
acetyl groups.  
 
Figure 1.20. Structure of ADP-ribose. 
• Mono-ADP-ribosylation. Mono-ADP-ribosylation is the process by which an 
ADP-ribose is transferred to specific proteins or amino-acids (usually argentine, cysteine, 
aspargine and glutamate). The metabolic functions of mono-ADP-ribosylation are believed to 
be related to DNA repair and transcription, extracellular signalling and to some 
immunological functions200, 203, 205-207 
• Poly-ADP-ribosylation. Poly-ADP-ribosylation is the process by which polymers 
of ADP-ribose are synthesized. The ADP-ribose polymers are found free or bound to proteins 
or amino acids. The metabolic function of poly-ADP-ribosylation is still under investigation, 
however it is closely related with DNA damage sensing and repair, genome integrity, 
telomere maintenance and synthesis, detoxification, anti-viral, and they have been shown to 
be closely involved with B and T cells 206-208 
• Formation of O-acetyl-ADP-ribose. O-acetyl-ADP-ribose and the enzymes 
involved and its synthesis are key compounds in many processes. For example, they are 
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involved controlling the metabolism homeostasis in situations of stress, prevention of 
oxidative damage in pancreas, induction of apoptosis, control of gene expression in 
mitochondria, regulation of glucose, lipid and fatty acids metabolism, synthesis of ketonic 
bodies and regulation of chromatin structure, maintenance of telomeres and DNA repair.206, 
209
 
• ADP-ribose cyclation. Cyclic ADP-ribose (cADP-ribose) is a second messenger 
involved in the Ca2+ homeostasis. cADP-ribose stimulates the uptake of Ca2+ by the 
endoplasmatic reticulum. 
1.4.2. Metabolism of nicotinamide adenine dinucleotide in cancer cells 
Cancer cells grow and divide uncontrollably, without being regulated by the organism 
and in many cases show an accelerated rate of cell division. Rapid ATP generation to 
maintain energy status, increased biosynthesis of macromolecules and a tight regulation and 
maintenance of the redox state of the cells are the three basic needs of dividing cells. In order 
to maintain cell growth and division, cancer cells acquire alterations in the metabolism. 210 
For example, in many cases cancer cells display an accelerated glycolysis rate, 
consuming an abnormal concentration of glucose and generating high quantities of NADH, 
which is used in the anaerobic reduction of pyruvate to produce some aminoacids, lipids and 
nucleotide precursors (Warburg effect). 210-212 
As a result of the abnormal accelerated metabolism, together with the effect of the 
immune response from the body, cancer cells generate elevated levels of reactive oxygen and 
nitrogen species (ROS, RNS) and they are in a state of constant oxidative stress.210 
ROS are essential molecules since they perform some bactericidal activities and they 
are involved in signal transduction pathways, regulating cell growth and redox state of the 
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cell. A moderate increase of ROS production may stimulate cell division and proliferation 
However, high levels of ROS can be toxic to cells. For example, elevated ROS levels are 
usually a cause of DNA damage. 210 In order to maintain optimum levels of ROS, a tight 
regulation of the oxidative stress in cancer cells is necessary. The concentrations of ROS in 
tumour cells must be compensated with that of antioxidants, ROS scavengers or enzymes that 
react with ROS.210 Small changes in the redox state of the malignant cells might lead to cell 
death. 
In general, cancer cells require high levels of NADH as a substrate for enzymatic 
reactions. However, the ratio of NAD+/NADH must be tightly controlled to avoid cell death 
by oxidative stress.211, 212 An excess of NADH, might also lead to inhibition of some of the 
abnormal metabolic processes which generate NADH 
Manipulating intracellular balance of NAD+/NADH, reducing the levels of NAD+ and 
destabilizing the redox balance of the cell, can be a suitable strategy for anticancer therapy.  
Recently, regulation of the NAD+ levels has been investigated for the treatment of 
cancer and some other diseases. 200, 213-215 For example, FK866 is a small organic drug, 
currently in clinical trials, which can stop the biosynthesis of NAD+ by inhibition of 
nicotinamide phosphoribosyl transferase.216 Other drugs in clinical trials, such as  
2-deoxyglucose, 3-bromopyrubate or TLN232, inhibit the glycolysis process by blocking the 
active side of hexokinase or pyruvate kinase.212 
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1.5. Previous work on transfer hydrogenation reactions with 
NAD+ 
Chemical, electrochemical, photochemical and enzymatic methods for the regeneration 
of NADH or regeneration of NAD+ have been intensively studied for many years. 217 
However, for the interest of this thesis, this section will be focussed on the chemical methods, 
and more specifically, hydrogenation and transfer hydrogenation reactions.  
In the field of hydrogenation and transfer hydrogenation reactions, the regeneration of 
NADH has been studied mainly for applications in enzymatic reduction of ketones for 
organic synthesis.217 The first series of complexes capable of reducing NAD+ to NADH via 
transfer hydrogenation was discovered by Steckhan et al. His group published the synthesis 
and catalytic properties of a series of Rh(III) bipyridine complexes.218 The most successful 
compound was [(Cp*)Rh(bipy)Cl]+, and its mechanism of action and possible applications 
were very well studied by Fish et al.219-224 Furthermore, the complex has been extensively 
studied by many groups.225, 226 
Süss-Fink et al. published in 2007 the catalytic reduction of NAD+ by using a series of 
Ru(II), Rh(III) and Ir(III) phenanthroline-containing catalysts.227 The complex 
[(Cp*)Rh(phen)Cl]+ was capable of conversions and turnover frequencies of up to twice that 
obtained previously with [(Cp*)Rh(bipy)Cl]+ in aqueous media, at 333 K and pH 7.227 Sadler 
et al. group the catalytic regeneration of 1,4-NADH with some Ru(II) complexes containing 
ethylenediamine or acetylacetonate was studied. However, the turnover frequencies were 
relatively low compared to the literature values.108 In 2011, Salmain et al. published a series 
of Rh(III) and Ru(II) complexes using dipyridyl amine ligands functionalised by maleimide. 
The complexes were not as active as the bipyridine-containing complex [(Cp*)Rh(bipy)Cl]+. 
However, similar turnover frequencies and conversions were achieved with one of their 
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Rh(III) complexes.228 More recently the complex [(Cp*)Ir(4-(1H-pyrazol-1-yl-κN2)benzoic 
acid κC3)H2O)]2SO4 synthesized by Fukuzumi et al. was reported to catalyze H2 oxidation 
while generating NADH by using a neutral and slightly basic media.229 Hollmann et al. 
published in 2012 a tethered Rh(III) complex containing an analogue of Noyori ligand 
(TsDPEN) immobilised in a poly(ethylene) polimmer.230 The catalytic activity of the 
heterogeneous catalyst was shown to be lower than that of other soluble Rh(II) complexes. 
The regeneration of NAD+ has also been achieved by transfer hydrogenation. In 2011, a 
series of water-soluble iron(III) porphyrins was synthesised and used for oxidation on 
NADH, using O2 as an electron catcher.217 Fukuzumi et al. presented the regeneration of 
NADH using [(Cp*)Ir(4-(1H-pyrazol-1-yl-κN2)benzoic acid κC3)H2O)]2SO4 and H2 when at 
neutral pH. However, the same compound can also react with NADH to give NAD+ in acidic 
conditions (pH ≈ 3). Mechanistic studies on this catalytic system are currently being carried 
out. Finally, a series of [(η6-arene)Ru(bpm)Cl]+ and [Cpx)Ir(phen)H2O]2+ were shown to be 
able to use NADH as a hydride donor for transfer hydrogenation reaction.109 The Ir(III) 
compounds have recently been shown to perform transfer hydrogenation reactions in vitro.110 
 
1.6. Aims 
The overall aim of this thesis is concerned with the rational design of catalytic 
organometiallic drugs which can reduce nicotinamide adenine dinucleotide (NAD+) under 
biologically relevant conditions. The aims of each individual chapters are as follows 
• Study the catalytic properties and mechanism of a series of Ru(II) complexes 
containing monosulfonamide ethyleneamine ligands towards the reduction of NAD+ by 
transfer hydrogenation using sodium formate as a hydride source 
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• Investigate the possibility to perform the catalytic reaction in cells by administering 
the complex to A2780 ovarian cancer cells, in combination of sodium formate 
• Explore the potential of Ru(II) complexes containing monosulfonamide 
ethyleneamine ligands, to interact with DNA 
• Explore the potential of Ru(II) complexes containing monosulfonamide 
ethyleneamine ligands, to interact with GSH 
• Explore the possibility to increase the catalytic activity of the complexes containing 
monosulfonamide ethyleneamine ligand towards reduction of NAD+ by changing the (η6-
arene)Ru(II) system to (CpX)Rh(III) 
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2. Materials, methods and instrumentation 
This chapter describes the experimental techniques and instrumentation used in this 
thesis. Detailed description of the synthesis of ruthenium and rhodium dimers, as well as the 
ligands used in the following chapters is also covered here. More detailed procedures for 
specific experiments are described in the appropriate chapters. 
 
2.1. Materials 
Ruthenium(III) trichloride (RuCl3 ·  X H2O) and rhodium(III) trichloride  
(RhCl3 ·  X H2O) was purchased from Precious Metals Online (PMO Pty Ltd.) and used as 
received. 4-(Trifluoromethyl)benzenesulfonyl chloride, 4-nitrobezenesulfonyl chloride,  
di-tert-butyl dicarbonate anhydride, 4-bromo-biphenyl, n-butyllithium in hexane 1.6 M, 
phenyllithium, 2,4-pentamethylcyclopentadiene, 2,3,4,5-tetramethyl-2-cyclopentanone, 
hexamethylbenzene (hmb), were obtained from Sigma-Aldrich. 3-phenyl-1,4-cyclohexadiene 
was synthesised by Dr Abraha Habtemariam following the procedure in the literature.1-3 
Magnesium sulphate, sodium carbonate and hydrochloric acid were obtained from Fisher 
Scientific. α-phellandrene was purchased from Sigma-Aldrich. Methylsulfonyl chloride, 
toluenesulfonyl chloride and triflic acid were obtained from Fluka. DMSO-d6, MeOD-d4, 
D2O, acetone-d6 and CDCl3 for NMR spectroscopy were purchased from Sigma-Aldrich and 
Cambridge Isotope Labs Inc. Dried solvents were purchased from Sigma-Aldrich. Non-dried 
solvents used in syntheses were obtained from Fisher Scientific and Prolabo. Solvents were 
used as received, except in the case of ethanol which was freshly distilled in the presence of 
magnesium/iodine. 
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2.1.1. Preparation of CpX ligands4 
 
3-Phenyl-1,2,4,5-tetramethyl-1,3-cyclopentandiene (CpxPh). A solution of phenyllithium 
(50 mL) was treated with 2,3,4,5-tetramethyl-2-cyclopentenone (12 mL) at 273 K. The 
reaction was allowed to warm slowly to 298 K with stirring overnight. The yellow solution 
was cooled down by addition of ice and then acidified with HCl (36 % v/v). The aqueous 
solution was extracted with diethyl ether (3 x 50 mL). The combined organic portions were 
dried over anhydrous magnesium sulphate, filtered, and the solvents evaporated to dryness on 
a rotary evaporator to obtain a yellowish oil. The product was purified by distillation under 
vacuum (fraction at 410 K, 0.5 mbar). Yield: 12.7 g (81.7 %). 1H NMR (400 MHz, CDCl3): 
The spectrum was very difficult to analyse due to the presence of 3 isomers. 
3-Biphenyl-1,2,4,5-tetramethyl-1,3-cyclopentandiene (CpxPhPh). A solution of  
4-bromo-biphenyl (16 g) in dried tetrahydrofuran (400 mL) was treated with a solution of  
n-butyllithium in hexane 1.6 M (50 mL) at 195 K. After reacting for 3 h, 2,3,4,5-tetramethyl-
2-cyclopentenone (12 mL) was added. The solution was allowed to warm slowly to 298 K 
with stirring overnight. The orange solution was acidified with HCl (36 %) and the organic 
phase removed. The aqueous layer was extracted with diethyl ether (3 x 50 mL). The 
combined organic portions were dried over anhydrous magnesium sulphate, filtered, and the 
solvents evaporated to dryness on a rotary evaporator to obtain a dark yellow powder. The 
product was washed in methanol (3 x 20 mL) to give a yellow powder. Yield: 14.1 g  
(94.38 %).1H NMR (400 MHz, CDCl3): δH = 7.63 (d, 2H, J = 7.4 Hz), 7.60 (d, 2H,  
J = 8.3 Hz), 7.45 (t, 2H, J = 7.5 Hz), 7.34 (m, 3H), 3.25 (q, 1H, J = 7.7 Hz), 2.09 (d, 3H,  
J = 1.4 Hz), 1.96 (s, 3H), 1.89 (s, 3H), 1.01 (d, 3H, J = 7.7 Hz). 
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2.1.2. Preparations of Rh(III) dimers5 
 
[(Cp*)RhCl2]2. Hydrated rhodium(III) trichloride (500 mg, 2.12 mmol) was reacted with  
2,4-pentamethylcyclopentadiene (302 mg, 2.22 mmol) dissolved in dry methanol (50 mL) 
and heated to reflux (343 K) under a nitrogen atmosphere for 48 h. The dark red precipitate 
obtained was filtered and washed with ether (3 x 20 mL) to give a dark red powder. The 
crude product product was then recrystallized from methanol. Yield: 410.6 mg (62.7 %).  
1H NMR (400 MHz, DMSO-d6): δH 1.627 (s, 10H).  
[(CpxPh)RhCl2]2. [(CpxPh)RhCl2]2 was synthesised following the same procedure described 
for [(Cp*)RhCl2]2 using 500 mg of hydrated rhodium(III) trichloride and 532 mg of CpxPhPh. 
The red precipitated obtained was recrystallized in methanol. Yield: 592.7 mg (75.47 %).   
1H NMR (400 MHz, DMSO-d6): δH 7.67 (m, 4H), 7.43 (m, 6H), 1.71 (s, 4H), 1.67 (m, 4H).  
[(CpxPhPh)RhCl2]2. [(CpxPhPh)RhCl2]2 was synthesised following the same procedure 
described for [(Cp*)RhCl2]2 using 1 g of hydrated rhodium(III) trichloride and 962 mg of 
CpxPhPh. The red-orange precipitate obtained was recrystallized from methanol.  
Yield: 613.4 mg (33.2 %). 1H NMR (400 MHz, DMSO-d6): δH 7.75 (m, 12H), 7.49 (t, 4H,  
J = 7.4 Hz), 7.40 (t, 2H, J = 7.4 Hz), 1.73 (s, 24H).  
 
2.1.3. Preparation of Ru(II) dimers1-3 
 
[(p-cymene)RuCl2]2. RuCl3 ·  X H2O (1.05 g, 0.57 mol) and α-phellandrene (9.3 mL,  
5.73 mol) were dissolved in freshly distilled ethanol (75 mL) and the reaction mixture heated 
to reflux (353 K) under a nitrogen atmosphere for 18 h. The red precipitate formed was 
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filtered and washed with ice cold ethanol (3 x 20 mL) and ether (3 x 20 mL) and dried under 
vacuum. Yield: 1.174 g (66.7 %).1H NMR (250 MHz, DMSO-d6): δH 5.82 (d, 2H,  
J = 6.4 Hz), 5.76 (d, 2H, J = 6.4 Hz), 2.84 (septet, 1H, J= 7.1 Hz), 2.09 (s, 3H), 1.20 (d, 6H,  
J = 6.9 Hz) 
[(hmb)RuCl2]2. [(p-cymene)RuCl2]2 (0.8 g, 1.3 mmol) and a large excess of 
hexamethylbenzene (9 g) were placed in a 50 mL round-bottom flask fitted with an air 
condenser and heated at 463 K for 4 hours. Sublimed hexamethylbenzene was scraped off the 
condenser every 10 minutes. The red precipitate formed was washed with hexane (6 x 30 mL) 
to remove excess hexamethylbenzene. The crude product product was redissolved in 
chloroform and filtered to give a red solution. The solvent was then removed on the 
rotavaporator to give a red powder which was recrystallized from chloroform/hexane (9:1). 
Yield: 237 mg (87.4 %).1H NMR (300 MHz, DMSO-d6): δH 2.27 (s, 18H). 
[(bip)RuCl2]2. 3-phenyl-1,4-cyclohexadiene (2.94 g, 18.9 mmol) was added to a solution of 
RuCl3 ·  X H2O (1.64 g, 6.29 mmol) in freshly distilled ethanol (100 mL). The reaction 
mixture was heated to reflux (363 K) under nitrogen atmosphere for 18 h. The brown 
precipitate formed was filtered and washed with ice cold ethanol (3 x 20 mL) and ether  
(3 x 20 mL) dried under vacuum. Yield: 2.00 g (81.9 %).1H NMR (250 MHz, DMSO-d6):  
δH 6.07 (m, 3H), 6.42 (d, 2H, J = 6.1 Hz), 7.50 (m, 3H), 7.82 (m, 2H). 
2.1.4. Preparation of the ligands6-8 
N-(2-Aminoethyl)-4-toluensulfonamide (TsEnH). A solution of ethylenediamine  
(14 mL, 0.21 mol) in dichloromethane (50 mL) was placed in a round-bottom flask.  
A solution of toluenesulfonyl chloride (4.0 g, 21 mmol) in dichloromethane (25 mL) was 
added slowly via a dropping funnel, and the mixture stirred vigorously for one hour. The 
solution was then washed with water (3 x 25 mL), and dried over MgSO4. The solvent was 
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removed on a rotary evaporator to give a white solid which was recrystallized from hot water. 
Yield: 2.63 g (52.3 %).1H NMR (400 MHz, CDCl3): δH 2.43 (s, 3H), 2.78 (t, 2H, J = 5.6 Hz), 
2.95 (t, 2H, J = 5.6 Hz), 7.30 (d, 2H, J = 8.0 Hz), 7.75 (d, 2H, J =8.0 Hz).  
N-(2-Aminoethyl)-4-(trifluoromethyl)benzenesulfonamide (TfEnH). This was obtained 
following the method described above using 2 g of trifluoromethylbenzenesulfonyl chloride. 
The compound was purified by recrystallisation from hot water. Yield: 1.59 g (72.5 %). 
1H NMR (300 MHz, CDCl3): δH 2.82 (m, 2H), 3.00 (m, 2H), 7.79 (d, 2H, J = 8.3 Hz),  
8.00 (d, 2H, J = 8.3 Hz).  
N-(2-Aminoethyl)-4-nitrobenzenesulfonamide (NbEnH). This was obtained following the 
method described above for TsEnH using 3 g of 4-nitrobenzenesulfonyl chloride. The crude 
product was washed with methanol (3 x 20 mL) to give a yellow compound. Yield: 1.78 g 
(53.6 %).1H NMR (250 MHz, CDCl3): δH 2.55 (t, 2H, J = 6.5 Hz), 2.80 (t, 2H, J = 6.5 Hz), 
8.05 (d, 2H, J = 9.0 Hz), 8.42 (d, 2H, J = 9.0 Hz).  
N-(t-Boc)-ethylenediamine. A solution of tBoc-anhydride (6.1 g, 28 mmol) in 
dichloromethane (250 mL) was added drop-wise over 2 h to a solution of ethylenediamine 
(11.2 mL, 166.7 mmol) in dichloromethane (50 mL) during which the mixture slowly turned 
cloudy. The mixture was stirred overnight at ambient temperature. The solvent was removed 
on a rotary evaporator to obtain a yellow oil which was redissolved in aqueous sodium 
carbonate (500 mL) and extracted with dichloromethane. The organic layer was dried over 
Na2SO4, filtered and concentrated in vacuo to afford a yellow oil. Yield: 3.64 g (81.3 %).  
1H NMR (300 MHz, CDCl3): δH 4.85 (s, 1H), 3.17 (m, 2H), 2.80 (t, 2H, J = 5.9 Hz),  
1.44 (s, 9H). 
N-(t-Boc)-N′-(2-aminoethyl)methylensulfonamide. A solution of methanesulfonyl chloride 
(1.85 mL, 25.77 mmol) in dichloromethane (25 mL) was added drop-wise over 45 min to a 
   Chapter 2 
67 
 
solution of t-Boc-protected ethylenediamine prepared above (3.64 g, 22.72 mmol) and 
triethylamine (5 mL). The reaction mixture was stirred overnight at ambient temperature. The 
solution was washed with water, dried over MgSO4 and filtered. After removal of the solvent 
on a rotary evaporator, a yellow oil was obtained. A white powder precipitated after washing 
with diethyl ether. Yield: 2.83 g (52.3 %).1H NMR (300 MHz, CDCl3): δH 4.89 (s, 1H),  
3.29 (m, 4H), 2.97 (s, 3H), 1.44 (s, 9H).  
N-(2-Aminoethyl)methylensulfonamide (MsEnH). To a cooled solution (273 K) of t-Boc 
protected N-(2-aminoethyl)methylensulfonamide (2.83 g, 11.87 mmol) in dry 
dichloromethane (50 mL) was added 3.11 mL of triflic acid (5 mol equiv.) under a N2 
atmosphere. The reaction mixture was stirred for 5 h at room temperature during which a 
white precipitate gradually formed. The solvent was removed on a rotary evaporator to give 
an orange oil which was washed with diethyl ether to precipitate an orange powder. After 
filtration, the orange product was washed with ether to remove the triflic acid and a white 
powder was collected by filtration. Yield: 3.25 g (95.3 %).1H NMR (400 MHz, 
D2O/dioxane): δH = 3.42 (t, 2H, J = 5.7 Hz),3.16 (t, 2H, J = 5.7 Hz), 3.10 (s, 3H).  
 
2.2. Methods and instrumentation 
 
2.2.1. pH measurements 
A minilab IQ125 pH meter equipped with a ISFET silicon chip pH sensor and 
referenced in KCl gel was used to measure the pH. The electrode was calibrated with Aldrich 
buffer solutions of pH 4, 7 and 10. pH* values (pH meter reading without correction for the 
effect of deuterium on glass electrode) of NMR samples in D2O were measured at 298 K. 
pH* values were adjusted with KOD or DClO4 solutions in D2O. pH values of the reaction 
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mixtures and UV-Vis samples H2O were also measured at 298 K. pH values were adjusted 
with KOH or HClO4 solutions in H2O. 
2.2.2. Nuclear magnetic resonance spectroscopy (NMR) 
1H NMR spectra were acquired in 5 mm NMR tubes at 298 K or 310 K on either a 
Bruker DPX-300, AV-400, DRX-500 or Bruker AV III 600 spectrometers. Data processing 
was carried out using XWIN-NMR version 3.6 (Bruker U.K. Ltd). 1H NMR chemical shifts 
were internally referenced to TMS via 1,4-dioxane in D2O (δ = 3.75) or residual DMSO  
(δ = 2.52 ppm), acetone (δ = 2.05 ppm), MeOH (δ = 3.31 ppm) or CHCl3 (δ = 7.26 ppm).  
1D spectra were recorded using standard pulse sequences. Typically, data were acquired with 
16-128 transients into 32 k data points over a spectral width of 14 ppm, and for the kinetic 
experiment 32 transient into 32 k data points over a spectral width of 30 ppm with the centre 
at 0 ppm, relaxation time of T1 = 2 s. 
Water suppression was performed by irradiation at the frequency of water in between 
pulse sequences. 
2.2.2.1. pKa determination9 
Changes in the chemical shifts of the peaks corresponding aqua-adducts of the 
complexes analyzed with the pH* over a range from 2 to 12 were followed by 1H NMR 
spectroscopy. The pH* (pH meter reading without correction for the effect of deuterium on 
glass electrode) were adjusted with KOD or DClO4 solutions in D2O. The data were fitted to 
the Henderson–Hasselbalch equation using Origin 7.5. 
Henderson–Hasselbalch equation:  
[AH]  [A-] + [H+] 
 = [
][	]
[]  
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− = − +  [
]
[] 
Considering that the chemical shift observed (δobs) corresponds to the weighted average of the 
chemical shifts according to the populations of the protonated and deprotonated species. 
δ[] = δ[][] + δ[][] 
Henderson–Hasselbalch:     δ = [	 	x 
 !"#∗ !∗%
	(!"#∗ !∗) ] 
Where δAH and δA- are the chemical shifts from the protonated and deprotonated forms 
respectively. 
 
2.2.2.2. Kinetics of reaction10,11 
A solution of the complex in D2O or MeOD-d4/D2O (5:1) was prepared in a glass vial. 
Solutions of sodium formate and β-nicotinamide adenine dinucleotide hydrate (NAD+) in 
D2O were also prepared and incubated at 310 K. In a typical experiment the corresponding 
volume of each solution (to reach the required concentrations) was added to a 5 mm NMR 
tube and pH* adjusted to 7.2 ± 0.1. The 1H NMR spectrum was recorded every 162 s at  
310 K until completion of the reaction. 
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Figure 2.1. 1H NMR spectra of NAD+ and 1,4-NADH in D2O. 
Molar ratios of NAD+ and NADH were determined by integrating the peaks 
corresponding to He of NAD+ (9.33 ppm) and He of 1,4-NADH (6.96 ppm). (Figure 2.1) 
Turnover number (TON, defined as the maximum number of molecules of substrate that a 
catalyst can convert to product) was calculated: 
TONt = I6.96 I6.96 +I9.93
,NAD+-
0
[Catalyst] 
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Where TONt is the turnover number at an specific time, In is the integral of the signal at  
n ppm and [NAD+]0 is the concentration of NAD+ at the start of the reaction. 
Turnover frequency (TOF, defined as the turnover number per unit of time) calculated 
using the equation obtained from the graphical plot of TON vs time (h) 
TOF=Kcat= Vreaction[catalyst] =
δ[NADH]
δt
1
[catalyst] 
 
TOF	?	t	=	 I6.96	I6.96	+I9.93
[NAD+]0
[Catalyst]	
Michaelis-Menten model12 
The Michaelis-Menten model is a simple approach to enzyme kinetics. It correlates 
reaction rate to substrate concentration for a system where a substrate (S) binds reversibly to 
an enzyme (E) (or catalyst in our case) to form an enzyme-substrate complex (ES), which 
then reacts irreversibly to generate a product (P) and to regenerate the free enzyme. 
E+S  [ES]  E+P 
 
1) Velocity defined as the rate of formation of the product:  G = HIH = J[KL] 
2) The rate of formation of the intermediate : H[MN]H = [L][K] − ( + J)[KL] = 0 
O =  + J =
[L][K]
[KL]  
3) If [K] = [K] − [KL] 
O =
[L]([K] − [KL])
[KL]  
[KL] = [K] [L][L] + O 
K1 
-K1 
K2 
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4) Replacing [ES] in G = HIH = J[KL] 
G = J[KL] = J[K] [L][L] + O 
5) Maximum velocity is obtained when [ES] is equal to [E]t, GPQ = J[K]: 
G = GPQ [L][L] + O 
 
Figure 2.2. Michaelis-Menten plot. 
 
Figure 2.3. Double reciprocal plot of the reaction rate versus concentration of substrate 
(Michaelis-Menten).  
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2.2.3. Elemental analysis  
Elemental analyses were performed by Warwick Analytical Service using an Exeter 
Analytical elemental analyzer (CE440). 
2.2.4. Electrospray ionization mass spectrometry (ESI-MS) 
Positive-ion mass spectra were obtained on a Bruker Daltonics Esquire 2000 ion trap 
mass spectrometer. All samples were prepared in double deionised water (ddw), methanol  
(95 %)/water (5 %), or methanol (100 %). Injection 2 mL min-1, nebuliser gas (N2) 25 psi, dry 
gas (N2) 9 L min-1, dry temp 300 ͦ C, capillary -4000V (positive mode) end plate offset  
-500 V. Capillary exit 70-170 V, and Octpole RF 50-400Vpp. Mass spectra were recorded 
with a scan range of 500 to 1000 m/z. Data were processed using Data-Analysis version 3.3 
(Bruker Daltonics). 
2.2.5. High resolution mass spectrometry (HR-MS) 
Positive-ion mass spectra were obtained on a Bruker MaXis UHR-TOF. All the 
samples were analised by positive electrospray ionization mass spectra. All samples were 
prepared in double deionised water (ddw), methanol (95 %)/water, or methanol (100 %). 
Injection 2 µL min-1, nebuliser gas (N2) 0.4 bar, dry gas (N2) 4 L min-1, dry temp 180 ͦ C, 
capillary -3000 V (positive mode) end plate offset -500 V. Capillary exit 166 V, funnel RF 
300 Vpp, Multiplole RF 300 vpp, quadrupole ion energy 4 eV, Collision cell 1200 eV, ion 
cooler RF settins, ramp from 50 to 250 V. Mass spectra were recorded with a scan range of 
50 to 3000 m/z. Data were processed using Data-Analysis version 3.3 (Bruker Daltonics). 
The HR-MS spectra were recorded by Dr Lijiang Song or Mr Philip Aston. Data were 
processed using Data-Analysis version 3.3 (Bruker Daltonics). 
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2.2.6. Electronic absorption spectroscopy (UV-Vis) 
UV-Vis absorption spectra were recorded on a Cary 300 spectrometer using quartz 
cuvettes of 1 cm pathlength (600 µL). The sample temperature was adjusted to 298 K or  
310 K by a PTP1 Peltier temperature controller. Spectra were recorded from 200 to 800 nm. 
Data were processed with UV Winlab software and Origin Lab 8.5. 
2.2.6.1. Thermal denaturalization of DNA 
Stability of DNA was monitored by measuring the absorbance at 260 nm (1 nm 
bandwidth) as a function of temperature (every 0.5 K between 293 and 371 K, ramp rate  
1 ͦ C/min. The experiment was run on 1 cm pathlength cuvettes of 0.6 ml volume. The data 
were fitted to the Boltzmann equation using Origin 7.5. The melting temperature value  
(Tm, temperature where 50% of the CT-DNA denaturalize) was determined as the inflection 
point. 
2.2.7. X-ray crystallography 
X-ray diffraction data were collected and the structures solved by Dr Guy Clarkson at 
the University of Warwick. 
Diffraction data were collected on an Oxford Diffraction Gemini four-circle system 
with a Ruby CCD area detector. All structures were refined by full-matrix least squares 
against F2 using SHELXL 9713 and were solved by direct methods using SHELXS14  (TREF) 
with additional light atoms found by Fourier methods. Hydrogen atoms were added at 
calculated positions and refined using a riding model, except the hydrogens on the NH 
nitrogens which were located in a difference map. Anisotropic displacement parameters were 
used for all non-H atoms; H-atoms were given an isotropic displacement parameter equal to 
1.2 (or 1.5 for methyl and NH H-atoms) times the equivalent isotropic displacement 
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parameter of the atom to which they are attached. The data were processed by the modelling 
program Mercury 1.4.1. 
The distances were considered statistically different when the difference between them 
was greater than 3σ. Where σ = √(σ12+σ22). Being σ1 and σ2 the standard deviations of the 
values 1 and 2. 
2.2.8. Circular dichroism (CD) 
CD spectra were recorded on a Jacso-815 spectrometer from Prof. Alison Rodger 
group, using quartz cuvettes of 0.1 cm pathlength (200 µL). Spectra were recorded from 190 
to 500 nm, bandwidth 1 nm, scan speed 100 nm min-1. Six scans over the wavelength range 
gave sufficient signal-to-noise ratio for each spectrum. Data were processed with Jasco 815 
spectra manager and Origin Lab 8.5. 
2.2.9. Flow linear dichroism (LD) 
LD spectra were recorded on a Jasco J-815 circular dichroism spectropolarimeter from 
Prof. Alison Rodger group, adapted for LD measurements using a microvolume couette flow 
cell manufactured by Crystal Precision Optics couette (70 µL). The flow cell consists of a 
fixed outer cylinder and a rotating solid quartz inner cylinder, separated by a gap of 0.5 mm, 
giving a total pathlength of 1 mm. The rotation motor potential of the cell was 3.0 V  
(~3000 rpm). Spectra were recorded from 190 to 500 nm, bandwidth 1 nm, scan speed  
100 nm min-1. Two scans over the wavelength range gave sufficient signal-to-noise ratio for 
each spectrum. Data were processed with Jasco 815 spectra manager and Origin Lab 8.5. 
For each sample, spectra were taken with cell rotation on and off. The spectra with cell 
rotation off were used as a baseline, and were subtracted from the spectra with cell rotation to 
give the LD spectra. 
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2.2.10. High performance liquid chromatography (HPLC) 
HPLC studies were performed in collaboration with Prof. P. Socorro Murdoch. 
HPLC was performed on a HP 1200 Series HPLC System (Agilent) with a 100 µL 
loop. The column used was an Agilent ZORBAX Eclipse Plus C-18 (250 x 4.6 mm, 5 µm 
pore size) column. The mobile phases were A: water (HPLC grade, Aldrich) containing  
0.1 % trifluoroacetic acid, and B: acetonitrile (HPLC grade, Aldrich) containing 0.1 % 
trifluoroacetic acid. Gradients of t = 0 – 10 % B, t = 30 – 80 % B, t = 40 – 80 % B, t = 41 – 
10 % B and t = 55 – 10 % B over a 55 min period. Flow rate was 1 mL min-1. A wavelength 
of detection of 254 nm with the reference wavelength at either 360 or 510 nm was used 
unless otherwise stated. Samples were prepared in ddw or a mixture methanol (5 %, HPLC 
grade)/ddw. Sample injections were half the loop volume (50 µL). All complexes described 
in other chapters were analyzed by HPLC and contain less than 5 % impurities detectable by 
HPLC.  
2.2.11. Liquid chromatography – mass spectrometry (LC-MS) 
LC-MS was performed on a HP 1200 Series HPLC System (Agilent) coupled to a 
Bruker HCT-Ultra ETD II PTR PTM mass spectrometer. The column used was an Agilent 
ZORBAX Eclipse Plus C-18 (4.6 x 250 mm, 5 µm pore size). The mobile phases were A: 
water (HPLC grade, Aldrich) containing 0.1% trifluoroacetic acid, and B: acetonitrile (HPLC 
grade, Aldrich) containing 0.1% trifluoroacetic acid. Specific gradients are described on the 
corresponding chapter. Samples were prepared in ddw. Sample injections were 50 µL. The 
mass spectrometer was operated in electrospray positive mode with scan range 50-2000 m/Z, 
Nebuliser gas (N2) 40 psi, dry gas (N2) 10 L min-1, dry temp 300 ͦC, HV capillary -4000 V 
(positive mode) end plate offset -500 V. Capillary exit 166 V, and  Octapole RF 200 Vpp.  
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2.2.12. Liquid chromatography – MAXIS (LC-HRMS) 
Liquid chromatography-MAXIS was carried out by Phil Aston at the University of 
Warwick 
LC-MS was performed on a Dionex Ultimate 3000 with a VWD detector coupled to a 
Bruker MaXis UHR-ESI-TOF mass spectrometer. The column used was an Agilent Eclipse 
Plus C-18 (2.1 x 100 mm, 1.8 µm pore size). The mobile phases were A: water (HPLC grade, 
Aldrich) containing 0.1 % trifluoroacetic acid, and B: acetonitrile (HPLC grade, Aldrich) 
containing 0.1 % trifluoroacetic acid. Specific gradients are described on the corresponding 
chapter. Samples were prepared in ddw. Sample injections were 50 µL. The mass 
spectrometer was operated in electrospray positive mode with scan range 50-3000 m/Z, 
Nebuliser gas (N2) 1.4 Bar, dry gas (N2) 8 L min-1, dry temp 180 ͦ C, capillary -4500 V 
(positive mode) end plate offset -500 V. Capillary exit 166 V, funnel RF 200 Vpp, Multiplole 
RF 200 vpp, quadrupole ion energy 4 eV, Collision cell 1200 eV, ion cooler RF settins, ramp 
from 50 to 250 V. Data were processed using Data-Analysis version 3.3 (Bruker Daltonics). 
2.2.13. Inductively coupled plasma mass spectrometry (ICP-MS) 
Ruthenium (101Ru) and rhodium (103Rh) content was determined using ICP-MS Agilent 
technologies 7500 series. Data acquisition was carried out on ICP-MS Top (B.03.05) and 
analysed on Offline Data Analysis (B.03.05). Standards for Ru (rhuthenium chloride  
1000 ppm in 10 % v/v hydrochloric acid) and Rh (rhodium nitrate 10 ppm in nitric acid  
0.5 M) were purchased from Inorganic Ventures and Fluka, respectively. Calibration curves 
were prepared in double deionised water (ddw) with 3% nitric acid, range between 500 and  
1 ppb (9 points). Standards and samples were freshly prepared in ddw with 3% metal free 
nitric acid. Readings were made in no-gas mode with a detection limit of 0.8 ppt for 101Ru 
and 7 ppt for 103Rh. 
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2.2.14. Computational Details  
All calculations were carried out by Prof. Rob Deeth at the University of Warwick 
All calculations used the ORCA program version 2.8. 15 Minimum-energy structures 
and transition states were located using the OPBE functional, spin restricted, in conjunction 
with the def2-TZVP basis sets16,17 and the resolution of identity approximation. Solvation 
effects were included via the conductor-like screening model implemented in ORCA with 
water as the solvent. Stationary points were confirmed as local minima or transition states via 
numerical frequency calculations. Final free energies were computed using the statistical 
mechanics corrections computed from the OPBE optimizations with B3LYP energies using 
the def2-TZVP basis sets plus the COSMO solvation corrections18 and Grimme’s empirical 
correction for dispersion. 19 
2.2.15. Biological studies 
All the biological studies were performed by Dr. Isolda Romero-Caneón at the University of 
Warwick. The following sections outline the general cell experiments used in this thesis. 
More specific experiments will be described in the appropriate chapter. 
2.2.15.1. Cell maintenance 20, 21 
A2780 human ovarian carcinoma cells were obtained from the European Collection of 
Cell Cultures (ECACC, Salisbury, UK). All cells were grown in Roswell Park Memorial 
Institute medium (RPMI-1640) supplemented with 10% of fetal calf serum, 1 % of 2 mM 
glutamine and 1 % penicillin/streptomycin and used between passages 5-15. The cells were 
grown as adherent monolayers at 310 K in a 5 % CO2 humidified atmosphere and passaged at 
approximately 70-80 % confluence, using 0.25 % trypsin/EDTA. 
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2.2.15.2. In vitro growth inhibition assay  
Stock solutions of the Ru(II) or Rh(III) complexes were freshly prepared in 5 % DMSO 
and a mixture 0.9 % saline (v/v): medium (1:1 v/v) following serial dilutions in RPMI-1640 
to achieve working concentrations. Metal concentrations were determined by ICP-MS. 
The antiproliferative activities of the complexes in A2780 ovarian cancer cells were 
determined. 96-well plates were used to seed 5000 cells per well. The plates were  
pre-incubated in drug-free media at 310 K for 48 h before addition of various concentrations 
of the compounds. The drug exposure period was 24 h, after which, the supernatant was 
removed by suction and each well washed with PBS. A further 48 h was allowed for the cells 
to recover in drug-free medium at 310 K. The sulforhodamine B (SRB) colorimetric assay 
was used to determine cell viability. IC50 values, as the concentration which caused 50 % of 
cell death, were determined as duplicates of triplicates in two independent sets of experiments 
and their standard deviations were calculated. 
The data were analysed using Origin 8.5. IC50 values were obtained from plots of the 
survival percentage of cells versus the logarithm of the concentration expressed in millimolar 
units and fitted to a sigmoidal curve. IC50 values of cisplatin were determined in each well-
plate as a validation. 
Sulforhodamine B assay (SRB) 22 
SRB is a pink dye which binds quantitatively to aminoacid residues in acid conditions, 
however under basic conditions the dye is liberated and can be extracted and analyzed by 
optical absorption spectroscopy (λ = 568 nm).  
To each well, 50 µL of trichloroacetic acid (TCA) (10 % v/v) was added and incubated for an 
hour at 277 K. The well plates were washed with water 10 times and then dried in air. 
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Aliquots of 50 µL of SRB (0.4 %, prepared in 1 % acetic acid) were added and the wells left 
standing for 30 min at ambient temperature. Excess dye was removed by washed with 1 % 
acetic acid 5 times and the plate left to dry. 
A 10 mM of Tris base solution (200 µL, pH 10.5) were added to each well plate and left to 
stand for 1 h to solubilise the dye. Absorbance was measured with a multi reader at 570 nm. 
2.2.15.3. Cell viability modulation experiments  
Cell viability assays were carried out in A2780 ovarian cancer cells. These experiments 
were performed as described above for IC50 determination with the following experimental 
modifications:  
1) Fixed concentration of complexes was 1/3 x IC50 
2) Co-administration of the complex with three different concentrations of 
sodium formate (0.5, 1 and 2 mM). Both solutions (complex and sodium formate) 
were added to each well independently, but within 5 min of each other 
Stock solutions of the Ru(II) or Rh(III) complexes were freshly prepared in 5 % DMSO 
and a mixture 0.9 % saline : medium (1:1 v/v). The stock solution was further diluted using 
RPMI-1640 to achieve working concentrations. Metal concentrations were determined by 
ICP-MS. 
Cell viability percentages were determined as duplicates of triplicates in two 
independent sets of experiments and their standard deviations were calculated. 
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3. Ruthenium(II) arene complexes for the catalytic 
reduction of NAD+ 
 
3.1. Introduction 
The coenzyme nicotinamide adenine dinucleotide (NAD+) and its reduced form  
1,4-NADH have crucial roles in many cellular processes such as regulation of energy 
metabolism, antioxidative function, DNA repair and transcription, immunological functions 
and cell death.1 These coenzymes are involved in many other processes acting as substrates 
and cofactors for enzymes.2, 3  
NAD+/NADH coenzymes have been studied intensively due to their important role in 
different areas such as medicine, industry and organic synthesis.4, 5 From the medical 
perspective, it has been demonstrated that changes in metabolism result in fluctuations in the 
ratio NAD+/NADH or, conversely, changes in this ratio can produce metabolic changes.3 In 
some cases, alterations in the cellular redox status have been shown to play an important role 
in cell death and therefore these coenzymes have become possible drug targets for chronic or 
autoimmune diseases such as Parkinson’s, hepatitis C, diabetic vascular dysfunction, 
hyperglycemia and cancer.6 
The concentration NAD+ as well as the ratio NAD+/NADH has been shown to be very 
important for cancer cells to maintain their redox balance.7 Furthermore, due to their 
increased metabolism, cancer cells generate high levels of oxidizing species and, therefore, 
they are under constant oxidative stress.7 This makes cancer cells more dependent on redox 
regulatory systems, and more sensitive to variations in the NAD+/NADH ratio. Furthermore, 
NAD+ is required as substrate for many enzymatic reactions such as ADP-ribosylation which 
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is crucial for genome stability and DNA repair.6 Due to the up-regulation of some enzymes 
required for the biosynthesis of NAD+ in cancer cells, a decrease in the NAD+ concentration 
can cause apoptosis of cancer cells while having little effect in normal cells.7 
From an industrial perspective, NADH regeneration is an important process due to its 
high applicability in chiral organic synthesis and biocatalysis.8,9 The coenzyme 1,4-NADH, 
for instance, is required as substrate for many enzymatic reactions used for stereo-selective 
synthesis, such as the formation of D-lactate from pyruvate or chiral alcohols by alcohol 
dehydrogenases.8,9  
Due to the high cost of the NAD+ and NADH, their stoichiometric use in organic 
synthesis, biocatalysis or enzymatic reactions is not sustainable, and hence nicotinamide 
adenine dinucleotide models have been developed.10 The capability of regenerating  
1,4-NADH has been the subject of intense studies by enzymatic, chemical, photochemical or 
electrochemical reactions.11,12 
Recently, the regeneration of NADH or NAD+ under mild conditions in aqueous media 
has been studied.13,14 Significant attention has been focused on transition metal complexes as 
catalysts for the regeneration of 1,4-NADH via hydrogenation13 (H2) or transfer 
hydrogenation using 2-propanol,15 glycerol,16 phosphate,17 formic acid together with a base,18 
or formate14 as hydride sources in water. Some Ru(II),19 Rh(III) 20,21 and Ir(III) 22 half-
sandwich complexes can catalyze the hydrogenation or transfer hydrogenation of ketones,23 
aldehydes,24 imines25 or carbon dioxide,26 although the optimum conditions for the reactions 
are usually not biologically relevant. In some cases, hydride adducts can be isolated showing 
that the mechanism involves a hydride formation.27, 28 Of particular interest in this field are 
ruthenium complexes that employ Noyori’s chelating ligand Ts-DPEN (N-[(1R,2R)-2-amino-
1,2-diphenylethyl]-4-toluenesulfonamide) and its derivatives (Figure 3.1) which allow high 
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enantioselectivity in transfer hydrogenation of ketones,29 imines30 and C=C double bonds,31 
affording up to 100 % conversions. However, the use of similar complexes under biologically 
relevant conditions requires high aqueous solubility and thermodynamic stability. The 
coordination of Noyori’s ligand renders the complexes highly insoluble in water, due to the 
presence of lipophilic phenyl groups. However, recently some water-soluble complexes have 
been synthesised.24,32,33 Given that enantioselectivity is not a requirement in NAD+/NADH 
catalysis, avoiding chiral centres offers an plausible strategy. 
 
Figure 3.1. Noyori’s catalyst [(p-cym)Ru(TsDPEN)Cl] and some well known derivatives 
It has been previously reported that the Ru(II) complexes of general formula  
[(η6-arene)Ru(en)Cl]+ (η6-arene = hexamethylbenzene, p-cymene, indane, and  
en = ethylenediamine) can reduce NAD+ to NADH using formate as the hydride source, and 
that such reactions might be feasible in cells since millimolar levels of formate can be 
tolerated by cells.34 However, due to the low catalytic activity of the complexes no effect 
attributed to the combination with formate was detected on A2780 human ovarian cancer 
cells in vitro. 34 In this chapter, the ethylenediamine chelating ligand has been modified by 
the addition of a sulfonamide group so that it resembles Noyori’s ligand with the main goal of 
improving the catalytic activity of the complexes. The synthesised series of Ru(II) complexes 
of the type [(η6-arene)Ru(N,N′)Cl], where N,N′ are water-soluble mono-sulphonate 
ethylenediamine ligands (Figure 3.2), N-(2-aminoethyl)-4-nitrobenzenesulfonamide (NbEn), 
N-(2-aminoethyl)-4-(trifluoromethyl)benzenesulfonamide (TfEn), N-(2-aminoethyl)-4-
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toluenesulfonamide (TsEn), or N-(2-aminoethyl)methylenesulfonamide (MsEn), derived from 
Noyori’s ligand Ts-DPEN (N-[(1R,2R)-2-amino-1,2-diphenylethyl]-4-toluenesulfonamide), 
were envisaged to give rise to good catalytic properties while maintaining their water 
solubility and facilitating the synthesis and purification by avoiding enantiomeric resolution.  
The catalytic activity of the complexes towards the reduction of NAD+ through transfer 
hydrogenation has been investigated and compared with reported ethylenediamine Ru(II) 
arene complexes. The mechanism of the catalysis has also been studied both experimentally 
and computationally in order to compare it to similar known compounds such as those 
reported by Steckhan and Fish.35, 36 The optimum conditions for the reaction have also been 
studied in relation to the potential of these complexes to act as catalytic anticancer drugs 
which modulate NAD+/NADH levels in cells. 
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Complex η6-arene (R) R1 
1 p-cym methyl (MsEn) 
2 p-cym p-toluene (TsEn) 
3 p-cym p-trifluoromethylbenzene (TfEn) 
4 hmb methyl (MsEn) 
5 hmb p-toluene (TsEn) 
6 hmb p-trifluoromethylbenzene (TfEn) 
7 bip methyl (MsEn) 
8 bip p-toluene (TsEn) 
9 bip p-trifluoromethylbenzene (TfEn) 
10 bn methyl (MsEn) 
11 bn p-toluene (TsEn) 
12 bn p-trifluoromethylbenzene (TfEn) 
13 o-terp methyl (MsEn) 
14 o-terp p-toluene (TsEn) 
15 o-terp p-trifluoromethylbenzene (TfEn) 
16 p-cym p-nitrobenzene (NbEn) 
Figure 3.2. Structures of the complexes studied in this chapter  
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3.2. Experimental 
 
3.2.1. Materials 
The Ru(II) arene precursor dimers [(η6-arene)RuCl2]2 where the η6-arene is p-cymene 
(p-cym), hexamethylbenzene (hmb), biphenyl (bip) or benzene (bn) were prepared following 
literature methods,37 as were the ligands N-(2-aminoethyl)-4-
(trifluoromethyl)benzenesulfonamide (TfEnH),22 N-(2-aminoethyl)-4-
nitrobenzenesulfonamide (NbEnH),31 N-(2-aminoethyl)methylensulfonamide (MsEnH),31  
N-(2-aminoethyl)-toluenesulfonamide (TsEnH).31 Ru(II) arene precursor dimer  
[(η6-arene)RuCl2]2 where the arene is o-terphenyl (o-terp) was kindly provided by Dr. Abraha 
Habtemariam from the Department of Chemistry at the University of Warwick and 
synthesised according to a published method.38,39 Magnesium sulphate, silver nitrate, 
potassium hydroxide, sodium chloride, perchloric acid and hydrochloric acid were obtained 
from Fisher Scientific. β-nicotinamide adenine dinucleotide hydrate, β-nicotinamide adenine 
dinucleotide, reduced dipotassium sal and sodium formate were purchased from Sigma-
Aldrich. Non-dried solvents used in syntheses were obtained from Fisher Scientific and 
Prolabo. Solvents were used as received, except in the case of 2-propanol and methanol, 
which were degassed prior to use by bubbling with nitrogen. 
3.2.2. Synthesis and characterisation of the complexes 
 
[(p-cym)Ru(MsEn)Cl] (1). [(p-cym)RuCl2]2 (84.2 mg, 0.138 mmol) and MsEnH (101.6 mg, 
0.35 mmol) were placed in a round-bottom flask to which 2-propanol (50 mL) and 
triethylamine (146 µL, 1.047 mmol) were added. The solution was heated under reflux in a 
nitrogen atmosphere overnight, after which the solvent was removed on a rotary evaporator to 
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obtain a light brown powder. The crude product was redissolved in dichloromethane and 
washed with brine, after which the organic layer was dried over MgSO4 and filtered. A 
brown-reddish powder was obtained after removal of the solvent in vacuo. Brown crystals 
were obtained after recrystallisation from methanol/ether (1:10 v/v) by standing in a freezer 
for two months at 253 K. Yield: 45.3 mg (40.4 %). 1H NMR (400 MHz, methanol-d4):  
δH 5.59 (s, 2H), 5.42 (d, 2H, J = 5.7 Hz), 2.85 (sept, 1H, J = 7.1 Hz), 2.74 (s, 3H),  
2.134 (s, 3H), 1.265 (d, 6H, J = 7.1 Hz). Anal: Calc for C13H23ClN2O2RuS C: 38.28, H: 5.68, 
N: 6.87; Found C: 38.27, H: 5.65, N: 6.82. ESI-MS: Calc for C13H23ClN2O2RuS (M-Cl)+ 
373.1 m/z found 373.0 m/z.  
 
[(p-cym)Ru(TsEn)Cl] (2). Complex 2 was obtained following the method described above 
for complex 1 using the ligand TsEnH (100.6 mg, 0.42 mmol). Recrystallisation from 
methanol resulted in dark red crystals. Yield: 58.8 mg (36.7 %).1H NMR (400 MHz,  
acetone-d6): δH 7.73 (d, 2H, J = 8.3 Hz), 7.11 (d, 2H, J = 8.3 Hz), 5.85 (s, 1H), 5.71  
(d, 1H, J = 5.6 Hz), 5.64 (d, 1H, J = 5.6 Hz), 5.52 (d, 1H, J = 5.6 Hz), 5.45  
(d, 1H, J = 5.6 Hz), 3.24 (s, 1H), 2.94 (sept, 1H, J = 7.1 Hz), 2.84 (m, 1H), 2.68 (m, 1H), 
2.31(s, 3H), 2.18(m, 1H), 2.15 (s, 3H), 1.27 (d, 3H, J = 7.0 Hz), 1.24 (d, 3H, J = 7.0 Hz). 
Anal: Calc for C19H27ClN2O2RuS C: 47.15, H: 5.62, N: 5.79; Found C: 46.70, H: 5.62,  
N: 5.79. ESI-MS: Calc for C19H27ClN2O2RuS (M-Cl)+ 449.1 m/z found 449.0 m/z.  
 
[(p-cym)Ru(TfEn)Cl] (3). Complex 3 was obtained following the method described above 
for complex 1 using ligand TfEnH (125.0 mg, 0.47 mmol). Purification by recrystallisation 
was not successful and the product was used as such. Yield: 171.1 mg (85.3 %) 1H NMR 
(400 MHz, acetone-d6): δH 8.00 (d, 2H, J = 8.1 Hz), 7.62 (d, 2H, J = 8.1 Hz), 5.74 (m, 1H), 
5.51 (m, 2H), 5.41 (d, 1H), 4.23 (s, 1H), 3.27 (s, 1H), 3.10 (s, 1H), 2.76 (sept, 1H, J = 6.9), 
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2.75 (m, 1H), 2.29 (m, 2H), 2.17 (s, 3H), 1.27 (m, 6H). Anal: Calc for C19H24ClF3N2O2RuS 
C: 42.42, H: 4.50, N: 5.21; Found C: 41.94, H: 4.45, N: 5.03. ESI-MS: Calc for 
C19H24ClF3N2O2RuS (M-Cl)+ 503.1 m/z, found 503.0 m/z. 
 
[(hmb)Ru(MsEn)Cl] (4). [(hmb)RuCl2]2 (81.2 mg, 0.12 mmol) and  
N-(2-aminoethyl)methylsulfonamide (MsEnH) (105 mg, 0.37 mmol) were dissolved in  
2-propanol (25 mL). Triethylamine (155 µL, 1.11 mmol) was added and the solution heated 
to reflux (363 K) under nitrogen atmosphere for 3 h. Solvent was removed on a rotary 
evaporator to give a dark orange product. The crude product was redissolved in 
dichloromethane and washed with brine, after which the organic layer was dried over MgSO4 
and filtered. The solution was concentrated in vacuo and the product recrystallised from 
methanol to afford an orange powder. Yield: 44.1 mg (41.6 %).1H NMR (400 MHz,  
acetone-d6): δH 2.11 (s, 18H), 2.32 (m, 2H), 2.72 (s, 3H), 2.67 (m, 2H), 4.58 (s, 2H).  
Anal: Calc for C15H27ClN2O2RuS C: 41.32, H: 6.24, N: 6.43; Found C: 41.92, H: 6.31,  
N: 6.32. ESI-MS: Calc. for C15H27ClN2O2RuS (M-Cl)+ 401.1 m/z, found  401.0 m/z.  
 
[(hmb)Ru(TsEn)Cl] (5). Complex 5 was obtained following the method described above for 
complex 4 using ligand TsEnH (64.1 mg, 0.267 mmol). The product was recrystallised from 
methanol giving yellow crystals. Crystals suitable for X-ray diffraction were obtained from a 
methanol solution stored at 255 K. Yield: 20.5 mg (13.4%). 1H NMR (400 MHz, acetone-d6): 
δH 7.83 (d, 2H, J = 8.3 Hz), 7.07 (d, 2H, J = 8.3 Hz), 4.56 (s, 1H), 2.54 (m, 1H), 2.29 (s, 3H), 
2.17 (s, 18H). Anal: Calc for C21H31ClN2O2RuS C: 49.35, H: 5.92, N: 5.48; Found C: 49.17, 
H: 6.04, N: 5.29. ESI-MS: Calc for C21H31ClN2O2RuS (M-Cl)+ 477.1 m/z, found 477.0 m/z.  
 
Chapter 3 
92 
 
[(hmb)Ru(TfEn)Cl] (6). Complex 6 was obtained following the method described above for 
complex 4 using ligand TfEnH (87.5 mg, 0.33 mmol). The product was recrystallised from 
methanol giving red crystals. Yield: 82.2 mg (58.9 %). 1H NMR (400 MHz, CDCl3): δH 8.05 
(d, 2H, J = 8.2 Hz), 7.56 (d, 2H, J = 8.2 Hz), 3.38 (s, 1H), 3.21 (s, 1H), 3.12 (m, 1H),  
2.74 (m, 1H), 2.34 (m, 1H), 2.18 (s, 18H). Anal: Calc for C21H28ClF3N2O2RuS C: 44.56, H: 
4.99, N: 4.95; Found C: 44.38, H: 5.04, N: 4.87. ESI-MS: Calc for C21H28ClF3N2O2RuS  
(M-Cl)+ 531.1 m/z, found 531.0 m/z. Crystals suitable for X-ray diffraction of 6 · 1/3 MeOH 
were obtained from a methanol solution stored at 277 K. 
 
[(bip)Ru(MsEn)Cl] (7). [(bip)RuCl2]2 (64 mg, 0.098 mmol) and MsEnH (70 mg,  
0.243 mmol) were placed in a round-bottom flask and disolved methanol (25 mL). 
Triethylamine (109 µL, 0.783 mmol) was added and the solution was stirred at ambient 
temperature under nitrogen overnight, after which solvent was removed on the rotary 
evaporator to give a dark brown product. The crude product was redissolved in 
dichloromethane and washed with brine, the organic layer was dried over MgSO4 and 
filtered. The solution was concentrated in vacuo and the product recrystallised from methanol 
to afford red crystals. Yield: 45.2 mg (54.3 %). Crystals suitable for X-ray diffraction were 
obtained from solution in methanol/ether (10:1 v/v) stored at 255 K. 1H NMR (400 MHz, 
CDCl3): δH 7.69 (m, 2H), 7.54 (m, 3H), 6.22 (t, 1H, J = 5.6 Hz), 6.01 (t, 1H, J = 5.6 Hz),  
5.82 (m, 3H), 3.78 (s, 1H), 3.23 (s, 1H), 3.09 (m, 1H), 2.81 (s, 3H), 2.64 (m, 1H),  
2.45 (m, 1H), 2.15 (m, 1H). Anal: Calc for C15H19ClN2O2RuS C: 42.10, H: 4.48, N: 6.55; 
Found C: 41.88, H: 4.49, N: 6.46. ESI-MS: Calc for C15H19ClN2O2RuS (M-Cl)+ 393.0 m/z, 
found 393.0 m/z.  
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[(bip)Ru(TsEn)Cl] (8). Complex 8 was obtained following the method described above for 
complex 7 using ligand TsEnH (69.9 mg, 0.29 mmol). The product was recrystallised from 
methanol to give a dark orange powder. Yield: 39.9 mg (33.9 %). Crystals suitable for X-ray 
diffraction were obtained from a methanol solution stored at 277 K. 1H NMR (400 MHz, 
CDCl3): δH 2.35 (s, 3H), 2.51 (m, 1H), 3.08 (m, 1H), 3.22 (m, 1H), 3.68 (m, 1H),  
5.77 (m, 1H), 5.96 (m, 1H), 6.03 (m, 1H), 6.39 (m, 1H), 7.17 (d, 2H, J = 7.7 Hz),  
7.53 (m, 3H), 7.71 (m, 2H), 7.77 (d, 2H, J = 7.7 Hz), Anal: Calc for C21H23ClN2O2RuS  
C: 50.04, H: 4.60, N: 5.56; Found C: 49.57, H: 4.60, N: 5.44. ESI-MS: Calc for 
C21H23ClN2O2RuS (M-Cl)+ 469.1 m/z, found 469.0 m/z.  
 
[(bip)Ru(TfEn)Cl] (9). Complex 9 was obtained following the method described above for 
complex 7 using ligand TfEnH (40 mg, 0.15 mmol). The product was recrystallised from 
methanol to give an orange solid. Yield: 45.6 mg (54.3%). 1H NMR (400 MHz, CDCl3):  
δH 2.17 (m, 1H), 2.31 (m, 1H), 2.55 (m, 1H), 3.11 (m, 1H), 3.21 (s, 1H), 3.74 (s, 1H),  
5.80 (m, 2H), 5.95 (d, 1H, J = 5.5 Hz), 6.04 (t, 1H, J = 5.3 Hz), 6.34 (t, 1H, J = 5.8 Hz),  
7.54 (m, 3H), 7.62 (d, 2H, J = 8.3 Hz), 7.70 (m, 2H), 8.00 (d, 2H, J = 8.3 Hz). Anal: Calc for 
C21H20ClF3N2O2RuS·0.5 H2O C: 44.49, H: 3.73, N: 4.94; Found C: 44.22, H: 3.59, N: 4.81. 
ESI-MS: Calc for C21H20ClF3N2O2RuS (M-Cl)+ 523.0 m/z, found 522.9 m/z.  
 
[(bn)Ru(MsEn)Cl] (10). [(bn)RuCl2]2 (64 mg, 0.098 mmol) and MsEnH (70 mg,  
0.243 mmol) were placed in a round-bottom flask and were dissolved in methanol (25 mL). 
Triethylamine (109 µL, 0.783 mmol) was added and the solution was stirred at ambient 
temperature under nitrogen overnight, after which solvent was removed on the rotary 
evaporator to give a dark brown oil that was dissolved in dichloromethane, washed with 
brine, dried over MgSO4 and filtered. After removal of solvent on a rotary evaporator, a dark 
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brown oil was obtained, which was washed with ether to give a brown solid. The product was 
recrystallised from methanol to give a brown solid. Yield: 30 mg (49.2 %).  
1H NMR (400 MHz, CDCl3): δH 5.67 (s, 6H), 2.80 (s, 3H). Anal: Calc for C9H15ClN2O2RuS 
C: 30.73, H: 4.30, N: 7.96; Found C: 30.29, H: 4.14, N: 7.76 ESI-MS: Calc. for 
C9H15ClN2O2RuS (M-Cl)+ 316.4 m/z found 317.0 m/z.  
 
[(bn)Ru(TsEn)Cl] (11). Complex 11 was obtained following the method described above for 
complex 10 using ligand TsEnH (100 mg, 0.417 mmol). The crude product was recrystallised 
from methanol to give an orange powder. Yield: 47 mg (52.4 %). 1H NMR (400 MHz, 
CDCl3): δH 7.75 (d, 2H, J = 7.8 Hz), 7.28 (d, 2H, J = 7.8 Hz), 5.71 (s, 6H), 4.89 (s, 1H),  
3.14 (s, 1H), 3.05 (s, 1H), 2.75 (s, 1H), 2.35 (m,1H), 2.35 (s, 3H), Anal: Calc for 
C15H19ClN2O2RuS C: 42.1, H: 4.48, N: 6.55; Found C: 41.83, H: 4.48, N: 6.74. ESI-MS: 
calc. for C15H19ClN2O2RuS (M-Cl)+ 393.0 m/z, found 393.0 m/z. 
 
[(bn)Ru(TfEn)Cl] (12). Complex 12 was obtained following the method described above for 
complex 10 using ligand TfEnH (100 mg, 0.380 mmol). The crude product was recrystallised 
from methanol to give a red powder. Yield: 53.6 mg (59.0 %).  1H NMR (400 MHz, CDCl3): 
δH 7.99 (d, 2H, J = 8.2 Hz), 7.62 (d, 2H, J = 8.2 Hz), 5.73 (s, 6H), 4.71 (s, 1H), 3.12 (m, 2H), 
2.79(m, 1H), 2.25 (m, 2H). Anal: Calc for C15H16ClF3N2O2RuS C: 37.39, H: 3.35, N: 5.81; 
Found C: 37.00, H: 3.39, N: 5.81 ESI-MS: Calc. for C15H16ClF3N2O2RuS (M-Cl)+ 447.0 m/z, 
found 446.9 m/z.  
 
[(o-terp)Ru(MsEn)Cl] (13). [(o-terp)RuCl2]2 (110.0 mg, 0.137 mmol) and MsEnH (79.3 mg, 
0.275 mmol) were placed in a round-bottom flask and dissolved 2-propanol (50 mL). 
Triethylamine (42 µL, 0.299 mmol) was added and the solution was heated overnight at 
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reflux temperature under nitrogen atmosphere, after which solvent was removed on the rotary 
evaporator to give a dark brown product. The crude product was redissolved in 
dichloromethane and washed with brine, the organic layer was dried over MgSO4 and 
filtered. The solution was concentrated in vacuo and the product recrystallised from methanol 
to afford a clear brown product. Yield: 33.3 mg (24.2 %). 1H NMR (250 MHz, acetone-d6): 
δH 7.57 (m, 4H), 7.39 (m, 6H), 6.23 (t, 1H, J = 5.6 Hz), 6.05 (t, 1H, J = 5.6 Hz),  
6.02 (t, 1H, J = 5.6 Hz), 5.80 (t, 1H, J = 5.6 Hz), 5.10 (s, 1H), 3.36 (s, 1H), 2.94 (m, 1H),  
2.78 (s, 3H), 2.75 (m, 1H), 2.31 (m,1H), 2.14 (m, 3H). Anal: Calc for C21H23ClN2O2RuS  
C: 50.04, H: 4.60, N: 5.56; Found C: 49.15, H: 4.48, N: 5.56. ESI-MS: Calc for 
C21H23ClN2O2RuS (M-Cl)+ 469.0 m/z, found 469.0 m/z. 
 
[(o-terp)Ru(TsEn)Cl] (14). Complex 14 was obtained following the method described above 
for complex 13 using ligand TsEnH (106.3 mg, 0.497 mmol). The crude product was 
recrystallised from methanol to give a brown powder. Yield: 51.2 mg (23.8 %). 1H NMR 
(250 MHz, acetone-d6): δH 7.76 (d, 2H, J = 7.6 Hz), 7.22-7.60 (m, 12H), 6.33  
(t, 1H, J = 5.6 Hz), 6.08 (d, 1H, J = 5.9 Hz), 6.05 (t, 1H, J = 5.9 Hz), 5.85 (t, 1H, J = 5.5 Hz), 
5.15 (s, 1H), 3.31 (s, 1H), 2.98 (m, 1H), 2.70 (s, 3H), 2.47 (s, 3H). Anal: Calc for 
C27H27ClN2O2RuS C: 55.90, H: 4.69, N: 4.83; Found C: 55.41, H: 4.77, N: 4.52. ESI-MS: 
calc. for C27H27ClN2O2RuS (M-Cl)+ 545.0 m/z, found 545.0 m/z. 
 
[(o-terp)Ru(TfEn)Cl] (15). Complex 15 was obtained following the method described above 
for complex 13 using ligand TfEnH (100.2 mg, 0.374 mmol). The crude product was 
recrystallised from methanol to give a reddish-brown crystalline powder. Yield: 58.8 mg 
(24.9 %). 1H NMR (250 MHz, acetone-d6): δH 7.97 (d, 2H, J = 8.4 Hz), 7.70 (d, 2H,  
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J = 8.4 Hz), 7.27-7.57 (m, 10H), 6.32 (t, 1H, J = 5.7 Hz), 6.14 (t, 1H, J = 5.7 Hz), 6.04 (t, 1H, 
J = 5.7 Hz), 5.88 (t, 1H, J = 5.7 Hz), 5.22 (s, 1H), 3.28 (s, 1H), 3.08 (m, 1H), 2.75 (m, 1H), 
2.33 (m,1H), 2.14 (m, 1H), Anal: Calc for C27H24ClF3N2O2RuS C: 51.14, H: 3.82, N: 4.42; 
Found C: 50.85, H: 3.77, N: 4.38. ESI-MS: calc. for C27H24ClF3N2O2RuS (M-Cl)+ 599.0 m/z, 
found 599.0 m/z. 
 
[(p-cym)Ru(NbEn)Cl] (16). Complex 16 was obtained following the method described 
above for complex 1 using ligand NbEnH (89.0 mg, 0.363 mmol). The crude product was 
recrystallised from methanol to give an orange crystalline powder. Yield: 117.3 mg  
(58.59 %). 1H NMR (400 MHz, acetone-d6): δH 8.25 (d, 2H, J = 8.8 Hz), 8.02 (d, 2H,  
J = 8.8 Hz), 5.81 (d, 1H, J = 6.0 Hz), 5.65 (d, 1H, J = 6.0 Hz), 5.56 ((d, 1H, J = 6.0 Hz),  
5.51 (d, 1H, J = 6.0 Hz), 5.34 (s, 1H), 3.03 (m, 2H), 2.94 (septet, 1H, J = 7.0 Hz), 2.76 (m, 
1H), 1.35 (m, 6H, J1 = 7.0 Hz, J2 = 4.6 Hz). Anal: Calc for C18H24ClN3O4RuS C: 41.98, H: 
4.70, N: 8.16; Found C: 41.94, H: 4.64, N: 8.22. ESI-MS: Calc for C18H24ClN3O4RuS (M-
Cl)+ 480.0 m/z, found 480.0 m/z. 
3.2.3. X-ray crystallography 
Crystals of complexes 5 and 8 were obtained by Dr. Pieter Bruijnincx. 
X-ray crystallographic data for complexes 1, 2, 5, 6 • 1/3 MeOH, 7 and 8 were 
collected by Dr. Guy Clarkson from the Department of Chemistry at the University of 
Warwick. The structures were solved by direct methods using  SHELXS40 (TREF) with 
additional light atoms found by Fourier transform methods. Hydrogen atoms were added at 
calculated positions and refined using a riding model, except the hydrogens on the NH 
nitrogens which were located in a difference map. Anisotropic displacement parameters were 
used for all non-H atoms; H-atoms were given an isotropic displacement parameter equal to 
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1.2 (or 1.5 for methyl and NH H-atoms) times the equivalent isotropic displacement 
parameter of the atom to which they are attached. The data were processed by the modeling 
program Mercury 1.4.1. Details of the instrumentation are described in Chapter 2.  
3.2.4. Aqueous solution chemistry 
 
Hydrolysis of the Ru-Cl bond 
Solutions of complexes 1-3, 5, 8, 11, 13, 14 and 16 (1.4 mM, 10 % MeOD-d4/90 % 
D2O) were prepared and monitored by 1H NMR spectroscopy. 1H NMR spectra were 
recorded at 310 K over a period of 24 h on a Bruker AV III 600 spectrometer  
(1H = 600 MHz) using 5 mm diameter NMR tubes. All data processing was carried out using 
Topspin 2.1.  
Aqua adducts of complexes 1-3, 5, 8, 11, 13, 14 and 16 were prepared by treatment of a 
solution of the corresponding chlorido complex (10 % MeOD-d4/90 % D2O) with silver 
nitrate (1 mol equiv.) overnight and followed by filtration through Celite to remove the AgCl 
salt formed.   
pKa* of Ruthenium aqua complexes 
Changes in the chemical shifts of the arene protons of the aqua adducts for complexes 
1-3, 5, 8, 11, 13, and 16 with the pH* over a range from 2 to 12 were followed by 1H NMR 
spectroscopy. pH* values were measured at ambient temperature using a minilab IQ125 pH 
meter, pH sensor and referenced in KCl gel. The pH* were adjusted with KOD or DClO4 
solutions in D2O. 1H-NMR spectra were recorded at 298 K on a Bruker AV III 600 
spectrometer (1H = 600 MHz) using 5mm diameter tubes. The data were fitted to the 
Henderson–Hasselbalch equation using Origin 7.5.  
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3.2.5. Reduction of NAD+ by [(η6-arene)Ru(XEn)Cl] and sodium formate 
Complexes 1-12 and 16 were dissolved in D2O or MeOD-d4/D2O (5:1) (1.4 mM, 4 mL) 
in a glass vial. Solutions of sodium formate (35 mM, 4 mL) and NAD+ in D2O (2.8 mM,  
2 mL) were also prepared and incubated at 310 K. In a typical experiment, an aliquot of  
200 µL from each solution was added to a 5 mm NMR tube and the pH* adjusted to 7.2 ± 0.1 
bringing the total volume to approximately 0.635 mL (final concentrations were: Ru complex 
0.44 mM; NAD+ 0.88 mM; sodium formate 11.02 mM; molar ratio 1:2:25). 1H NMR spectra 
were recorded at 310 K every 162 s until the completion of the reaction. 
Experiments with complexes 13-15 were performed as described above, however the 
reduction of NAD+ was too fast to be able to follow by NMR and so the reactions were 
performed with 5 mol equiv. of NAD+ (final concentrations: Ru complex 0.44 mM; NAD+ 
2.20 mM; sodium formate 11.02 mM; molar ratio 1:5:25). 
3.2.6. Mechanistic studies 
 
Hydride formation using sodium formate 
Solutions of complexes 1-3 and 13-15 (1.4 mM) in MeOD-d4/D2O (5:1) were reacted 
with sodium formate (11.02 mM, 25 mol equiv. ) at pH* 7.2 ± 0.1. 1H NMR spectra were 
recorded at 310 K every 162 s for a period of 4 h. 
High resolution mass spectrometry (HR-MS) was performed on the freshly prepared 
samples obtained from reacting sodium formate (1000 mol equiv.) with complex 13 in order 
to verify the formation of the hydride adduct. 
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Rate-limiting step 
A kinetic isotopic effect (KIE) experiment was performed by reacting complex 3 with 
sodium deutero-formate (25 mol quiv.) as a deuteride source. The procedure for the kinetic 
experiment is described in section 3.2.5 
Dependence on NAD+ and formate concentrations 
A series of experiments were performed on complex 2 (1.4 mM) which was selected as 
a model catalyst. Following the same procedure described in section 3.2.5, the kinetics of the 
reaction was studied using different concentrations of NAD+ (1, 2, 3, 4 and 6 mol equiv.).  
A second series of experiments using different concentrations of sodium formate  
(2, 5, 10, 25, 50, 100, 200 and 1000 mol quiv.) was also performed. 1H NMR spectra were 
recorded at 310 K every 162 s until completion of the reaction in each case 
Transfer hydrogenation reaction with 1,4-NADH 
An aqueous solution of complex 2 (200 µL, 1.4 mM) was added to a NMR tube 
containing 1,4-NADH (400 µL, 1.4 mM) in D2O and the pH* adjusted to 7.2 ± 0.1. 1H NMR 
of the reaction mixture was recorded every 162 s for 12 hours at 310 K.  
pH dependence 
The optimum pH range for the catalytic process was studied in a series of experiments 
following the same procedure described in section 3.2.5. Each experiment was performed at a 
different pH* over a range from 6 to 10. The pH* of the reactions was adjusted using 
deuterated aqueous solutions of KOD and DClO4. 
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Methanol effect 
A series of six experiments with complex 2 and different methanol-d4/D2O ratios  
(0, 5, 10, 23.3, 50, 66.6 % v/v of MeOD-d4 in D2O) was performed in order to elucidate the 
effect of the mixed solvent on the turnover frequency (TOF) of the complexes. 
 
3.3. Results 
3.3.1. Synthesis and characterization 
Ru(II) complexes 1-16 were synthesised (Figure 3.2) using a similar procedure. 
Typically, triethylamine (4 - 6 mol quiv.) and the ligand (2 - 2.5 mol equiv.), were added to 
an alcoholic solution of the ruthenium dimer [(η6-arene)RuCl2]2 and the reaction mixture 
stirred under an N2 atmosphere, heating reflux or at ambient temperature. The details for 
individual reactions are described in the experimental section. All of the synthesised 
complexes where characterized by elemental analysis (CHN), mass spectrometry (ESI-MS) 
and 1H NMR spectroscopy. X-ray crystal structures for complexes 1, 2, 5, 6 • 1/3 MeOH, 7 
and 8 were obtained. 1H-NMR spectra were fully assigned although peaks corresponding to 
the CH2 of the chelating ethylenediamine backbone, expected between 2 and 3 ppm, were 
broad. 
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Table 3.1. Complexes studied in this chapter 
 
Complex η6-arene (R) R1 
1 p-cym methyl (MsEn) 
2 p-cym p-toluene (TsEn) 
3 p-cym p-trifluoromethylbenzene (TfEn) 
4 hmb methyl (MsEn) 
5 hmb p-toluene (TsEn) 
6 hmb p-trifluoromethylbenzene (TfEn) 
7 bip methyl (MsEn) 
8 bip p-toluene (TsEn) 
9 bip p-trifluoromethylbenzene (TfEn) 
10 bn methyl (MsEn) 
11 bn p-toluene (TsEn) 
12 bn p-trifluoromethylbenzene (TfEn) 
13 o-terp methyl (MsEn) 
14 o-terp p-toluene (TsEn) 
15 o-terp p-trifluoromethylbenzene (TfEn) 
16 p-cym p-nitrobenzene (NbEn) 
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3.3.2. X-ray crystal structures 
Crystallographic data for complexes 1, 2, 5, 6 • 1/3 MeOH, 7 and 8  are listed in  
Table 3.2 and selected bond lengths and angles in Table 3.3 and Table 3.4 Their molecular 
structures are depicted in Figure 3.3. These complexes adopt the familiar pseudo-octahedral 
‘piano-stool’ geometry with the η6-bonded arene occupying one face of the complex. The 
chelating ligand appeared to be deprotonated and coordinated as a mono-anionic bidentate 
N,N′-ligand (amine and amide coordination). A chloride anion completes the coordination 
sphere around ruthenium. Especially interesting for further discussion are the distances Ru-Cl 
2.4444(11) Å for [(bip)Ru(TsEn)Cl] (8), 2.4331(6) Å for [(bip)Ru(MsEn)Cl] (7), 2.4425(4) Å 
for [(p-cym)Ru(MsEn)Cl] (1), 2.4576 (5) Å for [(p-cym)Ru(TsEn)Cl] (2), 2.4146(8) Å for 
[(hmb)Ru(TsEn)Cl] (5) and 2.4344(6), 2.4229(6), 2.4240(6) Å for [(hmb)Ru(TfEn)Cl]  
(6 • 1/3 MeOH). 
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Table 3.2. Crystallographic data for complexes 1, 2, 5, 6 · 1/3 MeOH, 7 and 8. 
  1 2 
Crystal character orange plate orange block 
Formula C13H23ClN2O2RuS C19H27ClN2O2RuS 
FW 407.91 484 
Temp (K) 100(2) 150(2) 
Crystal system Monoclinic triclinic 
Space group P2(1)/c P-1 
a (Å) 12.9751(2) 6.2342(4) 
b (Å) 11.28045(16) 10.7643(7) 
c (Å) 11.08448(19) 15.3024(9) 
α (º) 90 89.632(5) 
β (º) 105.2614(17) 85.868(5) 
γ (º) 90 74.757(5) 
U(A3) 1565.17(4) 988.11(11) 
λ (Å) 0.71073 0.71073 
Z 4 2 
Dcalc (mg/cm3) 1.731 1.627 
µ (mm-1) 1.308 1.05 
F (000) 832 496 
Crystal size (mm3) 0.30 x 0.30 x 0.02 0.23 x 0.20 x 0.14 
Reflections measured 8294 16141 
Indep reflection 3210 5329 
R1 [I>2σ(I)]a 0.0198 0.0283 
wR2 (all data)b 0.0506 0.0709 
CCDC no. 885977 N/a 
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  5 6 • 1/3 MeOH 
Crystal character orange needle orange block 
Formula C22H37ClN2O2RuS C21.33H29.33ClF3N2O2.33RuS 
FW 560.12 576.71 
Temp (K) 273(2) 100(2) 
Crystal system Monoclinic Triclinic 
Space group C2/c P-1 
a (Å) 19.0923(5) 13.5906(3) 
b (Å) 20.2170(5) 15.0052(4) 
c (Å) 13.6455(3) 20.2331(5) 
α (º) 90 94.602(2) 
β (º) 111.5680(10) 105.333(2) 
γ (º) 90 116.927(2) 
U(A3) 4898.2(2) 3450.54(14) 
λ (Å) 0.71073 0.71073 
Z 8 6 
Dcalc (mg/cm3) 1.519 1.665 
µ (mm-1) 0.863 0.936 
F (000) 2328 1764 
Crystal size (mm3) 0.34 x 0.04 x 0.02 0.60 x 0.10 x 0.08 
Reflections measured 30276 35851 
Indep reflection 5608 16507 
R1 [I>2σ(I)]a 0.0412 0.0313 
wR2 (all data)b 0.0922 0.0562 
CCDC no. 885979 885978 
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  7 8 
Crystal character orange rod orange needle 
Formula C15H19ClN2O2RuS C25H23ClN2O2RuS 
FW 427.9 503.99 
Temp (K) 296(2) 120(2) 
Crystal system trigonal Monoclinic 
Space group R3c P2(1)/c 
a (Å) 25.556(5) 13.6614(4) 
b (Å) 25.556(5) 6.16380(10) 
c (Å) 12.7090(2) 23.7143(7) 
α (º) 90 90 
β (º) 90 120.2320(10) 
γ (º) 120 90 
U(A3) 7188.1(3) 1951.59(9) 
λ (Å) 0.71073 0.71073 
Z 18 4 
Dcalc (mg/cm3) 1.779 1.715 
µ (mm-1) 1.287 1.068 
F (000) 3888 1024 
Crystal size (mm3) 0.4 x 0.1 x 0.5 0.15 x 0.03 x 0.01 
Reflections measured 14136 26659 
Indep reflection 3939 4453 
R1 [I>2σ(I)]a 0.0194 0.0485 
wR2 (all data)b 0.0352 0.0973 
CCDC no. 885976 885980 
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Figure 3.3. ORTEP diagrams for complexes 1, 2, 8, 7, 6 and 5. Ellipsoids are shown at the  
50 % probability level. All hydrogen atoms and solvent molecules have been omitted for 
clarity. 
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Figure 3.3. ORTEP diagrams for complexes 1, 2, 8, 7, 6 and 5. Ellipsoids are shown at the  
50 % probability level. All hydrogen atoms and solvent molecules have been omitted for 
clarity.  
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Table 3.3. Selected bond length (Å) angles (º) for complexes 1, 2, 5, 7 and 8.  
  1a 2b 5c 7a 8c 
Ru1-Na 2.1331(15) 2.1201 (18) 2.141(3) 2.1276(19) 2.122(3) 
Ru1-N- 2.1339(13) 2.1055 (18) 2.129(3) 2.1073(16) 2.096(4) 
Ru1-Cl1 2.4425(4) 2.4576 (5) 2.4146(8) 2.4331(6) 2.4444(11) 
Ru1-
arene(centroid) 
1.672 1.658 1.6742 1.672 1.6742 
N--Ru1-Na 78.74(6) 78.13 (7) 78.00(11) 77.80(7) 78.54(14) 
Na-Ru1-Cl1 87.91(4) 86.66 (5) 89.44(8) 82.57(6) 85.44(11) 
N--Ru1-Cl1 84.53(5) 84.61 (5) 85.63(8) 88.61(5) 82.97(11) 
a
 N- = N3, Na = N6, b N- = N9, Na = N12, c N- = N4, Na = N1 (see Figure 3.3 for labels) 
 
Single crystal X-ray diffraction studies for complex 6 • 1/3 MeOH showed three 
crystallographic independent structures in the asymmetric unit (Figure 3.4), 6a and 6a′ 
correspond to one enantiomer, 6a′ forms a H-bond to MeOH and 6b corresponding to the 
other enantiomer. 
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Figure 3.4. Molecular structures of the three crystallographically-independent molecules 
present in the unit cell of [(η6-hmb)Ru(TfEn)Cl] x 1/3 MeOH (6 • 1/3 MeOH). All C-H 
hydrogen atoms and a methanol solvent molecule have been omitted for clarity. 
Displacement ellipsoids are drawn at the 50 % probability level. Structure 6a and 6a′ are the 
same enantiomer but have a different bond length due to the hydrogen bond to the methanol 
molecule. Structure 6b correspond to the second enantiomer. 
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Table 3.4. Selected bond lengths (Å) angles (º) for the three crystallographically 
independent molecules of complex 6 • 1/3 MeOH. 
Bond length 6a 6a′ 6b 
Ru1-N104 2.1234(18) 2.116(2) 2.133(2) 
Ru1-N101 2.134(2) 2.151(2) 2.142(2) 
Ru1-Cl1 2.4229(6) 2.4344(6) 2.4240(6) 
Ru1-
arene(centroid) 
1.675 1.679 1.674 
Angle 6a 6a′ 6b 
N4-Ru1-N1 77.69(8) 77.58(8) 77.54(8) 
N3-Ru1-Cl1 87.49(5) 90.39(6) 89.43(5) 
N6-Ru1-Cl1 84.81(6) 84.74(6) 84.64(6) 
 
3.3.3. Aqueous solution chemistry 
Hydrolysis of complexes of the type [(η6-arene)M(N,N’)Cl] and [(η5-Cpx)M(N,N’)Cl] 
has been previously described and it is believed to precede further reactions in aqueous 
media. 21,41  In order to study the hydrolysis process, aquation of complexes 1-3, 5, 8, 11, 13, 
14 and 16 was followed by 1H NMR over a period of 24 h and no apparent changes on the 
spectra were observed. The peaks in the 1H NMR spectra were assigned to the aqua adducts 
of the complexes since the chemical shifts of the resonances correlate to those obtained when 
silver nitrate (1 mol equiv.) was reacted with the corresponding chlorido complex (to remove 
the Cl- ligand by formation of AgCl insoluble salt), leading to formation of the aqua complex. 
The rate of aquation was too fast to be determined by 1H NMR. 
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Figure 3.5. Dependence of the chemical shift of the protons in the arene rings of complexes 
1, 2, 3, 16, 8 and 11 on the pH*. The red line represent computer fits corresponding to the 
pKa* values in Table 3.5 (Henderson-Hasselbalch equation). 
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Changes in the 1H NMR chemical shifts of the arene protons from the aqua adduct of 
complexes 1-3, 5, 8, 11 and 16 were followed by changing the pH* over the range from 2 to 
12. The data were fitted to the Henderson–Hasselbalch equation. pKa* values for complexes 
1-3, 5, 8, 11 and 16 are shown in Table 3.5 (Figure 3.5). 
Table 3.5. pKa* values for the aqua adducts of complexes 1-3, 5, 8, 11 and 16 at 298 K. 
Compound pKa* 
[(p-cym)Ru(MsEn)Cl] (1) 9.86 ± 0.01 
[(p-cym)Ru(TsEn)Cl] (2) 9.78 ± 0.06 
[(p-cym)Ru(TfEn)Cl] (3) 9.71 ± 0.01 
[(hmb)Ru(TsEn)Cl] (5) NCa 
[(bip)Ru(TsEn)Cl] (8) 9.22 ± 0.04 
[(bn)Ru(TsEn)Cl] (11) 9.33 ± 0.05 
[(p-cym)Ru(NbEn)Cl] (16) 9.56 ± 0.04 
a
 pKa* could not be determined. 
3.3.4. Kinetics of transfer hydrogenation reactions 
Catalytic transfer hydrogenation of nicotinamide adenine dinucleotide (NAD+) in 
aqueous media using complexes 1-12 and 16 as catalyst and formate as hydride source  
(25 mol equiv.) was studied by 1H NMR at 310 K and pH* 7.2  ± 0.1. In order to compare the 
catalytic activity of the complexes and due to the poor solubility of complexes 6-9, the 
experiments were also performed in the mixed solvent MeOD-d4/D2O (2:9 v/v).  
Molar ratios of NAD+ and NADH were determined by integrating the signals 
corresponding to H of NAD+ (9.33 ppm) and H of 1, 4-NADH (6.96 ppm) (Scheme 3.1). The 
turnover numbers (TON) for the reactions were determined as described in the experimental 
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section. An important increase on the catalytic activity due to the effect of methanol on the 
TON was discovered (vide infra).  
 
Scheme 3.1. Scheme of the reduction of NAD+ to 1,4-NADH in the presence of formate as 
an hydride source. 
The turnover frequencies (TOF, the increment of turnover number over time), showed a 
marked dependence of the catalytic activity on the arene (Table 3.6). Complexes of the type 
[(η6-arene)Ru(XEn)Cl], where X is Nb, Tf, Ts or Ms, are more active when the arene is 
benzene and activity decreases in the order bn > bip > p-cym > hmb. It was also evident from 
the turnover frequencies that catalytic activity depends on the XEn ligand. The complex with 
the chelated ligand containing the more electron-withdrawing sulfonamide substituent 
(NbEn) exhibited the highest activity while the complex with the least electron-withdrawing 
sulfonamide substituent (MsEn) was the least active (Table 3.6). [(bn)Ru(TfEn)Cl] (12) with 
a TOF of 10.4 ± 0.5 h-1 was the most active. 
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Table 3.6. Turnover frequencies for transfer hydrogenation reactions using catalysts 1-12 
and 16. 
 
Complex η
6
-arene 
(R) 
XEn ligand 
(R1) 
TOF (h-1) 
D2O/MeOD-d4a 
TOF (h-1) 
D2O 
Complex 1 p-cym MsEn 1.25 ± 0.03 1.11 ± 0.02 
Complex 2 p-cym TsEn 2.88 ± 0.06 1.58 ± 0.04 
Complex 3 p-cym TfEn 5.77 ± 0.27 3.06 ± 0.05 
Complex 4 hmb MsEn 0.15 ± 0.01 0.14 ± 0.01 
Complex 5 hmb TsEn 0.38 ± 0.01 0.34 ± 0.02 
Complex 6 hmb TfEn 1.47 ± 0.04 __b 
Complex 7 bip MsEn 3.04 ± 0.19 __b 
Complex 8 bip TsEn 4.28 ± 0.14 __b 
Complex 9 bip TfEn 7.45 ± 0.38 __b 
Complex 10 bn MsEn 4.09 ± 0.16 2.94 ± 0.16 
Complex 11 bn TsEn 6.76 ± 0.45 4.50 ± 0.12 
Complex 12 bn TfEn 10.39 ± 0.51 6.62 ± 0.16 
Complex 16 p-cym NbEn 9.63 ± 0.31 4.05 ± 0.11 
a
 23 % MeOD-d4/ 77 % D2O, b not soluble in D2O  
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Figure 3.6. 1H NMR spectra recorded during NAD+ reduction using complex 1  
[(p-cym)Ru(MsEn)Cl] as a catalyst, (ratio 1:2:25, Complex:NAD+:formate). The experiment 
was performed in D2O at pH* 7.2 ± 0.1 and temperature 310 K. Green = NAD+, Blue =  
1,4-NADH and Red = 1,6-NADH. 
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The reaction was regioselective giving 1,4-NADH in 93% yield when complex 4 was 
used. A similar regioselectivity was achieved with complexes containing hexamethylbenzene 
(5 and 6). Use of the p-cymene complexes 1, 2, 3 and 16 as catalysts also produced  
1,6-NADH (up to 18 %) with complex [(p-cym)Ru(NbEn)Cl] (16) giving the lower 
regioselectivity from the three p-cymene complexes (17.5 % of 1,6-NADH formed). Finally 
complexes 10, 11 and 12 containing benzene as arene, gave 23 to 25 % of 1,6-NADH. 
Transfer hydrogenation reactions with complexes containing ortho-terphenyl 
Catalytic transfer hydrogenation to nicotinamide adenine dinucleotide (NAD+) in 
MeOD-d4/D2O (2:9 v/v) using complexes 13-15 as catalyst and formate as a hydride source 
(ratio 5:1:25 mol equiv, NAD+:complex:formate) was studied by 1H NMR at 310 K and pH* 
7.2 ± 0.1. During the reaction, formation of a brown precipitate was observed. As a 
consequence, the TON of these complexes could not be determined since the concentration of 
the ruthenium catalyst in solution was unknown. 
 
Completion of the catalytic reaction was achieved within the first 10 min of using any 
of the complexes (13-15). When comparing the reaction times of the complexes 13-15 with 
complex 12 [(bn)Ru(TfEn)Cl], which shows higher catalytic activity amongst those 
previously described (19 min for completion), a significant improvement can be observed. 
Furthermore the reaction using complexes 13-15 were performed with 2.5 x times higher 
concentration of NAD+ compared to the experiments using complex 12. 
In order to determine whether the precipitation of the complex could lead to quenching 
of the catalytic process, experiments with 100 mol equiv. of NAD+ (46.6 mM) were 
performed. 1H NMR recorded every 162 s at 310 K for 5 h 48 min showed a 88.5 % 
conversion from NAD+ to NADH of which 20 % was 1,6-NADH.  
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3.3.5. Mechanistic studies 
The rate-limiting step of the catalytic cycle in the NAD+ reduction was investigated by 
studying the reaction of complex 3 ([(p-cym)Ru(TfEn)Cl]) with deutero-formate  
(25 mol quiv.) as a deuteride source. The turnover frequency (TOF = 1.26 ± 0.02 h-1) was  
2.4 times slower than that obtained using formate as the hydride source (TOF = 3.06 h-1). 
The dependence of the rate of catalytic activity on the concentrations of NAD+ and 
formate was determined using complex 2 ([(p-cym)Ru(TsEn)Cl]) as a model system. 
Accordingly, five experiments were performed with complex 2, sodium formate and NAD+ 
with ratio of 1:25:x, respectively, where x = 1, 2, 3, 4 or 6 mol equiv., and 1H NMR spectra 
were recorded every 2 min until 100 % conversion was achieved. The analysis of the 
experiments gave an unchanged turnover frequency (1.58 h-1). 
A second series of experiments was performed in order to investigate the dependence of 
the reaction rate on the formate concentration. Experiments with complex 2, sodium formate 
and NAD+ in the ratio 1:x:2, respectively, where x = 2, 5, 10, 25, 50, 100 or 200 mol equiv. 
of formate were performed. The plot of the data obtained shows a strong dependence of the 
turnover frequency on formate concentration (Figure 3.7). 
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Figure 3.7. Plot of the turnover number against time for the reduction of NAD+ by complex 2 
using formate as a hydride source (ratio 2:1:x, x=2, 5, 10, 25, 50, 100 or 200 mol equiv., 
respectively. pH* 7.4, temperature 310 K, solvent D2O). Time is referenced to the mixing 
time. 
 
Figure 3.8. Plot of the TOF against the formate concentration, for the reduction of NAD+ in 
the presence of different formate concentrations, catalysed by complex 2. 
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A typical Michaelis-Menten kinetic behaviour is apparent from a plot of turnover 
frequency versus formate concentration (Figure 3.8).34 Thus, from the double-reciprocal plot 
(Figure 3.9), the Michaelis constant (KM = 42.1 mM) and the maximum turnover frequency 
(TOFmax = 6.9 h-1) were calculated. 
 
Figure 3.9. A plot of the reciprocal of the TOF against formate concentration, for the 
reduction of NAD+ in the presence of different mol equiv. of formate, catalysed by complex 
2. For a reaction following Michaelis-type kinetics, TOF = TOFmax [S]/(KM+[S]), where 
TOFmax is the turnover frequency at infinite substrate (formate) concentration, [S] is the 
substrate concentration, and KM is the Michaelis constant. Hence,  
TOF-1= (KM/TOFmax)(1/[S])+(1/TOFmax) and KM (42.14 mM) and TOFmax (6.93 h-1) can be 
obtained from the gradient and y intercept, respectively, of the double-reciprocal plot. 
In order to explore the possibility of hydride transfer from 1,4-NADH to ruthenium(II) 
arene complexes containing XEn chelating ligands (X = Ts,Tf, Ms, Nb) an experiment with 
complex 2 and 1,4-NADH (ratio 1:2) in D2O and pH* 7.2 ± 0.1 was performed. 1H NMR 
spectra of the reaction mixture were recorded every 162 s for 12 hours at 310 K. Neither the 
formation of hydride adducts nor NAD+ was observed.  
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The pH* dependence of the catalytic reaction (from pH* 6 to 10) was also investigated 
via a series of experiments using complex 2, sodium formate and NAD+ (ratio 1:25:2, 
respectively) in D2O. A strong dependence on pH* was observed. The highest TOF (1.58 h-1) 
was achieved at pH* 7.2, followed by a decrease in the activity when the pH* increased 
(Figure 3.10).  
 
Figure 3.10. Dependence of turnover frequency on the pH* for the reduction of NAD+ by 
complex 2 using formate as a hydride source (mol ratio 2:1:25, respectively, 310 K in D2O). 
Maximum turnover frequency is achieved at pH 7.2 ± 0.1. 
The catalytic activity of all the complexes was initially studied in D2O, but complexes 
6-9 and 13-15 could not be dissolved at the same concentration (1.4 mM). For this reason, 
experiments were also performed in a D2O/methanol (9:2 v/v) mixture in order to increase the 
solubility. The addition of methanol in the reaction mixture resulted in higher turnover 
frequencies (Table 3.6) for catalysts 1-5 and 10-12 compared to the reaction in pure D2O. In 
order to study the effect of methanol on the reaction, five experiments with catalyst 2, sodium 
formate and NAD+ (ratio 1:25:2, pH* 7.2 ± 0.1, 310 K) were performed in D2O/MeOD-d4  
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(5, 10, 23.3, 50 or 66% v/v in MeOD-d4). Increased percentage of methanol resulted in faster 
reaction rate and therefore higher turnover frequency (Figure 3.11). 
 
Figure 3.11. Dependence of the turnover number on time for the reduction of NAD+ by 
complex 2 in various D2O/MeOD-d4 mixtures (5, 10, 23, 50 or 66 % v/v of MeOD-d4).  
Hydride formation using sodium formate 
Solutions of complexes 1-3 and 12 (0.4 mM in D2O) and 13-15 (0.44 mM in  
MeOD-d4/D2O 2:9 v/v) were added to an aqueous solution of sodium formate (4.4 mM) and 
pH* adjusted to 7.4 ± 0.1. 1H NMR experiments were recorded every 162 s at 310 K for a 
period of 4 h. No signals corresponding to hydride adducts were detected for complex 1-3 
and 15 in the high field region (0 to -20 ppm). However peaks assigned to the hydride adduct 
for complexes 12-14 were identified at -7.0 ppm, -5.5 ppm and -5.6 ppm, respectively. 
(Figure 3.12). Interestingly, complex 12 decomposes releasing benzene (Figure 3.13). 
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Figure 3.12. 1H NMR spectra of the reaction between complex 13 and sodium formate 
(ratio 1:1000). The experiment was performed in D2O, pH* 7.2 and temperature 310 K. 
Green arene, blue phenyl groups of the arene and red hydride. 
 
Figure 3.13. 1H NMR spectra of the reaction between complex 12 and sodium formate 
(ratio 1:1000). The experiment was performed in D2O, pH* 7.2 and temperature 310 K. red 
hydride. 
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In order to confirm the formation of the ruthenium hydride species HR-mass spectrum 
was recorded (Table 3.7). A peak with a mass-to-charge ratio of 493.0499 was detected and 
assigned as hydride adduct. Interestingly, a peak identified as a formate adduct of complex 13 
with a mass-to-charge ratio of 537.0392 was also detected (Figure 3.14, Figure 3.15).  
Table 3.7. All relevant mass-to-charge ratios from the high resolution-mass spectrum of the 
reaction between sodium formate and complex [(o-terp)Ru(MsEn)Cl] (13) at pH 7.3 ± 0.1. 
Proposed chemical 
formula 
 Calculated 
(m/z) 
Found 
(m/z) 
C21H23N2O2RuS+ [M-Cl]+ 469.0518 469.0533 
C21H22N2NaO2RuS+ [M-HCl+Na]+ 491.0343 491.0377 
C21H24N2NaO2RuS+ [M(H)+Na]+ 493.0499 493.0456 
C22H24N2NaO4RuS+ [M(HCOO)+Na]+ 537.0392 537.0396 
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Figure 3.14. High resolution mass spectrum of the reaction mixture between complex 13 
and formate. (A) Calculated spectra (red) hydride adduct of complex 13, (blue) complex  
13 - HCl, (B) experimental spectrum.  
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Figure 3.15. High resolution mass spectrum of the reaction mixture between complex 13 
and formate. (A) Calculated spectrum for the formate adduct of complex 13, (B) 
experimental spectrum. 
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DFT Calculations 
Computational experiments were carried out by Prof. Rob Deeth at university of 
Warwick. 
A DFT mechanistic study was performed with the aqua complex 
[(bn)Ru(MsEn)(H2O)]+ (10) in the presence of formate. The energy of the formate complex 
plus water was found to be lower than the energy of the aqua complex plus formate, so the 
formate complex was taken as the reference point for determining barriers to CO2 
elimination. 
 
Figure 3.16. Calculated DFT structures for the formate adduct of {(bn)Ru(MsEn)}+ (from 
10). (A) Intermediate complex with formate bound via a single oxygen with an H-bond 
between the second formate oxygen and NH from the chelating ligand. (B) Transition state 
for the rotation of formate which orients the hydrogen towards the metal centre.  
(C) Intermediate showing the hydrogen now oriented towards the Ru centre, and finally  
(D) the transition state for the formation of the ruthenium-hydride bond and CO2 elimination. 
Chapter 3 
127 
 
The formate coordinates via a single oxygen with the carbonyl moiety making an H-bond 
with an NH proton (Figure 3.16). It then rotates via a low-energy transition state to an 
intermediate with the formate H now oriented towards the Ru centre. From here, the Ru-H 
bond is formed via a higher energy transition state (TS). 
The energies of this process and for CO2 elimination for the formate adducts of the 
complexes {(bn)Ru(MsEn)}+ (10), {(bn)Ru(TsEn)}+ (11) and {(bn)Ru(TfEn)}+ (12) and for 
the formate adduct of the hmb complex {(hmb)Ru(MsEn)}+ (4) are shown in Table 3.8 
Table 3.8. Computed DFT(B3LYP) free energy barriers ∆G≠ (kcal mol-1) leading to CO2 
elimination. 
Complex ∆G≠ Twist ∆G≠ CO2 elim 
10 5.9 13.7 
11 4.2 12.9 
12 4.2 12.6 
4 - 18.1 
 
 
3.4. Discussion 
3.4.1. Structures of the complexes 
The ligands NbEnH, TsEnH, TfEnH and MsEnH (Figure 3.17) were selected in order 
to compare the catalytic activity properties of the complexes of the type  
[(η6-arene)Ru(XEn)Cl], where X = Ms, Ts, Tf or Nb, with an increasing  
electron-withdrawing power of the sulfonamide.  
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Figure 3.17. Structures of the N,N′ ligands used for this chapter 
Single crystals of complexes [(p-cym)Ru(MsEn)Cl] (1), [(p-cym)Ru(TsEn)Cl] (2), 
[(hmb)Ru(TsEn)Cl] (5), [(bip)Ru(MsEn)Cl] (7) and [(bip)Ru(TsEn)Cl] (8) were obtained and 
analyzed by X-ray diffraction. The crystal structure of complex [(hmb)Ru(TfEn)Cl] x 1/3 
MeOH (6 • 1/3 MeOH) shows an asymmetric unit containing three crystallographically-
independent molecules. One of the ruthenium molecules (6a′) establishes an intramolecular 
hydrogen bond with a methanol molecule. The other two molecules (6a and 6b) are 
enantiomers with similar bond lengths and angles (Table 3.4) which are slightly different than 
those of complex 6a. 
Comparison with the analogous ethylenediamine complex,42,43 shows no significant 
difference between the Ru-NH2 distance and the distance Ru-N- despite the higher electron 
density on the imino nitrogen (2.130 (3) Å for [(p-cym)Ru(en)Cl]), 2.1331 (15) Å for  
[(p-cym)Ru(MsEn)Cl] 1), (2.11 Å for [(bip)Ru(en)Cl], 2.096 (4) Å and 2.1073 (16) Å for 
complexes 8 and 7, respectively). However, comparing with the complexes containing hmb, 
the distance Ru-N- is slightly shorter (ca. 0.02 - 0.03 Å). The Ru-N- distance of  
[(p-cym)Ru(en)Cl] (2.130 (3) Å) compared with that from complex 2 [(p-cym)Ru(Ts)Cl]  
( 2.1055 (18) Å) is also slightly shorter. The respective Ru-Cl bond lengths in complexes 1, 2, 
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5, 6, 7 and 8 (2.4146 (8) - 2.4576 (5) Å) are within the range displayed by other compounds 
of the type [(η6-arene)Ru(en)Cl]+ (2.41 – 2.44 Å).42  
When comparing the complexes with different η6-arene but the same N,N′ chelating 
ligand (1 and 7/ 2, 5 and 8), the Ru-N- and the Ru-Cl distances both differ by ca. 0.01-0.03 
and 0.01-0.04 Å, respectively. Similarly, comparing the influence of the chelating ligand 
when the same arene is used, an increase in the electron-withdrawing effect of the R1 group 
(Tf > Ts > Ms) appears to increase the Ru-Cl bond length, whereas the Ru-N- bond length 
decreases (Table 3.3).  
3.4.2. Hydrolysis of the chlorido complexes and acidity of the aqua 
complexes 
Aquation of the complexes 1-3, 5, 8, 11, 13 and 16 in D2O was confirmed by 
comparing the 1H NMR spectra of the D2O solution of the complexes and the solution 
obtained after removal of the chloride by reaction with silver ions (AgNO3). Hydrolysis of 
the complexes appeared to be rapid under biologically relevant conditions (310 K, pH* 7.2), 
since equilibrium was reached by the time the first 1H-NMR spectrum was recorded  
(< 6 min). Consequently the turnover frequency for the transfer hydrogenation to form NAD+ 
does not depend on whether the chlorido or aqua adduct are used. 
A 1H-NMR pH* titration of complexes 1-3, 5, 8, 11 and 16 gave a pKa* values between 
9.22 and 11 for the deprotonation of the water from the aqua adducts (Table 3.5). These 
results suggest that those complexes would exist mainly as aqua adducts over the pH* range 
used during the experiment (pH* 7.2 ± 0.1). 
Complexes with higher electron density on the metal centre display higher pKa*. 
Therefore the more electron donating arenes will produce an increase in the basicity of the 
aqua adducts, hence an increase in the pKa* value compared to the more electron 
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withdrawing arenes (pKa* p-cym > bip > bn). Similarly more electron withdrawing N,N′ 
chelating ligands will result in a lower pKa* value (pKa* NbEn < TfEn < TsEn < MsEn). 
3.4.3. Mechanism of the catalytic reduction of NAD+ 
Use of deuterated-formate and complex 3 gave a turnover frequency 2.4 times smaller 
than that with protonated formate. Since the formation rate of the hydride (β-elimination) 
with the heavier atom is lower, the difference in the turnover frequency between the two 
reactions suggests that the rate-limiting step of the reaction is the hydride transfer. However 
whether the limiting step is the transfer from formate to the ruthenium complex or from the 
ruthenium hydride to the NAD+ is not clear. Previously reported studies with similar 
complexes suggest that hydride formation will be the rate-limiting step.44 Furthermore, the 
high reactivity of the hydride ruthenium species suggests the transfer from the ruthenium to 
the NAD+ will be fast. 
To determine the factors that influence the reaction rate, a series of experiments using 
complex 2 were performed varying the concentration of the different reactants. When the 
NAD+ concentration was changed, no significant alterations in the rate were observed, 
implying that the reaction rate does not depend on the NAD+ concentration. However the 
reaction rate decreased with lower concentrations of the hydride source (sodium formate) 
suggesting that formate is involved in the reaction rate (Figure 3.7).  
The plot of turnover frequency against formate concentration showed Michaelis-
Menten behaviour (Figure 3.8). The maximum turnover frequency for complex 2  
(TOFmax = 6.9 h-1) is about 4 x times higher than that previously determined for the 
ethylenediamine complex [(hmb)Ru(en)Cl]+ (TOFmax=1.46 h-1),34 so achieving the desired 
increased efficiency in the reaction. 
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The possibility of employing 1,4-NADH as the hydride source as reported previously, 
was also attempted. 45 However experiments with complex 2 and 1,4-NADH did not show 
formation of the hydride adduct or NAD+. The results obtained imply that hydride transfer 
between NAD+ and the complexes is not a reversible process. 
Based on the data obtained, it can be proposed a plausible catalytic cycle for the 
reduction of NAD+ via transfer hydrogenation with formate as a hydride source  
(Scheme 3.2). This cycle is comparable with that proposed by Fish et al. 36 for the reduction 
of NAD+ via transfer hydrogenation using [(Cp*)Rh(bipy)H2O]2+ as the catalyst and formate 
as hydride source. In the first step, the pre-catalyst chlorido complex is converted to the aqua 
adduct. The reaction of the aqua complex with HCOO- generates the formate adduct  
[(η6-arene)Ru(N,N′)(OHCO)]. The formate coordinates via a single oxygen with the carbonyl 
moiety making an H-bond with an NH proton. It then rotates to form an intermediate with the 
formate H now oriented towards the Ru centre. From here, the formate adduct undergoes  
β-elimination to give the hydride adduct, [(η6-arene)Ru(N,N′)(H)], and CO2.36 Transfer of 
hydride to produce 1,4-NADH regenerates the aqua adduct. 
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Scheme 3.2. Proposed mechanism for the reduction of NAD+ to 1,4-NADH via transfer 
hydrogenation using formate as the hydride source. R1 = Ms (CH3), Ts (-(C6H4)CH3) or  
Tf (-(C6H4)CF3), R = p-cym, hmb, bip or bn.  
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The low Michaelis constant for complex 2 (KM = 42.1 mM) indicates a stronger affinity 
for formate compared to complexes [(hmb)Ru(en)Cl]+ (KM = 58 mM) 34 and 
[(Cp*)Rh(bipy)H2O]2+ (KM 140 mM) 43, while the maximum turnover frequency  
(TOFmax = 6.9 h-1) of the reaction indicated an increase in the catalytic activity compared to 
[(hmb)Ru(en)Cl]+ (TOFmax=1.46 h-1)34 but lower catalytic activity compared with the 
complex [(Cp*)Rh(bipy)H2O]2+ (TOF= 77.5 h-1 concentration of formate 0.5 M). 43  
The reaction rate is dependent on the pH (Figure 3.10). The optimum pH* for the 
reaction is 7.2 ± 0.1. At higher pH*, OH- inhibits the reaction, and also at pH* 10 or higher, 
the complex decomposes. At lower pH* the protonation of the amido ligand and of the 
formate decreases the reaction rate (see section 1.3.1.).46 
Catalytic experiments with complexes 1-12 and 16 were performed in both D2O and in 
D2O/methanol (9:2). The addition of methanol resulted in an increase in the turnover 
frequency (Figure 3.11). Such an increase cannot be attributed to a simple solvent effect, but 
indicates the participation of methanol in the rate-limiting step of the reaction. The role of 
methanol in the transfer hydrogenation reactions has not been determined. However it has 
been shown that polar solvents, acting as hydrogen donors, form hydrogen bonds and interact 
with the substrate or formate, stabilizing the transition intermediates.46,47 
The energies of the intermediates calculated by DFT correlate well with other 
experimental data, and predict increasing barriers (and hence slower reactions) for bn 
complexes in the order TfEn (12) < TsEn (11) < MsEn (10), although it should be noted that 
the difference between barriers is small (ca 1.1 kcal mol-1). For MsEn, the barrier for 
{(hmb)Ru(MsEn)}+ (4) is substantially larger than for {(bn)Ru(MsEn)}+ (10), which also 
agrees with experiment. Overall, the computational protocol appears to provide a very good 
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description of these systems. DFT thus could provide, in the future, a useful tool to help the  
a priori design of new complexes with desired properties. 
3.4.4. Hydride adduct formation 
1H NMR experiments of the reaction between formate and complex 13 and 14 show a 
new set of signals that was assigned to the hydride adduct. The hydride resonance for 
complex 13-14 were identified at -5.5 ppm and -5.6 ppm respectively. (Figure 3.12) Similar 
values have been reported for other Ru-H complexes (from -5 to -20 ppm).45,48-50 
The hydride adduct for the complexes 1-3 and 15 could not be detected by 1H NMR 
probably due to the high reactivity of the species. However high steric hindrance of the  
o-terphenyl complexes (13-15) complexes stabilized the hydride adduct. The increase on the 
hydride stability does not translate to a decrease in the reaction rate since the rate-limiting 
step has been determined to be the hydride formation and not hydride transfer to NAD+.51 
HR-MS spectrum of the reaction mixture containing complex 13 and sodium formate in 
a ratio 1:1000 shows a peak at 493.04 m/z which was identified as the hydride adduct of the 
complex plus sodium (C21H24N2NaO2RuS+). Interestingly, a peak at 537.04 m/z was also be 
identified suggesting the existence of a stable formate adduct (Table 3.7). However, the 
lifetime for both species is very short and none of the adducts could be isolated.  
The formate adduct was generated by the direct binding of the reactive Ru(II) centre in 
the aqua species to the negatively-charged oxygen from the formate. Formation of stable 
formate adducts and other carboxylate adducts has been previously reported for similar 
complexes.45 
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3.4.5. Kinetics of transfer hydrogenation reactions  
The catalytic reduction of NAD+ under biologically relevant conditions (310 K, pH* 
7.2) using complexes 1-16 as catalysts and formate as a hydride source showed a general 
trend in which the more electron-withdrawing sulfonamides on the chelating ligand give 
higher catalytic activity (table 3.6). Accordingly, complexes containing NbEn  
(N-(2-aminoethyl)-4-nitrobenzensulfonamide) as the chelating ligand show the highest 
activity followed by complexes using TfEn, which are more active than those with TsEn 
ligand, and, in turn, all of them are more active than the complexes containing the MsEn 
ligand. Such a trend has been previously reported for the catalytic transfer hydrogenation to 
aldehydes52 and quinoxalines.22  
The nature of the arene had a dramatic effect on the reaction rate. The more electron 
withdrawing arene ligands such as benzene or biphenyl accept electron density from the 
central Ru(II) through back π-bonding. Consequently the lower electron density on the Ru(II) 
centre for complexes [(bn)Ru(N,N′)Cl] (10, 11 and 12) compared with complexes 
[(hmb)Ru(N,N′)Cl] (4, 5 and 6) stabilizes the coordination of the negatively-charged formate 
to Ru making hydride transfer from formate difficult.53,54 However, the experimental data 
show higher catalytic activity when the arene is more electron deficient (Table 3.6), 
[(bn)Ru(N,N′))Cl] being the more active complexes while [(hmb)Ru(N,N′)Cl] are the less 
active. This unexpected trend may be due to steric hindrance since the more sterically 
hindered arene (hmb) shows the lower activity while the less sterically hindered arene (bn) 
shows higher activity. 
Several other Ru(II), Rh(III) and Ir(III) complexes have previously been reported to 
catalyze the regioselective reduction of NAD+ to 1,4-NADH using formate as a hydride 
source.55,56 The complexes studied in the present work show comparable TOFs  
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(ca. 0.2 - 7 h-1) to reported [(η6-arene)Ru(N,N′)Cl] complexes (ca. 0.0056-10 h-1), although 
the turnover frequencies are much lower than those obtained using Rh(III) or Ir(III) 
complexes.55,56  
 
3.5. Conclusions 
In this chapter a series of water-soluble Ru(II) half-sandwich complexes of the type 
[(η6-arene)Ru(N,N′)(Cl)] where N,N′ are mono-sulfonamide chelating ligands derived from 
ethylenediamine have been studied. The X-ray crystal structures of complexes 1, 2 and 5-9 
showed the familiar piano stool geometry common to all [(η6-arene)Ru(X,Y)(L)] compounds.  
1H NMR studies show fast hydrolysis of the complexes in water to form the aqua 
adducts. The pKa* values of the aqua adducts of the complexes were higher than 9 for all the 
complexes, which suggests that the aqua adduct predominates over the hydroxido adduct at 
physiological pH. pKa* studies of the complexes show the expected trend where complexes 
with lower electron density on the metal centre show lower pKa* values.  
The ability of the complexes to act as catalysts for the regioselective transfer 
hydrogenation of NAD+ to form 1,4-NADH was studied. The catalytic activity decreases in 
the order NbEn > TfEn > TsEn > MsEn showing that more electron-withdrawing 
sulfonamides increase the activity. The nature of the arene significantly influences the 
catalytic activity. Benzene complexes are the most active compounds while the activity 
decreases in the order biphenyl > p-cymene > hexamethylbenzene. Complex 
[(bn)Ru(TfEn)Cl] (12) was the most active with a TOF of 10.4 h-1 when in MeOD-d4/D2O 
5:1 v/v.  
Chapter 3 
137 
 
The formation of a hydride adduct by complexes (13) [(o-terp)Ru(MsEn)(Cl)] and  
(14) [(o-terp)Ru(TsEn)(Cl)] was demonstrated by 1H NMR spectroscopy and HR-MS, as well 
as formation of a stable formate adduct. Mechanistic studies on complex (2)  
[(p-cym)Ru(TsEn)(Cl)] showed a dependence of the reaction rate on the formate 
concentration but not on NAD+ concentration. The formation of the hydride complex was 
shown to be the rate-limiting step through deuterium isotope experiments. The optimum pH* 
for the reaction was found to be (7.2 ± 0.1) which is close to physiological pH. 
DFT calculations were performed for the coordination of formate, and subsequent CO2 
elimination to generate the hydride. The elimination of CO2 occurs via a two-step process 
with the coordinated formate first twisting to present its hydrogen towards the metal centre 
followed by β-elimination and Ru-H formation. The computed barriers for complexes using 
η
6
-benzene follow the order MsEn > TsEn > TfEn and, for the MsEn chelating system the 
barrier follows the order bn < hmb, both consistent with the observed rates.  
The series of compounds studied here showed improved catalytic activity by an order 
of magnitude higher compared to the ethylenediamine analogues, which could be significant 
if such catalytic reactions are to be used to modulate NADH levels in cells. 
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4. Performing transfer hydrogenation reactions in cancer 
cells 
 
4.1. Introduction 
During the last few years, an increasing number of publications have been focused on 
the use of metal-based drugs with catalytic activity.1, 2, 3 So far the applications of those 
catalytic drugs have been mainly focused on the regulation of ROS levels in cells, depletion 
or transformation of specific biomolecules, functional group transformations and in situ 
synthesis of active compounds. However, catalytic drugs are still a recent research area and 
many other applications are likely to be found with time. Some examples on this area are as 
follows. 
•  SOD mimics like the manganaese(II) Mn40403, can dismutate superoxide into O2 
and H2O2 with similar efficiency to the enzyme.4 This compound is currently undergoing 
clinical trials in co-administration with opioid Agent for treatment of pain in cancer patients 
(NCT00101621). 
• Complexes of the type of [(bip)Ru(2(p-N,N-dimethylaminophenylazo)pyridine)I] 
catalytically oxidise GSH to GSSG.5 
• Meggers et al. synthesised a series of Ru(II) complexes which are capable of 
catalysing the cleavage of allylcarbamates from protected imine molecules in biological 
systems. This provides a strategy for the in-cell activation of fluorophores.6  
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• Complex [Fe(5,10,15,20-tetraphenylporphyrin)Cl] has been shown to catalyse the 
reduction of azides to imines in cells.7 This method could be useful for the synthesis of amine 
chromophores using biologically inhered organic azides as a substrate. 
• Numerous Pd-catalyzed C-C bond formations reaction have also been shown to work 
in cells. 8, 9, 10 
In the field of transfer hydrogenation reactions with biological applications, the regeneration 
of NADH has been intensively studied. The aim of this process is to regenerate NADH as a 
substrate for enzymes which can be used for the  reduction of ketones in organic synthesis.11 
Currently, the most successful compound in this area is [(Cp*)Rh(bipy)Cl]+ synthesised by 
Stekhan et al. and intensively studied by Fish et al. 12-16 
More recently, other complexes capable of regenerating NADH have been reported. In 
2007 Süss-Fink et al. published the catalytic reduction of NAD+ using a series of Ru(II), 
Rh(III) and Ir(III) phenantroline-containing catalysts. The complex [(Cp*)Rh(phen)Cl]+ was 
capable of good conversions and turnover frequencies of up to twice that obtained previously 
with [(Cp*)Rh(bipy)Cl]+ 17 In 2011, Salmain et al. published a series of Rh(III) and Ru(II) 
complexes using dipyridyl amine ligands functionalised by maleimide. The complexes were 
not as active as the bipyridine containing analogue [(Cp*)Rh(bipy)Cl]+.18 The complex 
[(Cp*)Ir(4-(1H-pyrazol-1-yl-κN2)benzoic acid κC3)H2O)]2 SO4 synthesised by Fukuzumi  
et al. was also reported to be able to catalyse H2 oxidation while generating NADH in a 
neutral and slightly basic media.19  
Interestingly, the application of transfer hydrogenation reactions was not attempted  
in cellulo until 2005, when Sadler et al. published the regeneration of 1,4-NADH with Ru(II) 
complexes containing ethylenediamine or acetylacetonate as chelating ligands. However, the 
turnover frequencies were relatively low compared to the literature values.20 When treating 
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A549 lung cancer cells with the complex and sodium formate as a hydride source, no 
significant effect was observed. 20 
Sodium formate was selected as a hydride source for these type of experiments. Despite 
the fact that high doses of formate (10-20 mM in human blood plasma) have been shown to 
be toxic in humans and primates, clinical reports suggest that irreversible damage occurs only 
when concentration of formate in plasma is 7 mM or higher for at least 24 continuous hours. 
Therefore the tolerance of the body to large amounts of formate appears to be relatively high 
and it can be used as a co-drug.21, 22 
In Chapter 3, the synthesis of a series of Ru(II) complexes containing Noyori type 
ligands which can effectively reduce NAD+ to NADH at pH 7.2, 310 K and aqueous media, 
was described.23  
In this Chapter, the possibility to perform transfer hydrogenation reactions in cellulo, 
using the Ru(II) complexes described in Chapter 3 ([(η6-arene)Ru(XEn)Cl]) is investigated. 
The use of these complexes as anticancer agents, and the potentiation of the antiproliferative 
activity achieved due to the catalytic transfer hydrogenation using sodium formate as a 
hydride donor is also studied.  
 
4.2. Experimental 
The experiments in biology were carried out in collaboration with Isolda Romero-
Canelón (Warwick university) 
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4.2.1. Materials 
Ruthenium(II) complexes are shown in Figure 4.1, [(p-cym)Ru(MsEn)Cl] (1),  
[(p-cym)Ru(TsEn)Cl] (2), [(p-cym)Ru(TfEn)Cl] (3), [(p-cym)Ru(NbEn)Cl] (16),
 
[(hmb)Ru(MsEn)Cl] (4), [(hmb)Ru(TsEn)Cl] (5), [(hmb)Ru(TfEn)Cl] (6), 
[(bip)Ru(MsEn)Cl] (7), [(bip)Ru(TsEn)Cl] (8), [(bip)Ru(TfEn)Cl] (9), [(bn)Ru(MsEn)Cl] 
(10), [(bn)Ru(TsEn)Cl] (11), [(bn)Ru(TfEn)Cl] (12) [(o-terp)Ru(MsEn)Cl] (13),  
[(o-terp)Ru(TsEn)Cl] (14) and [(o-terp)Ru(TfEn)Cl] (15) were synthesised in Chapter 3. 
Ruthenium complex RM175 used for comparison was obtained following published 
procedures by Dr. Abraha Habtemarian.24 Ruthenium ICP-MS standard was obtained from 
Inorganic Ventures. RPMI-1640 medium, foetal bovine serum, L-glutamine, 
penicillin/streptomycin mixture, trypsin, trypsin/EDTA, phosphate buffered saline (PBS) 
were purchased from PAA Laboratories GmbH. Cisplatin (≥ 99.9%), trichloroacetic acid  
(≥ 99 %), sulforhodamine B (75%), sodium phosphate monobasic monohydrate (≥ 99 %), 
sodium phosphate dibasic heptahydrate (≥ 99 %), acetic acid (≥ 99%) and pyocyanine were 
obtained from Sigma Aldrich. 
 
Figure 4.1. Structures of the complexes studied in this chapter 
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4.2.2. Cell maintenance  
A2780 human ovarian carcinoma cells were obtained from the European Collection of 
Cell Cultures (ECACC) and their maintenance procedure has been described in Chapter 2. 
4.2.3. In vitro growth inhibition assay 
The antiproliferative activity of the complexes 1-16 and RM175 was determined in 
A2780 ovarian cancer cells. The experimental details are described in Chapter 2. The SRB 
assay was used to determine cell viability. IC50 values were determined as duplicates of 
triplicates in two independent set of experiments and their standard deviations were 
calculated. 
4.2.4. Cell viability modulation experiments  
Cell viability assays with complexes 1-3, 13-16 and RM175 in combination with 
sodium formate and sodium acetate, were carried out in A2780 ovarian cancer cells. These 
experiments were carried out as described in Chapter 2 with the following modifications: a 
fixed concentration of each ruthenium complex equal to 1/3 x IC50 was used with  
co-administration of three different concentrations of sodium formate (0.5, 1 and 2 mM). In 
order to prepare the stock solution of the drug, the solid complex was dissolved first in 5 % 
DMSO to be then diluted in a 1:1 mixture of 0.9 % saline:cell culture medium. This stock 
was further diluted using RPMI-1640 until working concentrations were achieved. 
Separately, stock solutions of sodium formate were prepared in saline. Both solutions were 
added to each well independently, but within 5 min of each other. 
Cell viability assays with Complex 2 in combination with sodium acetate were carried 
out as described above. The concentrations of sodium acetate were 0.5, 1 and 2 mM. 
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4.2.5. IC50 modulation experiments of complex 2 by co-administration 
with sodium formate  
Antiproliferative activity of complex 2 co-administered with 2 mM of sodium formate 
was carried out using A2780 ovarian cancer cells. This experiment was performed as 
described in Chapter 2, using a fixed concentration of formate and variable concentrations of 
the metal complex. The SRB assay was used to determine cell viability. IC50 values were 
determined as duplicates of triplicates in two independent set of experiments and their 
standard deviations were calculated. 
4.2.6. Metal accumulation in cancer cells 
On a 6-well plate, 1.5 x 106 cells per well were seeded. After 24 h of pre-incubation 
time in drug free medium, the cells were treated with a fixed concentration of complexes 1-3 
and 12-16 (final concentrations equal to 1/3 x IC50) for 24 h. After this time, cells were 
washed with trypsin-EDTA, counted, and the cell pellets collected. Each pellet was digested 
overnight in concentrated nitric acid (73%) at 353 K; the resulting solutions were diluted 
using double-distilled water to a final concentration of 5 % HNO3, and the amount of Ru 
accumulated by the cells was determined by ICP-MS. These experiments did not include any 
cell recovery time in drug-free media. The experiments were carried out in duplicates of 
triplicates. 
This experiment was also carried out using complex 2, co-administered with 2 mM of 
sodium formate.  
4.2.7. Hydrophobicity 
The relative hydrophobicity of the Ru(II) compound was measured by HPLC. The 
retention times were obtained using a HP 1200 Series HPLC System (Agilent). The column 
used was an Agilent ZORBAX Eclipse Plus C-18 (250 x 4.6 mm, 5 µm pore size). or  
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t = 0 – 10 % B, t = 25 – 70 % B, t = 30 – 70 % B, t = 31 – 10 % B and t = 36 – 10 % B over a 
36 min. Flow rate was 1 mL min-1. A wavelength of detection of 254 nm with the reference 
wavelength at either 360 nm was used. Samples were prepared in ddw or a mixture methanol 
(5 %, HPLC grade)/ddw. Sample injection 50 µL. 
4.2.8. NAD/NADH determination  
Experiments to determine the ratio of NAD+/NADH of A2780 ovarian cancer cells 
exposed to complex 2 were carried out using the NAD+/NADH assay kit from Abcam 
(ab65348) according to the manufacturer’s instructions. A2780 cells were seeded in 6 well 
plates at a density of 1.0 x 106 cells/well. After 24 h of pre-incubation time, cells were treated 
with a fixed concentration of complex 2, equal to its IC50, and in combination with four 
different concentrations of sodium formate (0, 0.5, 1 and 2 mM). These concentrations of 
sodium formate were also used on their own as a second set of negative controls. Drug 
exposure was allowed for 24 h, after which the supernatants were removed by suction and the 
wells washed with PBS. The cells were treated with trypsin, detached and counted before 
being pelleted by centrifugation. Cell pellets were extracted using the NAD/NADH extraction 
buffer and filtered using a 10 KDa molecular weight filter. Samples were split into two, the 
first half was used to determine total NADt (NAD+ + NADH), and the second half was used 
to determine NADH after heating the samples at 333 K for 30 min. Values obtained 
measuring the absorbance at 450 nm were normalised against the protein content in each 
sample which was determined using a Bradford assay. 25 
4.2.9. Time-dependence of the NAD+/NADH ratio 
Experiments to determine the variation of NAD/NADH ratio over time in A2780 
ovarian cancer cells exposed to complex 2 (concentration equal to its IC50) co-administered 
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with sodium formate (2 mM) were carried out using the NAD/NADH assay kit as described 
above. The NAD+/NADH were determined after 0, 2, 4, 12, 18 and 24 h drug exposure. 
TOF was calculated using the formula: TOF=Kcat=
Vreaction
[catalyst] =
δ[NADH]
δt
1
[catalyst] 
Where []

=

[][]

[[]
[] and [NADH]0 is the initial concentration of 
NADH 
4.2.10. ROS determination  
Flow cytometry analysis of total induction of ROS in A2780 cells caused by exposure 
to complex 2 and sodium formate was carried out using the Total ROS detection kit (Enzo 
Life Sciences) according to the supplier’s instructions. 6-well plate were seeded with  
1.0 × 106 A2780 cells per well. Cells were pre-incubated in drug-free media at 310 K for 24 h 
in a 5% CO2 humidified atmosphere, after which they were exposed to either sodium formate 
(2 mM), complex 2 (concentration equal IC50) or a combination of both. After 1 or 24 h of 
drug exposure, supernatants were removed by suction and the cells washed and harvested. 
Staining was achieved by re-suspending the cell pellets in buffer containing a green 
fluorescent reagent. Cells were analysed in a Becton Dickinson FACScan Flow Cytometer 
using Ex/Em: 490/525nm for the oxidative stress. Data were processed using Flowjo 
software. The experiment included cells treated with pyocyanin for 30 min as positive 
control. 
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4.3. Results 
4.3.1. In vitro growth inhibition  
The antiproliferative activity of complexes 1-16 and RM175 was evaluated in A2780 
ovarian cancer cells. Complexes 1-3, 7-9 and 13-16 were found to be moderately active with 
IC50 values ranging from 11.92 and 14.7 µM, which is an order of magnitude higher than 
complex RM175 (2.17 µM) and the clinically approved cisplatin (1.2 µM). Complexes 
[(hmb)Ru(TsEn)Cl] (5), [(bn)Ru(TsEn)Cl] (10), [(bn)Ru(TsEn)Cl] (11) and 
[(bn)Ru(TfEn)Cl] (12), containing hexamethylbenzene (hmb) or benzene (bn) as the  
η
6
-arene, displayed IC50 value higher than 100 µM (ie. were inactive). Interestingly, in the 
active series the most active complexes are the MsEn derivatives and their potency follows 
the order MsEn>TsEn>TfEn. IC50 values are depicted in Table 4.1. 
Cellular accumulation in the A2780 ovarian cell line for complexes 1-3 and 13-15 was 
determined. Ru accumulation in A2780 for p-cymene complexes 1-3 (0.16-0.31 ng x 106 
cells) was ca. 13 x times lower than for the more hydrophobic o-terphenyl complexes 13-15 
(2.1-2.8 ng x 106 cells) (Table 4.1). There was no direct correlation between the amount of 
metal determined in cells, and the anticancer activity of the complexes. 
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Table 4.1. Antiproliferative activity of complexes 1-3, 13-16 and RM175 in A2780 ovarian 
cancer cells and their cellular accumulation expressed as ng of ruthenium per million cells. 
The latter experiments were carried out using equipotent concentrations of the complexes 
(1/3 x IC50) and 24 h of drug exposure, without recovery time.  
Complex  IC50 (µM) 
Ru in cells 
(ng x 106 cells) 
[(p-cym)Ru(MsEn)Cl] (1) 11.92 ± 0.8 0.16 ± 0.02 
[(p-cym)Ru(TsEn)Cl] (2) 13.6 ± 0.6 0.15 ± 0.04 
[(p-cym)Ru(TfEn)Cl] (3) 14.2 ± 0.8 0.31 ± 0.04 
[(p-cym)Ru(NO2En)Cl] (16) 14.7 ± 0.6 n/d 
[(hmb)Ru(TsEn)Cl] (5) >100 n/d 
[(bip)Ru(MsEn)Cl] (7) 11.4 ± 1.0 n/d 
[(bip)Ru(TsEn)Cl] (8) 11.5 ± 0.7 n/d 
[(bip)Ru(TfEn)Cl] (9) 13.0 ± 0.9 n/d 
[(bn)Ru(TfEn)Cl] (10) >80 n/d 
[(bn)Ru(TfEn)Cl] (11) >80 n/d 
[(bn)Ru(TfEn)Cl] (12) >80 n/d 
[(o-terp)Ru(MsEn)Cl] (13) 12.4 ± 0.9 2.8 ± 0.3 
[(o-terp)Ru(TsEn)Cl] (14) 15.8 ± 0.8 2.1 ± 0.4 
[(o-terp)Ru(TfEn)Cl] (15) 21.2 ± 0.1 2.4 ± 0.3 
[(bip)Ru(en)Cl]+ (RM175) 2.17 ± 0.08 n/d 
n/d = not determined. 
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Relative hydrophobicity of the complexes was measured by plotting the HPLC 
retention times (Figure 4.2). The more hydrophilic complexes will move faster, while the 
more hydrophobic will interact better with the column (ie. longer retention times). The 
hydrophobicity is dependent on the η6-arene following the order o-terp > bip > p-cym > hmb 
> bn. The chelating ligand also affects greatly the hydrophobicity of the complexes, the more 
hydrophilic compound being those containing MsEn and following the order MsEn < TsEn < 
NbEn < TfEn.  
 
Figure 4.2. Relative hydrophobicity of complexes 1-16, measured as retention time in HPLC. 
XEn = NbEn, TfEn, TsEn or MsEn. 
4.3.2. In vitro experiments with co-administration of a hydride source 
In order to investigate the possibility of in cellulo catalysis, as a potentiation strategy 
for metal-based anticancer agents, A2780 cells were co-incubated with equipotent 
concentrations of ruthenium complexes 1-3, 13-16 and RM175 (1/3 x IC50) and three 
different concentrations of sodium formate (0.5, 1 and 2 mM). The potency of all complexes 
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increases upon co-administration of the hydride source (formate), with decrease of the cell 
survival of ca. 69.5 to 97.9 % was achieved using 2 mM formate, Figure 4.3. A linear relation 
between cell viability and the formate concentration can be observed (Figure 4.4). The largest 
increment in potency is observed for complexes [(p-cym)Ru(MsEn)Cl] (1) and  
[(p-cym)Ru(TsEn)Cl] (2) respectively, with a cell viability decrease from ca. 69.9 to 1.5 % 
and 68.4 to 1.5 %, when using 2 mM sodium formate, keeping Ru concentration constant. 
Within the o-terp derivatives, the greatest improvement is observed for complex  
[(o-terp)Ru(TfEn)Cl] (15), with a decrease from ca. 40.0 to 2.5 %. In contrast, results for 
complex RM175, show a decrease of cell survival from 71.3 to 38.9 %. These experiments 
included two different sets of negative controls. In the first, cells were kept untreated, in the 
second set, cells were exposed to the different concentrations of sodium formate. In all cases 
there was no difference in cell viability between the two sets of controls; excluding the 
hypothesis that formate is responsible for the decrease in the population. 
Chapter 4 
155 
 
 
Figure 4.3. Plot of cell survival of A2780 ovarian cancer cells, in the presence of complex  
1-3, 13-15 and RM175 (concentration equal to 1/3 IC50) co-administered with sodium 
formate at 0, 0.5, 1 and 2 mM. Complex 2 was selected for further experiments. 
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Figure 4.4. Plot of cell survival versus concentration of sodium formate. The experiment was 
performed with complex 2 at a concentration equal to 1/3 IC50. A linear relationship is 
observed. 
Complex 2 was selected for further experiments. Results for the cellular accumulation 
studies on A2780 cells exposed to complex 2 and different concentrations of sodium formate 
showed no statistically significant differences in intracellular ruthenium concentration, 
regardless the amount of sodium formate used, Table 4.2. The IC50 values determined when 
complex 2 was co-administered with sodium formate were determined (Table 4.2). An 
improvement of ca. 13-fold is observed (from 13.57 ± 0.62 µM to 1.02 ± 0.15 µM) upon 
addition of 2 mM formate, which places this ruthenium complex at the same potency level as 
cisplatin. 
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Table 4.2. Antiproliferative activity and cellular uptake of complex 2 in A2780 ovarian 
cancer cells when co-administered with different concentrations of sodium formate  
(0, 0.5, 1 and 2 mM). 
 
Sodium formate concentration (mM) 
 
0 0.5 1 2 
IC50 (µM) 13.6 ± 0.6 10.8 ± 0.6 5.4 ± 0.8 1.0 ± 0.2 
Accumul. (ng Ru x 106 cells) 0.15 ± 0.03 0.145 ± 0.009 0.129 ± 0.005 0.13 ± 0.02 
 
Complexes 2 and RM175 were also co-administered with sodium acetate on A2780 
cells, maintaining the same conditions as in previous experiments (complex concentration at 
1/3 x IC50, sodium acetate concentration at 0.5, 1 and 2 mM). No statistically significant 
changes in potency upon addition of increasing concentrations of acetate were observed 
(Table 4.3). For complex 2, the cell viability varies from 70.78 ± 0.56 % to 67.1 ± 0.6 %, and 
for complex RM178, the variation is between 75.4 ± 2 % and 71.8 ± 1.4 %. 
Table 4.3. Cell viability percentages of A2780 ovarian cancer cells exposed for 24 h to 
equipotent concentrations of complexes 2 and RM175 (1/3 x IC50) co-administered with 
different concentrations of sodium acetate (0, 0.5, 1 and 2 mM). 
Complex 
Sodium acetate concentration (mM) 
0 0.5 1 2 
[(p-cym)Ru(TsEn)Cl] (2) 70.8 ± 0.6 69.4 ± 0.9 68.9 ± 0.3 67.1 ± 0.6 
[(bip)Ru(en)Cl]+ (RM175) 75.4 ± 2 73.1 ± 0.8 72 ± 1 71 ± 1 
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4.3.3. Modulation of NAD+/NADH in cells 
In order to investigate whether complex 2 in combination with formate can be used for 
transfer hydrogenation reactions, and to catalytically regenerate NADH in cellulo, the 
concentrations of NAD+ and NADH in A2780 cancer cells were determined. 
In a first experiment, A2780 cells were exposed for 24 h to complex 2, in combination 
with different concentration of sodium formate (0, 0.5, 1, 2 mM). Negative controls with 
untreated cells, and cells exposed only to sodium formate were included. There is no 
significant difference between the NAD+/NADH ratio for both sets of controls and those 
from cells exposed only to IC50 concentrations of complex 2. The experiment demonstrates 
that there is a decrease in the NAD+/NADH ratio (Figure 4.5), which directly correlates with 
the concentration of sodium formate added.  
 
Figure 4.5. Perturbation of the NAD+/NADH ratio in A2780 cells exposed to complex 2 
(concentration equal to IC50) and sodium formate (0, 0.5, 1 or 2 mM). A) NAD+/NADH 
ratios determined after 24 h of drug exposure. B) Inverse linear correlation between the 
concentration of sodium formate and the NAD+/NADH ratio. 
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Figure 4.6. Perturbation of A) NAD+ concentration, B) NADH concentration and  
C) NAD+/NADH ratios in A2780 cells exposed to complex 2 (concentration equal to IC50) 
and sodium formate (2 mM). NAD+ and NADH concentrations were determined at variable 
drug exposure times (0, 2, 4, 12, 18 and 24 h). 
A second experiment was carried out, at variable drug exposure times (2, 4, 12, 18 and 
24 h). The experiment was performed using fixed concentrations of complex 2 (IC50) and 
sodium formate (2 mM). The NAD+/NADH ratio decreases with exposure time, changing 
from 4.70 (t = 0 h, untreated cells) to 0.65 (t = 12 h), (Figure 4.6). After 12 h the 
NAD+/NADH ratio starts to increase slightly, going up to 0.98 (t = 24 h). NAD+ 
concentration decreases with exposure time changing from 1.97 (t = 0 h, untreated cells) to 
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0.91 (t = 4 h). After 4 h the concentration of NAD+ is constant, and after 12 hours the 
concentration of NAD+ continues to drop. The NADH concentration increases over the initial 
period of 4 h. After that it follows a similar pattern as the NAD+ concentration. 
An apparent TOF of 0.19 ± 0.01 h-1 was calculated with the concentrations of NAD+ 
and NADH determined in pmol per 105 cells. However, the linear regression was performed 
with only 3 points. 
4.3.4. ROS detection 
Flow cytometry analysis of A2780 cells exposed to complex 2 (concentration equal to 
IC50) and 2 mM of sodium formate was performed to detect the ROS levels in cells. The 
levels of ROS in treated cells are comparable to those treated with NAC, an important 
reductant (Figure 4.7).26 
 
Figure 4.7. Induction of ROS in A2780 cancer cells. In green, (positive control) cells treated 
with pyocyanin, which generates ROS.  
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4.4. Discussion 
4.4.1. In vitro growth inhibition  
The antiproliferative activity of complexes 1-16 and RM175 was evaluated in A2780 
ovarian cancer cells. Complexes containing biphenyl, p-cymene or o-terphenyl as a η6-arene 
(1-3, 7-9 and 13-16) were shown to be active towards A2780 ovarian cancer cells. However, 
complexes containing hexamethylbenzene or benzene as the η6-arene (5, 10-12) were shown 
to have IC50 values higher than 100 µM, and are considered inactive. IC50 values are depicted 
in Table 4.1. 
Cell accumulation experiments were carried out with complexes 1-3 and 13-15. It can 
be observed that the more hydrophobic complexes (o-terphenyl complexes 13-15) have 
higher accumulation in cells than the p-cymene containing complexes 1-3. However, the 
correlation between hydrophobicity and cellular accumulation does not occur within the 
complexes containing the same arene (Figure 4.2). Cellular accumulation decreases in the 
order [(p-cym)Ru(TfEn)Cl)] (3) > [(p-cym)Ru(MsEn)Cl)] (1) > [(p-cym)Ru(TsEn)Cl)] (2) 
and in the case of o-terphenyl complexes, [(o-terp)Ru(MsEn)Cl)] (13) >  
[(o-terp)Ru(TfEn)Cl)] (15) > [(o-terp)Ru(TsEn)Cl)] (14). 
4.4.2. In vitro experiments with co-administration of an hydride source 
In order to investigate the possibility of in cellulo catalysis, a series of experiments in 
A2780 cancer cells, using the complexes 1-3, 13-16 and RM175 co-administered with 
sodium formate, were performed.  
Complexes of the type [(η6-arene)Ru(en)Cl]+ have been intensively studied during the 
last few years due to their antiproliferative activity. In particular, complex RM175 was 
shown to be active, with an IC50 in the range of cisplatin, in a variety of cancer cell lines. 
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Studies with Ru(II)-ethylenediamine compounds, in order to elucidate the mechanism of 
action, have been carried out. It has been reported that the ethylenediamine-Ru(II) complexes 
react with GSH. The GSH is then oxidized to its sulphenato form, the complex then 
undergoes ligand substitution, releasing the GSH(O) and binding to DNA.27, 28 Some of these 
en complexes were tested in 2005 for their catalytic activity towards reduction of NAD+  
via transfer hydrogenation. The complexes were catalysts, however, the catalytic activity was 
low compared with other Ru(II) complexes reported. Furthermore, the compounds were 
tested in A549 lung cancer cells, in combination with formate, but no significant effect was 
observed.20 For these reason, RM175 was used here for comparison purposes.  
Complexes containing p-cym (1-3 and 16) were selected for these studies since they 
display good catalytic activity towards transfer hydrogenation, good water solubility and 
good stability (Table 4.4). Furthermore, complex [(p-cym)Ru(TsEn)Cl] (2) has been used as 
a model in Chapter 3 to understand the catalytic cycle of this type of complexes, and 
therefore, the knowledge on this compound is more extensive. 
Table 4.4. Summary of the properties of the complexes [(η6-arene)Ru(XEn)Cl] where  
η
6
-arene is bip, bn, p-cym or hmb. 
 [(η6-arene)Ru(XEn)Cl] 
η
6
-arene 
Property bn hmb bip p-cym 
Solubility in water Very high High Low High 
Stability in water + formate Poor a Stable Stable Stable 
Catalytic activity High b Low b High b High b 
a The complex decomposes in the presence of formate when there is no hydride 
acceptor (Figure 3.13.). b TOFs values in Table 3.6., Chapter 3.  
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Complexes containing o-terp (13-15) were also selected for these studies due to the 
high catalytic activity. Per contra, the solubility of those complexes is a major drawback. It 
has been previously described in Chapter 3, that these type of complexes need to be dissolved 
in a mixture 23.3 % methanol/water v/v in order to achieve working concentrations. 
Furthermore, although the transfer hydrogenation reaction proceeds, a brown precipitate can 
be observed. 
Cell viability experiments were performed with equipotent concentrations of the 
ruthenium complexes 1-3, 13-16 and RM175 (1/3 x IC50) and three different concentrations 
of sodium formate (0.5, 1 and 2 mM). The potency of all complexes is enhanced upon  
co-administration with increasing concentrations of formate, Figure 4.3. However, no 
antiproliferative activity can be observed when cells are treated only with sodium formate. 
Those results suggest that the enhancement of the potency is due to the combination of Ru(II) 
complex and sodium formate. In contrast, results for complex RM175, show the lower 
decrease of cell survival from 71.3 to 38.9 %. Interestingly, despite the higher catalytic 
activity of the o-terp complexes 10-13 compared to the p-cym analogues, lower potenciation 
of the antiproliferative activity in the presence of formate was observed. This behaviour could 
be due to the fact that upon reaction with formate the complexes partially precipitate, either 
due to decomposition products or poor water solubility of a neutral formate adduct. This 
effect has previously been discussed in Chapter 3, section 3.3.4.1.  
The largest increment in potency is observed for complexes [(p-cym)Ru(MsEn)Cl] (1) 
and [(p-cym)Ru(TsEn)Cl] (2) respectively, with a cell viability decrease from ca. 69.87 to  
1.5 % and 68.4 to 1.5 %, when using 2 mM sodium formate, keeping metal the Ru constant. 
This results were unexpected, since the catalytic activity of the p-cym complexes follows the 
order NbEn (16) > TfEn (3) > TsEn (2) > MsEn (1) (Table 4.5).  
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Table 4.5. Turnover frequencies for transfer hydrogenation using catalysts 1-3 and 16. 
Complex TOF (h
-1) 
D2O/MeOD-
d4a 
TOF (h-1) 
D2O 
[(p-cym)Ru(MsEn)Cl] (1) 1.25 ± 0.03 1.11 ± 0.02 
[(p-cym)Ru(TsEn)Cl] (2) 2.88 ± 0.06 1.58 ± 0.04 
[(p-cym)Ru(TfEn)Cl] (3) 5.7 ± 0.3 3.06 ± 0.05 
[(p-cym)Ru(NbEn)Cl] (16) 9.6 ± 0.3 4.1 ± 0.1 
a
 23% MeOD-d4/ 77% D2O 
These results can readily be explained if it is considered that the reaction occurs in a 
cellular environment. Cells are complex systems which contain a large amount of molecules 
capable of coordinating with metals, and can poison metal anticancer drugs, or in this case, 
poison the catalyst. Examples of side reactions between biomolecules and metal drugs can 
easily be found in the literature. In particular glutathione (GSH), a tripeptide containing 
cystein (nucleofil S), has been shown to have an important role as a detoxifier in cells. 29, 30 
The clinically approved drug cisplatin, for instance, reacts with glutathione (GSH) to form a 
GS-Pt adduct that can be excreted from the cells.31 
Complexes [(p-cym)Ru(NbEn)Cl] (16) and [(p-cym)Ru(TfEn)Cl] (3) could be more 
reactive and therefore easier to poison by reaction with other biomolecules such as GSH 
(reactions with GSH explained in Chapter 5). 
A linear relationship between cell viability and the formate concentration is observed 
(Figure 4.4). Furthermore, cellular accumulation studies on A2780 cells exposed to complex 
2 and different concentrations of sodium formate exclude the possibility that the  
co-incubation with both agents resulted in an enhanced uptake that could translate in to a 
decrease of cell survival (Table 4.2). Taking into account that the concentration of sodium 
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formate (0.5, 1 or 2 mM) is in high excess compared to the concentration of the complexes, it 
suggests that the reaction between the complex and formate is catalytic. 
IC50 values for complex 2 co-administered with sodium formate were determined 
(Table 4.2). A linear decrease on the IC50 versus formate can be observed. Upon addition of  
2 mM sodium formate the antiproliferative activity of complex 2 decreases from 13.6 ± 0.6 to 
1.0 ± 0.2 µM, which is comparable to that of cisplatin (1.2 ± 0.1 µM).  
Platinum-based anticancer drugs are the most common in a course of treatment for a 
wide variety of cancers. The mechanism of action of cisplatin, carboplatin and oxaliplatin is 
believed to involve DNA binding and distort replication. However, these drugs display major 
side effects due to unespecificity towards cancer cells and binding to undesired targets. 
Furthermore, cancer cells develop resistance to the drugs. Some of the mechanisms of 
resistance towards platinum drugs are detoxification by GSH conjugates, metallothioneins 
and other antioxidants, increase of the DNA damage repair levels or alterations of membrane 
protein trafficking. These drawbacks expose the need to develop drugs with new mechanisms 
of action.32 
The Ru(II) complexes here described are capable of achieving similar IC50 values as 
cisplatin. However, the mechanism of action does not involve DNA coordination  
(see Chapter 5) but disruption of the NAD+ and NADH. The modulation of NAD+/NADH 
levels is closely related to the redox balance of the cells, and therefore, the full signalling 
system of the cells is compromised.33, 34 
Recently, Sadler et al. reported a series of Ir(III) anticancer catalytic compounds 
designed to target the redox system. In contrast with the drugs here described, the mechanism 
of the Ir(III) compounds involves the catalytic oxidation of NADH to generate a hydride Ir 
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adduct and NAD+.26 The catalytic process was also shown to occur in cellulo. During this 
process, increasing ROS levels are observed which results in cell death.26  
In order to demonstrate that the catalytic process is due to transfer hydrogenation, an 
experiment using sodium acetate, instead of sodium formate, was performed. Acetate is a 
carboxylate which defers from formate in a methyl group, however, acetate does not have the 
ability to act as a hydride donor.  
 
Figure 4.8. Structures of acetate and formate. Transfer hydrogenation reactions with 
carboxylates as a hydride source require hydrogen in the β position (β elimination). Ru(II) 
coordinates via the negatively charged oxygen. 
In experiments in which A2780 ovarian cancer cells were treated with complexes 2 or 
RM175 (concentration equal to 1/3 IC50) in combination with sodium acetate (0.5, 1 or 2 m), 
no statistically significant changes in potency upon addition of increasing concentrations of 
acetate were observed (Table 4.3). Therefore, it is probable that the hydride donation ability 
of formate is essential for the observed increase in potency.  
4.4.3. Modulation of NAD+/NADH in cells 
In a first experiment, A2780 cells were exposed for 24 h to complex 2  
(IC50 concentrations), in combination with different concentration of sodium formate (0, 0.5, 
1, 2 mM). Control experiments, untreated cells, cells treated with only complex 2  
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(IC50 concentrations) or only formate at different concentrations (0, 0.5, 1, 2 mM), were also 
performed.  
The NAD+/NADH ratio of untreated cells (4.8 ± 0.3) is the same as that obtained for 
cells treated only with complex 2 or formate at different concentrations (Figure 4.5). 
However, a decrease on the NAD+/NADH ratio in observed upon treatment of A2780 cells 
with complex 2 and increasing concentrations of formate (Figure 4.5). These experiments 
show that the decrease in NAD+/NADH ratios directly correlates with the concentration of 
sodium formate added (Figure 4.5). This experiment demonstrates that the co-administration 
of complex 2 and sodium formate can reduce the NAD+/NADH ratio in A2780 ovarian 
cancer cells.  
In a second experiment, A2780 cancer cells were treated with complex 2  
(IC50 concentration) and sodium formate (2 mM). The NAD+/NADH ratio was determined at 
time 0 (untreated cells) and at time 2, 4, 12 18 and 24 h. The experiments were performed 
with the aim to observe the kinetic decrease of the ratio and the behaviour of NAD+ and 
NADH and calculate a turnover frequency. The TOF that would be obtained from this 
experiment will be an apparent TOF, since many processes occur in cells and NAD+/NADH 
could be involved in more than one process.  
A decrease on the NAD+/NADH ratio in A2780 cells can be observed during a period 
of 12 h. The apparent TOF (0.19 ± 0.01 h-1) was calculated. However, the number of points is 
insufficient to obtain an accurate value.  
After 12 h, the catalyst is probably poisoned, and there is an apparent slight recovery of 
the NAD+/NADH ratio. However, observing the individual concentrations of NAD+ and 
NADH, a decrease of the total concentration of NAD+ and NADH was detected after 12 h 
(Figure 4.6). It is probable that the cell is undergoing a process of destruction of the 
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coenzymes. Whether this reduction of NADH and NAD+ concentrations is due to a side 
effect of the poisoned catalyst or due to cellular processes, either in an attempt to restore the 
redox balance or as a shut-down process when the cell dies, has not yet been investigated. 
4.4.4. ROS detection 
As mentioned previously, NAD+ and NADH are closely involved in the redox system 
of the cells. The coenzymes are involved in the synthesis of NADP+ and NADPH, which at 
the same time is involved in the regeneration of GSH from GSSG. Furthermore NADH itself 
is a reductant.34, 35 Increasing concentrations of NADH should translate into a reducing 
environment, and lower levels of ROS. 
In a final experiment, ROS levels in A2780 cancer cells were measured after cells were 
treated with complex 2 (concentration equal to IC50) and 2 mM of sodium formate. 
Interestingly, low levels of ROS were detected (Figure 4.7). This result is in agreement with 
the hypothesis of in cellulo transfer hydrogenation. Reduction of reactive oxygen species 
could occur by direct transfer hydrogenation or be due to an increase in the level of reducing 
agents in the cell, such as NADH.  
These results are also in agreement with the literature. The Ir(III) complex 
[(CpxPhPh)Ir(PhPy)py]+ has been was shown to catalyze hydride transfer from the NADH to 
O2 to form H2O2. 26 This process generates ROS, and simultaneously, reduces the levels of 
NADH. In their report, Sadler et al. demonstrate that the ROS levels in cells increase 
significatively, and relates this increase of reactive oxygen species with a redox imbalance 
which translates in cell death.26 
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4.5. Conclusions 
This Chapter aimed to demonstrate that ruthenium complexes containing Noyori-type 
ligands, originally designed for catalytic reduction of ketones and imines, can be modified for 
the purpose of exerting biological applications. In Chapter 3 it was shown that complexes  
1-16 can be catalysts for transfer hydrogenation reactions, and allowed the conversion of 
NAD+ into NADH in the presence of sodium formate as a hydride source. This chapter 
highlights the possibility of potentiating the antiproliferative activity of these ruthenium 
complexes in A2780 cells by co-administration with non-toxic doses of sodium formate.  
Cell viability experiments in A2780 cells, using the Ru(II) complex  
[(p-cym)Ru(TsEn)Cl] and different concentrations of formate, demonstrate that the 
antiproliferative activity of this kind of complexes can be greatly potentiated by the addition 
of formate. Furthermore, a linear relationship between formate concentration and decreasing 
cell survival was obtained, suggesting that the formate is directly correlated with such an 
increase of the anticancer activity. 
Cellular accumulation experiments exclude the possibility of disruption of Ru(II) 
accumulation in cells. Together with the cell viability experiments, this suggests that a 
catalytic reaction between the complex and formate might be the cause of the reduction in the 
IC50 values and, therefore, increasing the potency.  
Experiments with sodium acetate, instead of sodium formate, were performed. 
However, no potenciation of the anticancer activity could be observed with acetate. These 
results can readily be explained, since acetate cannot act as a hydride donor. The lack of 
effect of acetate in A2780 cells, suggests that hydride is required for the potenciation, and 
therefore, transfer hydrogenation might occur. 
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The possibility of in cellulo NAD+ reduction, by transfer hydrogenation was studied in 
two series of experiments. The NAD+/NADH ratio in cells was first determined using 
different concentrations of formate. The NAD+/NADH ratio decreases as a function of the 
concentration of formate, when in the presence of complex 2, indicating that the presence of 
formate directly affects the NAD+/NADH ratio. 
A second experiment, where the NAD+ and NADH concentrations were determined at 
different time points, was also performed. This decrease in the NAD+/NADH ratio, continued 
over time during the initial 12 hours. After which, the catalyst is poisoned and no more 
transfer hydrogenation occurs. However, both, NAD+ and NADH concentration decrease. 
The co-administration of the Ru(II) complex and the hydride source (formate) caused 
the inhibition of ROS species, comparable to the effect of NAC, a powerful reductant. This is 
consistent with the transfer hydrogenation process (reduction) and the generation of high 
levels of reducing agents like NADH and NADPH. 
This Chapter provides evidence that transfer hydrogenation reactions can be carried out 
in cells. 
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5. Interactions of half sandwich Ru(II) mono-sulfonate 
complexes with DNA and GSH  
In the previous chapters, a series of [(η6-arene)Ru(XEn)Cl] compounds,  
(XEn = N-(2-aminoethyl)-4-nitrobenzenesulfonamide (NbEn), N-(2-aminoethyl)-4-
(trifluoromethyl)benzenesulfonamide (TfEn), N-(2-aminoethyl)-4-toluenesulfonamide (TsEn) 
or N-(2-aminoethyl)methylenesulfonamide (MsEn)), were synthesized with the aim of 
obtaining a catalytic anticancer drug. In an ideal situation the complexes will not show 
antiproliferative activity towards cancer cells unless activated upon reaction with sodium 
formate. However, in vitro experiments performed in Chapter 4 showed that the complexes  
1-3 and 7-16 exhibit moderate antiproliferative activity against A2780 ovarian cancer cells in 
the absence of sodium formate. Therefore, it is important to understand the chemical and 
biological behaviour of those complexes in the absence of sodium formate. Nevertheless, the 
activity of the complexes can be significantly increased by the addition of sodium formate. 
This chapter is focused on the reactivity of the complexes towards DNA and GSH.  
 
5.1. DNA 
The history of metal based cancer drugs starts in 1965 with B. Rosenberg and 
cisplatin.1, 2 Soon cisplatin demonstrated limitations like acquired resistance in some tumours 
or severe side effects.3-5 Since then, there has been research aiming to understand the 
mechanism of cisplatin, and to develop alternative drugs which complement or replace 
cisplatin. Currently, DNA is commonly accepted as the primary target for the platinum 
drug.6-8 The activated form of cisplatin (after hydrolysis) binds to N7-guanine (Less common 
binding sites are N7-adenine and N3-cytosine). Binding to a second N7-guanine gives a 
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bisfunctional crosslink.6-8 The most common DNA-platinum adducts are 1,2-intrastrand cross 
links, where a [Pt(NH3)2]2+ unit is bound to two guanines from the same DNA strand, causing 
the bending of the DNA and inhibiting replication. 6-8 
Ruthenium, osmium, rhodium and iridium complexes have also been designed with the 
aim of targeting DNA.9-11 For instance, the family of organometallic ruthenium(II) arene 
compounds [(η6-arene)Ru(en)Cl]+ , has shown similar affinity for DNA as some platinum 
drugs.12-16 Furthermore, direct correlation between cytotoxicity of those complexes and DNA 
binding has been reported.12-17 Specifically, [(bip)Ru(en)Cl]+ (RM175), displayed good  
in vitro and in vivo activity due to its dual mode of interaction with DNA; direct metal 
coordination to DNA and intercalation between DNA bases through the aromatic ligand.18 
DNA intercalation is the process where extended planar aromatic molecules are inserted in 
between base pairs. These interactions are stabilized by π-interaction of the intercalator and 
the nearby nucleobases. Intercalation increases the separation between base pairs and 
unwinding of the DNA. DNA becomes more rigid and stiff.19 
Another common type of interaction with DNA is groove binding. These molecules 
bind through van-der-Waals interactions, hydrogen bonds and hydrophobic interactions with 
nuchleobases.11 The presence of DNA groove binders inhibits the action of transcription 
proteins. Furthermore, steric hindrance can play a role in DNA bending in cases where there 
is groove binding. 
Complexes of the type [(η6-arene)Ru(XEn)Cl] (X= Nb, Tf, Ts or Ms), derived from the 
ethylenediamine analogues, have shown reasonably high in vitro anticancer activity  
(11-20 µM). However, the possible targets for those compounds are still unknown. Due to the 
resemblance of those complexes with their ethylenediamine analogues, and RM175, their 
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interactions of those complexes with DNA and the possibility of DNA being the primary 
target will be studied in this chapter. 
 
5.1.1. Experimental 
 
5.1.1.1. Materials 
Ruthenium(II) complexes [(p-cym)Ru(MsEn)Cl] (1), [(p-cym)Ru(TsEn)Cl] (2),  
[(p-cym)Ru(TfEn)Cl] (3), [(hmb)Ru(TsEn)Cl] (5), [(bip)Ru(TsEn)Cl] (8), [(bn)Ru(TsEn)Cl] 
(11) and [(p-cym)Ru(NbEn)Cl] (16) were synthesised as described in Chapter 3. Complex 
[(bip)Ru(en)Cl]PF6 was synthesized by Dr Pieter Bruijninx following the method described 
in the literature. 9-ethylguanine (9-EtG) and 9-methyladenine (9-MeA) were obtained from 
Sigma-Aldrich. silver nitrate, potassium hydroxide, sodium chloride and perchloric acid were 
obtained from Fisher Scientific. Calf thymus DNA was obtained in water solution from 
Invitrogen and as a solid from Sigma-Aldrich. Concentration of calf thymus DNA was 
measured by UV-Vis as described in Chapter 2. Sodium cacodylate was obtained from Fluka. 
Absolute ethanol was purchased in AnalaR NORMAPUR. The solvents used for UV-Vis 
absorption, linear dichroism, fluorimetry and circular dichroism were double distilled water 
(18 MΩ·cm) (ddw) and acetonitrile (HPLC grade). Double distilled water (18 MΩ·cm) (ddw) 
was collected from Purelab UHQ system model UHQ-PS-MK3. Acetonitrile (HPLC grade) 
was obtained from Fisher Scientific. MeOD-d4 and 99.9 % D2O for NMR spectroscopy were 
purchased from Sigma-Aldrich and Cambridge Isotope Labs Inc.  
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Figure 5.1. Complexes used for the studies with nucleobases and DNA. 
5.1.1.2. Interaction with nucleobases 
Solutions of the complexes 1-3, 5, 8, 11 and 16 in D2O (1.4 mM) were prepared and 
added to 5 mm diameter NMR tubes containing 9-ethylguanine or 9-methyladenine (final 
ratio 1:1 complex to 9-EtG, 1:2 complex to 9-MeA). The pH* of the reaction mixture was 
adjusted to 7.2 ± 0.1 and the reaction monitored by 1H NMR spectroscopy. 1H NMR spectra 
at 310 K were recorded at time < 10 min and 24 h (5 h for reactions with 9-MeA) on a Bruker 
AV III 600 spectrometer (1H = 600 MHz). All data processing was carried out using Topspin 
2.0. 1H NMR chemical shifts were internally referenced to TMS via 1,4-dioxane in D2O  
(δ = 3.75).  
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Exact concentrations of the Ru were determined by ICP-MS. Concentration of the 
substrate was verified by integration of the 1H NMR peaks and compared to those from the 
complex. Binding constants were calculated using the equation:20, 21 
K =
[MS]
[S][M]
 
[M]	
 = [MS] + [M] =
I[]
I[] + I[]
[M]	
 +
I[]
I[] + I[]
[M]	
 
where Ix is the integral of the peak at x ppm. 
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High resolution mass spectra of the reaction mixture obtained from reacting complexes 
1-3, 5, 8, 11 and 16 with 9-EtG were recorded on freshly prepared samples. 
Changes in the chemical shifts of protons from the complex  
[(p-cym)Ru(TsEn)(9-EtG)]+ (2-9EtG) with the pH* over a range from 2 to 12 were followed 
by 1H NMR spectroscopy. 1H-NMR spectra were recorded at 278 K on a Bruker AV III 600 
spectrometer (1H = 600 MHz). 
5.1.1.3. CT-DNA binding kinetics 
Solutions of CT-DNA (200 µM) in cacodylate buffer (2 mM, pH 7.4) and NaCl (20 mM or 
2 mM) were incubated at 310 K with complexes [(p-cym)Ru(TsEn)Cl] (2) and 
[(bip)Ru(TsEn)Cl] (8) (66 µM, final ratio 1:3) for 27 h. Aliquots of 300 µL were withdrawn 
from the incubator, cooled down on an ice bath and treated with absolute ethanol to 
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precipitate the DNA (700 µL, final concentration 70 % ethanol). Samples were centrifuged 
for 10 minutes and the ruthenium content of the supernatant was determined by ICP-MS. 
The experiment was also performed with complex [(bip)Ru(en)Cl]+ (RM175) in 2 mM 
cacodylate and 2 mM NaCl. This experiment was used as a control since it is well known that 
RM175 can coordinate to DNA.22 
5.1.1.4. CT-DNA melting temperature 
CT–DNA (100 µM) was incubated at 310 K for 2 h in the presence and absence of 
complex 2 or 8 (33.3 µM in 5 % acetonitrile/95 % ddw, ratio 1:3 complex:DNA) in 
cacodylate buffer (2 mM, pH 7.4) and NaCl (20 mM) or cacodylate buffer solution (2 mM, 
pH 7.4) containing NaCl (2 mM). 
Thermal denaturation of CT-DNA in the presence and absence of complex 2 or 8 was 
recorded by following the changes of absorbance at 260 nm while increasing the temperature 
from 283 to 371 K. The melting curve for unruthenated DNA was determined under the same 
conditions as for complex 2 and 8. The data were fitted to the Boltzmann equation using 
Origin 7.5. The melting temperature value (Tm, temperature where 50 % of the CT-DNA was 
denatured) was determined as the inflection point. 
Experiments with complex RM175 under the same conditions as described for complex 
2 and 8 were performed for comparison purposes. 
5.1.1.5. Conformational changes of CT-DNA 
CT–DNA (1 mM) was incubated at 310 K for 24 h in the presence and absence of 
complex 2 and 8 (0.3 mM in 5 % acetonitrile/95 % ddw, final ratio 1:3 complex:DNA) in 
cacodylate buffer (2 mM, pH 7.4) and NaCl (20 mM). Circular dichroism spectra of the 
reaction mixture were recorded at 0 h and after incubation 24 h at 310 K. Titration of  
CT–DNA (1 mM) in cacodylate buffer (2 mM, pH 7.4) and NaCl (20 mM) with different 
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concentrations of complex 8 (ratios 1:3, 1:5, 1:10, 1:20 and 1:4 complex:DNA) was followed 
by circular dichroism 
Titration of CT–DNA (300 µM) in cacodylate buffer (2 mM, pH 7.4) and NaCl  
(20 mM) using complex [(bip)Ru(TsEn)Cl] (8) and [(p-cym)Ru(TsEn)Cl] (2)  
(5 % acetonitrile/95 % ddw, ratios 1:3, 1:5, 1:10, 1:20 and 1:40 complex:DNA) was followed 
by linear dichroism. A final experiment with CT–DNA (150 µM) in cacodylate buffer  
(2 mM, pH 7.4) and NaCl (20 mM) using 150 µM complex 8 or 2 (5 % acetonitrile/95 % 
ddw, ratios 1:1) was monitored by linear dicroism 
 
5.1.2. Results 
A series of complexes of the type [(η6-arene)Ru(XEn)Cl] (arene = p-cym, hmb, bn or 
bip, X= Nb, Tf, Ts or Ms) was selected to investigate the potential of DNA interactions. 
Nuclebases binding studies were performed with all the complexes depicted in Figure 5.1. 
However, reactions with CT-DNA were explored using complex [(p-cym)Ru(TsEn)Cl] (2) 
and [(bip)Ru(TsEn)Cl] (8). Some DNA-binding experiments were also carried out with 
complex RM175 for comparison purposes. 
5.1.2.1. Interaction with nucleobases 
 
Figure 5.2. Atom numbering scheme for 9-EtG and 9-MeA. 
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Solutions of 9-ethylguanine (9-EtG) and 9-methyladenine (9-MeA) were reacted with 
complexes 1-3, 5, 8, 11 and 16. 
 
Figure 5.3. 1H NMR spectra of 9-EtG, complex 2 and the reaction mixture of complex 2 + 9-
EtG (ratios 1:1). All the samples were prepared in D2O and pH* 7.2 ± 0.1, the spectra were 
recorded within 10 min after preparation at 310 K. 
1H NMR spectra of the reaction of complexes 1-3, 5, 8, 11 and 16 with 9-EtG recorded 
at time 0 h (<10 min) show two sets of peaks corresponding to 9-EtG (Figure 5.3). One set 
was assigned to unbound 9-ethylguanine and the other set assigned to the complex-(9-EtG) 
adduct. The chemical shift of H8 from (9-EtG)-adducts of complexes 1-3, 5, 11 and  
16 was displaced downfield by approximately ca. 0.33-0.72 ppm. In the case of 
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 [(bip)Ru(TsEn)(9-EtG)]+ (8-G), the chemical shift for H8 was displaced downfield only by 
0.04 ppm. The 1H NMR spectra exhibits no further change over a period of 24 h at 310 K. 
Table 5.1. Chemical shift of H8 (9-ethylguanine)-adducts. The reaction was carried out in 
D2O, pH* 7.2 ± 0.1 and 310 K. 
 
R1 = p-cym, bn, hmb or bip. R2 = Ms, Ts, Tf or Nb. 
Complex  δH8 (ppm) ∆δH8 a (ppm) 
[(p-cym)Ru(TsEn)(9-EtG)]+ (1-G) 8.15 0.33 
[(p-cym)Ru(MsEn)(9-EtG)]+ (2-G) 8.18 0.36 
[(p-cym)Ru(TfEn)(9-EtG)]+ (3-G) 8.24 0.42 
[(hmb)Ru(TsEn)(9-EtG)]+ (5-G) 8.54 0.72 
[(bip)Ru(TsEn)(9-EtG)]+ (8-G) 7.85 0.04 
[(bn)Ru(TsEn)(9-EtG)]+ (11-G) 8.17 0.35 
[(p-cym)Ru(NbEn)(9-EtG)]+ (16-G) 8.30 0.48 
a
 ∆δH8 = δH8 - δH8(9-EtG), δH8(9-EtG) = 7.82 ppm. 
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Table 5.2. Binding constant of complexes 1-3, 5, 8, 11, 13, and 16 with 9-EtG determined 
by 1H NMR. The experiments were performed in D2O, pH* 7.2 ± 0.1 and 310 K. Equilibrium 
was reached by the time the first 1H NMR spectrum was recorded (< 10 min). 
Complex  Binding constant (mM-1) 
[(p-cym)Ru(MsEn)Cl] (1) 105.4 ± 2.3 
[(p-cym)Ru(TsEn)Cl] (2) 104.9 ± 3.9 
[(p-cym)Ru(TfEn)Cl] (3) 60.5 ± 6.0 
[(hmb)Ru(TsEn)Cl] (5) 97.8 ± 0.5 
[(bip)Ru(TsEn)Cl] (8) 39.3 ± 3.6 
[(bn)Ru(TsEn)Cl] (11) 478.3 ± 44.8 
[(p-cym)Ru(NbEn)Cl] (16) 92.8 ± 1.0 
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No reaction between complexes 1-3, 5, 8, 11 and 16 and 9-MeA was detected by 1H 
NMR during a period of 5 h.  
 
Figure 5.4. 1H NMR spectra of 9-MeA, complex 2 and the reaction mixture of complex  
2 + 9-MeA (ratios 1:2). All the samples were prepared in D2O and pH* 7.2 ± 0.1, the spectra 
were recorded within 10 min after preparation at 310 K. 
High resolution mass spectrometry was performed on freshly prepared samples 
obtained from reacting 9-EtG with the complexes 1-3, 5, 8, 11 and 16 in order to verify the 
formation of the corresponding adduct. Calculated and found mass-to-charge ratios for the  
9-EtG adducts are shown in Table 5.3.  
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Table 5.3. Mass-to-charge ratios for the 9-EtG adducts of complexes 1-3, 5, 8, 11, 13, and 
16. 
Complex 
 
Chemical Formula 
Calc. mass 
m/z 
Found mass 
m/z 
[(p-cym)Ru(MsEn)(9-EtG)]+  (1-G) C20H32N7O3RuS+ 552.1330 552.1337 
[(p-cym)Ru(TsEn)(9-EtG)]+  (2-G) C26H36N7O3RuS+ 628.1644 628.1647 
[(p-cym)Ru(TfEn)(9-EtG)]+ (3-G) C26H33F3N7O3RuS+ 682.1362 682.1362 
[(hmb)Ru(TsEn)(9-EtG)]+  (5-G) C28H40N7O3RuS+ 656.1958 656.1971 
[(bip)Ru(TsEn)(9-EtG)]+  (8-G) C28H32N7O3RuS+ 648.1332 648.1333 
[(bn)Ru(TsEn)(9-EtG)]+  (11-G) C22H28N7O3RuS+ 572.1017 572.1020 
[(p-cym)Ru(NbEn)(9-EtG)]+  (16-G) C25H33N8O5RuS+ 659.1339 659.1338 
 
Coordination to position N7 of 9-EtG as preferred binding site for the Ru(II) complexes 
was confirmed via pH* titration. Changes on the chemical shifts of H8 of  
[(p-cym)Ru(TsEn)(9-EtG)]+ (2-G), with increasing pH* were plotted and fitted to a 
Henderson–Hasselbalch equation to obtain a pKa* value of 8.78 ± 0.04. 
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Figure 5.5. Dependence of the 1H NMR chemical shifts of H8 in [(p-cym)Ru(TsEn)(9-EtG)]+ 
on the pH*. pKa* 8.78 ± 0.04 determined using the Henderson-Hasselbalch equation. 
5.1.2.2. Interactions with calf thymus DNA 
Solutions of CT-DNA (200 µM) in cacodylate buffer (2 mM, pH 7.4) and NaCl (2 mM) 
were incubated at 310 K with either complexes [(p-cym)Ru(TsEn)Cl] (2), [(bip)Ru(TsEn)Cl] 
(8) or [(bip)Ru(en)Cl]+ (RM175) (60 µM, final ratio 1:3 complex:DNA) for 27 h. Aliquots of 
300 µL were withdrawn every hour, cooled down in a ice bath and the DNA precipitated by 
addition of absolute ethanol (700 µL, final concentration 70 % v/v). The concentration of Ru 
in the supernatant was measured by ICP-MS. No change in the ruthenium concentration of 
the supernatant, compared with the initial concentration, was observed for complexes 2 and 8. 
However, a decrease of ≈ 14 % in ruthenium was observed for complex RM175, indicating 
binding to CT-DNA. 
The experiment with complex 2 and 8 was repeated using a 2 mM cacodylate buffer 
and 20 mM NaCl. Similarly to the above experiment, no change on the ruthenium 
concentration of the supernatant, compared with the initial concentration was observed for 
complexes 2 and 8.  
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Table 5.4. Concentrations of Ru measured by ICP-MS in the supernatant from the reaction 
between complex 2, 8 or RM175 and CT-DNA. The reaction was carried out in 2 mM NaCl 
and 2 mM cacodylate buffer, pH 7.4 ± 0.1, temperature 310 K 
 Ru in supernatant (µM) 
Time  
(h) 
[(bip)Ru(TsEn)Cl]  
(8) 
[(p-cym)Ru(TsEn)Cl]  
(2) 
[(bip)Ru(en)Cl]+  
(RM175) 
Initial 
(No DNA) 
53.4 ± 1.2 64.2 ± 0.7 58.3 ±0.3 
0.5 -a 66.7 ± 0.6 50.3 ± 0.3 
1 52.8 ± 1.1 59.2 ± 1.0 49.3  ± 0.4 
2 53.9 ± 1.1 63.6 ± 1.1 - a 
3 53.7 ± 0.9 67.4 ± 0.7 - a 
4 50.6 ± 0.6 65.0 ± 0.1 - a 
5 53.2 ± 0.2 63.3 ± 1.0 50.3 ± 0.8 
12 51.4 ± 1.2 64.2 ± 1.1 51.2 ± 0.8 
24 53.7 ± 0.5 65.1 ±0 .3 48.5 ± 0.6 
a Not determined. 
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Table 5.5. Concentrations of Ru measured by ICP-MS in the supernatant from the reaction 
between complex 2 or 8 and CT-DNA. The reaction was carried out in water, 20 mM NaCl 
and 2 mM cacodylate, pH 7.4 ± 0.1, temperature 310K. 
 Ru in supernatant (µM) 
Time (h) [(bip)Ru(TsEn)Cl] (8) [(p-cym)Ru(TsEn)Cl] (2) 
Initial 
(No DNA) 
47.6 ± 1.3 81.2 ± 0.5 
0.5 48.2 ± 0.9 81.6 ± 1.6 
1 44.9  ± 1.5 76.7 ± 1.0 
2 47.7 ± 1.3 77.6 ± 1.0 
3 46.1 ± 0.4 77.0 ± 0.3 
4 46.1  ± 0.6 78.8 ± 0.7 
5 44.3 ± 2.4 74.9 ± 1.4 
6 45.8 ± 0.9 76.8 ± 1.0 
7 44.0 ± 1.3 75.6 ± 0.3 
18 47.3 ± 0.8 75.8 ± 2.2 
27 46.5 ± 1.6 81.1 ± 0.6 
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Thermal stability of CT-DNA 
The melting curve for CT-DNA (100 µM) in the presence of complexes 2 or 8  
(33.3 µM, 5 % v/v acetonitrile/water) was recorded. CT-DNA was prepared in cacodydate 
buffer (2 mM, pH 7.4) and NaCl (20 mM). A decrease in the melting temperature of 4-5 
degrees was observed. Exact Tm values are listed in Table 5.6. 
Experiments performed in cacodylate buffer (2 mM, pH 7.4) and 2 mM NaCl result in a 
3-5 degrees decrease of the melting temperature compared to the DNA. Exact Tm values are 
depicted in Table 5.6.(Figure 5.6).  
Table 5.6. Melting temperature (Tm) of CT-DNA in the presence of RM175, complex 2 or 
complex 8 (ratio 1:3, complex:DNA). The reaction was carried out in cacodylate buffer  
(2 mM, pH 7.4). The samples were incubated for 2 h at 310 K. 
Complex [NaCl] Tm (K) ∆Tma 
- 20 mM 332.3 ± 1.0 - 
RM175 20 mM 340.2 ± 0.6 7.9** 
2 20 mM 327.5 ± 0.7 4.9** 
8 20 mM 328.1 ± 0.8 4.2** 
 
  
 
- 2 mM 322.7 ± 1.3 - 
RM175 2 mM 336.9 ± 0.8 14.0** 
2 2 mM 320.3 ± 1.6 2.4 
8 2 mM 318.7 ± 1.3 4.0* 
a
 variation in melting temperature between free DNA and DNA in the presence of the 
corresponding complex. * 95 % statistically different from free DNA using a T test analysis. 
** 91 % statistically different from free DNA using a T test analysis 
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Figure 5.6. Comparison of CT-DNA melting curves in the absence and presence of complex 
[(bip)Ru(en)Cl]+ (RM175), [(p-cym)Ru(TsEn)Cl] (2) and [(bip)Ru(TsEn)Cl] (8); ratio 1:5 
(DNA:complex). (A) 2 mM cacodylate buffer and 20 mM NaCl (B) 2 mM cacodylate buffer 
and 2 mM NaCl. 
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Conformational changes of CT-DNA 
Conformational changes in DNA when interacting with complexes  
[(p-cym)Ru(TsEn)Cl] (2) and [(bip)Ru(TsEn)Cl] (8) were studied by CD using solutions of 
CT-DNA (1 mM) in buffer (2 mM, pH 7.4) and NaCl (20 mM) with different concentrations 
of complex (ratios 3:1, 5:1, 10:1, 20:1 and 40:1 DNA:Complex). No changes or very small 
changes were observed in the CD spectra after incubation at 310 K for 24 h using complex 2, 
Figure 5.7. 
 
Figure 5.7. Circular dichroism spectra of CT-DNA (1 mM) in red and CT-DNA  
(1 mM)/complex 2 (ratio 3:1) in black. Both spectrum were recorded under the same 
conditions, using (A) cacodylate buffer (2 mM, pH 7.4) and NaCl (20 mM) at 298 K,  
(B) PBS buffer (2 mM, pH 7.4) and NaCl (20 mM). 
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For complex [(bip)Ru(TsEn)Cl] (8), a decrease on the negative band (260 nm) of the 
CD spectrum, and an increase on the positive band (275 nm) was observed in addition to a 
small shift of the band (ca. 9 nm). Induced bands due to the complex are observed between 
350 and 425 nm. Changes in the CD spectra with different concentration of complex can be 
observed in Figure 5.8. 
 
Figure 5.8. Circular dichroism spectra of CT-DNA (1 mM) titration with complex 
[(bip)Ru(TsEn)Cl] (8) (ratios 3:1, 5:1, 10:1, 20:1 and 40:1 DNA:Complex). All the 
experiments were recorded under the same conditions; using (A) cacodylate buffer (2 mM, 
pH 7.4) and NaCl (20 mM) at 298 K. Intensity of the induction band at 390 nm was plotted 
against Ru/DNA ratio.  
Linear dichroism spectra of CT-DNA on adding complex 8 were recorded with 
different concentrations of complex (ratios 3:1, 5:1, 10:1, 20:1 and 40:1). A very small 
decrease in the signal at 190 and 260 nm was observed. An experiment with CT-DNA after 
addition of 1 mol equiv. of complex 8 was recorded, weak induction bands are observed after 
substracting the signal of CT-DNA. (Figure 5.9).  
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LD spectra of a solution containing complex [(p-cym)Ru(TsEn)Cl] (2) and CT-DNA 
were also recorded, showing similar results as the experiments with complex 
[(bip)Ru(TsEn)Cl] (8) (Figure 5.10). 
 
Figure 5.9. Reaction between CT-DNA and complex [(bip)Ru(TsEn)Cl] (8) (mol. ratio 1:1)  
2 mM cacodylate buffer (pH 7.4) and 20 mM NaCl. (A) LD spectra of CT-DNA (black) and 
CT-DNA/complex 8 (red). (B) Induced LD signal from complex 8 (red) and UV spectrum of 
complex 8.  
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Figure 5.10. Reaction between CT-DNA and complex [(p-cym)Ru(TsEn)Cl] (2)  
(mol. ratio 1:1) in 2 mM cacodylate buffer (pH 7.4) and 20 mM NaCl. (A) LD spectra of  
CT-DNA (black) and CT-DNA/complex 2 (red). (B) Induced LD signal from complex 2 (red) 
and UV spectrum of complex 2. 
 
5.1.3. Discussion 
DNA is believed to be the main target for [(bip)Ru(en)Cl]+ (RM175). 23-25  Due to the 
structural similarity of the complexes 1-3, 5, 8, 11, 13 and 16 with RM175, the possibility of 
DNA being a target was investigated. 
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5.1.3.1. Interactions with nucleobases  
Initially, model nucleobases, 9-ethylguanine and 9-methyladenine, were reacted with 
complexes 1-3, 5, 8, 11, 13 and 16 in D2O, 310 K and pH* 7.2 ± 0.1. The binding of the 
complexes to 9-EtG or 9-MeA was monitored by 1H-NMR spectroscopy. Peaks for the 9-EtG 
adducts were observed by the time the first spectrum was recorded (< 10 min after mixing, 
Figure 5.3), but no change in the NMR spectrum after 24 h was observed, indicating that the 
equilibrium was reached rapidly. The peak corresponding to H8 of coordinated 9-EtG is 
shifted down field by 0.04-0.8 ppm with respect to the H8 peak of free 9-EtG (Table 5.1), a 
chemical shift behaviour typical of [(η6-arene)Ru(N,N′)Cl].26 Calculated binding constants of 
the complexes with 9-EtG by NMR were between 40 and 450 mM-1. The binding constants of 
the complexes are in the same range as that from the ethylenediamine complex 
[(bip)Ru(en)Cl]+ (KDNA= 60.26 mM-1).27 The calculated binding constants are relatively high, 
which suggests that binding to DNA is possible, similar to [(bip)Ru(en)Cl]+.12, 13 High 
resolution mass spectra was recorded to confirm the formation of  
[(η6-arene)Ru(XEn)(9-EtG)]+. Binding of complexes 1-3, 5, 8, 11, 13 and 16 with 9-MeA 
was also investigated, although no reaction was detected by 1H-NMR. 
It is well established that N7 of guanine (G) is the preferred nucleotide binding site for 
many transition metals ions. 12, 13, 27-31 Furthermore, strong and selective binding to N7 of  
9-EtG, has been observed for [(η6-arene)Ru(en)Cl]+.12, 13 A pH* titration of  
[(p-cym)Ru(TsEn)(9-EtG)]+ was used to confirm that the complex binds to N7. A plot of the 
chemical shift of H8 from bound 9-EtG (Figure 5.5), versus pH* gave a pKa* of 8.77, which 
can be attributed to the deprotonation of N1 from coordinated 9-EtG and therefore we 
conclude that the binding of complex 2 to 9-EtG occurs though N7.32 The selectivity of these 
Ru(II) complexes for N7 of 9-EtG is not surprising, since similar behaviour has been 
previously described for [(η6-arene)Ru(en)Cl]+, and many Ru(II) arene complexes. 
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5.1.3.2. Interaction with CT-DNA 
To study the interactions of complexes of the type [(η6-arene)Ru(XEn)Cl]  
(X = mono-sulfonamide) with DNA, two complexes were chosen as models. Complex 2,  
[(p-cym)Ru(TsEn)Cl], was selected due to its good water solubility and the fact that its 
reactivity has been intensively studied previously in this thesis. However, it has been well 
reported previously that complexes containing extended arenes can intercalate DNA, in 
addition of other interactions; therefore, complex 8, [(bip)Ru(TsEn)Cl], has also been used 
for these studies.33 
Stock solutions of complex 2 and 8 (0.7 mM in 5 % acetonitrile/water) were prepared 
and aliquots of µL were added to a solution of CT-DNA in water, 2 mM cacodylate buffer 
and 20 mM NaCl or water, 2 mM cacodylate buffer and 2 mM NaCl. The reaction mixture 
was incubated at 310 K, while aliquots of 300 µL were taken at different intervals during a 
period of 27 h. The DNA was then precipitated by addition of ethanol (700 µL, final 
concentration 70 % v/v). The Ru complexes which are strongly bound to CT-DNA 
(coordination) will precipitate together with the DNA upon addition of ethanol, and, therefore 
the ruthenium concentration in the supernatant should decrease. However, no changes in the 
Ru concentration could be detected by ICP-MS which suggest no strong interaction between 
the complexes and the DNA. These results are in disagreement with those previously 
obtained when reacting the complexes with 9-EtG and 9-MeA. Strong binding constant does 
not always correlate with strong DNA binding, probably due to the bulk of the NN′ chelating 
ligand. In addition to the fact that DNA nucleobases are more hindered than the model 9-EtG 
or 9-MeA, due to the double helix backbone. 
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Thermal stability of CT-DNA 
The melting temperature of CT-DNA in the presence and absence of complex [(p-
cym)Ru(TsEn)Cl] (2) or [(bip)Ru(TsEn)Cl] (8) were determined by UV-Vis (Table 5.6). 
Higher melting temperature indicates increased stabilization of the DNA which is usually the 
effect of DNA-intercalators, or complexes coordinated to the nuchleobases.34 Per contra, 
destabilization of the DNA could translate in a decrease of the melting temperature, which 
could be the case of groove binding. 
The melting temperature of CT-DNA in the presence of complex RM175 was 
determined as a control. In agreement with the literature,22 an increase in the melting 
temperature of CT-DNA (14 degrees) was observed after addition of RM175, when the 
reaction was carried out in 2 mM NaCl and 2 mM cacodylate buffer. The increase is due to 
Ru binding to DNA as well as intercalation.22 However, upon increasing the chloride 
concentration by ca. 10 x times  (20 mM NaCl) the melting temperature of CT-DNA in the 
presence of RM175, increases only by 7 ͦ. This effect has previously been reported and it is 
attributed to the partial inhibition of hydrolysis, and, therefore, inhibition of coordination to 
DNA.22, 35 
Experiments performed in the presence of complex 8, when using 2 mM cacodylate 
buffer and 2 mM NaCl, show a 4 degrees decrease in the melting temperature. Furthermore, 
when increasing the salt content by ca. 10 times (20 mM NaCl) to inhibit hydrolysis, a 4 
degrees decrease of the melting temperature can still be observed. Similar results were 
obtained when using complex 2. These experiments support the results obtained on previous 
experiments, since a decrease on the melting temperature does not agree with coordination to 
DNA. Per contra, the decrease in the melting temperature, indicates that the complex 
destabilises CT-DNA, which could be due to electrostatic interactions or groove binding. 
Interestingly, increasing concentration of NaCl does not have a major influence on the 
Chapter 5 
198 
 
reaction. Hence, the possibility of electrostatic interactions has been discarded, since higher 
ionic strength stabilized DNA and should weaken the effect of the complex. 
Conformational changes of CT-DNA 
Circular dichroism is a common technique to study conformational changes in chiral 
systems, and is often used to study DNA interactions with metal complexes. CT-DNA is a 
chiral macromolecule, so changes induced by metal complexes are easily detected. 
Furthermore, strong binding of a metallodrug to DNA can induce chirality on the metal 
complex, generating a CD signal.36 
In order to have a more clear idea on the type of interaction and the effect of complexes 
2 and 8 on CT-DNA, CD spectra of DNA with different concentrations of complex were 
recorded. Reaction between complex 8 and CT-DNA in water, 2 mM cacodylate buffer and 
20 mM NaCl, resulted in the shifting of the CD signals (9 nm), in addition to a slight increase 
of the positive band at 280 nm and a small decrease of the band at 250 nm. A new band was 
also observed between 350-450 nm, and its intensity increased with the level of DNA 
ruthenation (Figure 5.8). These change indicates that complex 8 binds strongly to DNA, and 
possibly, induces slight conformational changes. However, it is not clear if the changes on the 
CD spectrum are due to alterations in the DNA conformation in addition to the induced 
signals from the complex. By analogy with the changes in CD obtained by reacting CT-DNA 
with [(bip)Ru(en)Cl]+ (RM175), it is reasonable to suggest that complex 8 binds to double 
helical DNA, and generates slight conformational changes.22 Furthermore, the induction 
bands from the complex, seem to be related to the presence of the extended arene, probably 
due to intercalation into the DNA. 13, 22 
Interaction between complex 2 and CT-DNA was also studied by CD, although no 
changes could be observed in the spectrum (Figure 5.7). The CD results obtained for complex 
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[(p-cym)Ru(TsEn)Cl] (2), suggest that the conformational changes induced on DNA are 
different from those induced by [(bip)Ru(TsEn)Cl] (8). The different behaviour when using 
the arene p-cym or bip can also be observed with the ethylenediamine analogues.22 
Flow linear dichroism is a technique used to study the structure and relative orientation 
of a molecule. The spectra obtained are the result of the difference in absorption of parallel 
and perpendicular polarized light to an orientation axis. The technique has been used to study 
interactions between DNA and ligands or metal complexes.36 
In a typical spectrum of CT-DNA, negative bands at 260 and 190 nm can be observed. 
These bands correspond to the absorbance of DNA bases which are oriented with an angle of 
80 ͦ from the DNA backbone. An increase on the LD absorbance at 260 nm is indicative of 
more stiff or rigid DNA.36 Per contra, a decrease on the LD absorbance at 260 nm is a 
response to the loss of linearity and orientation, in general, due to curling, bending or 
aggregation of DNA.36 
Intercalating molecules are typically responsible for and increase the absorbance at  
260 nm, as a consequence of the loss of flexibility and the increase in the linearity of the 
DNA strings. Furthermore, intercalating molecules bind to DNA in a specific orientation, and 
therefore, induced bands due to intercalator absorbance can be observed.36 Groove binding 
molecules, on the other hand, induce bending curling and aggregation on the DNA, and 
therefore a decrease on the absorbance at 260 nm. Similar to the case with intercalators, the 
binding is generally oriented and induction bands can be observed.36 
A series of LD experiments were performed using complex 2 and 8. In both cases, 
interaction with DNA shows a slight decrease in the intensity of the LD signal. Those 
changes are probably due to the complexes binding in the minor groves of DNA, and the 
nucleic acid chain bending or aggregating.22 However, the effect of the Ru(II) complexes on 
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the DNA is remarkably weak, suggesting that the complex does not have a great affinity for 
DNA. Subtraction of the LD absorbance of CT-DNA for the spectra obtained when reacting 
with the complexes, gave induced spectra which can be overlapped with the corresponding 
UV spectrum of the complex, although, the induced bands are very weak.  
With all of the information obtained previously we can postulate that complexes 2 and 
8 have the ability to interact with DNA. However, the interaction is very weak. The 
complexes do not coordinate directly to DNA, but probably by binding to the minor grooves. 
Comparing with the ethylenediamine complexes we can predict that compound 8 probably 
binds to the groove generating bending or aggregation of DNA but also intercalates through 
the biphenyl arene.22 
 
5.1.4. Conclusions 
In this section, the ability of complexes of the type [(η6-arene)Ru(XEn)Cl]  
(X = mono-sulfonamide) to bind selectively to 9-ethylguanine though the N7 was 
demonstrated. Binding constants for the binding to 9-EtG (mM) are of the same order of 
magnitude as for complex [(bip)Ru(en)Cl]+ (60.3 mM). Such binding constants indicate that 
complexes 2 and 8 have an ability to bind 9-EtG, and possibly, DNA. However, coordination 
with DNA does not occur, probably due to sterically effects. DNA melting temperatures 
show that the complexes interact with DNA and destabilize its structure, which indicates that 
intercalation and coordination are not the main binding mode of the Ru(II) complexes to 
DNA. Instead, groove binding seems more plausible. Interestingly, complex  
[(p-cym)Ru(TsEn)Cl (2) and [(bip)Ru(TsEn)Cl] (8) have similar effects on the DNA. On the 
other hand, complex RM175, stabilizes the DNA (∆ melting temperature = +14 degrees), 
which is in concordance with the compound coordinating DNA, reported previously.37 
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Complex 8 seems to affect the conformation of the DNA slightly, probably through a certain 
degree of intercalation of the biphenyl unit into the nucleobases. Finally, LD experiments 
demonstrate that both complexes, 2 and 8, are capable of bending or aggregating DNA, 
probably through groove binding.  
Complexes 2 and 8 interact weakly with DNA. Furthermore, the complexes react in a 
very different manner than their analogous ethylenediamine complexes, such as RM175, 
which coordinates directly to DNA and stabilises its structure. 
More studies are necessary to assess the relevance of this interaction and if those 
complexes can target DNA. However, DNA as a target seems improbable since the 
interactions with DNA are not strong.  
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5.2. Glutathione (GSH) 
5.2.1. Introduction 
Glutathione (GSH) is a tri-peptide (γ-L-glutamate-L-cysteineyl-glycine) present in cells 
(Figure 5.11). GSH exists in two different forms, oxidized (GSSG) and reduced (GSH). 
Under normal conditions, the GSH concentrations in mammalian cells are between 5 and  
10 mM, with the reduced GSH predominating over the oxidized form.38 Although GSH is 
synthesized in the cytosol, it is distributed to different intracellular organelles. In addition to 
the cytosolic pool, GSH is mainly found in the endoplasmic reticulum, nucleus, and 
mitochondria. Each organocell GSH pool is relatively independent. At physiological pH, 
glutathione has a negative charge since the two carboxylic acids (pKa1 = 2.12, pKa2 = 3.59) 
are deprotonated while the amine (pKa = 8.75) is found in the protonated form. 
 
Figure 5.11.  Structure of glutathione (GSH) and glutathione disulfide (GSSG) at pH 7.4 
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The glutathione couple (GSH/GSSG) is a critically important redox player together 
with other redox active couples. GSH acts as an antioxidant which prevents damage caused 
by reactive oxygen species (ROS) and reactive nitrogen species (RNS). Under normal 
conditions, when a cell is not stressed, the processes that generate ROS are well 
counterbalanced by antioxidant systems, with the GSH couple often considered to be the 
main defence system. 38, 39 
GSH can also act as a scaffold to transport some toxins outside the cell for later 
disposal from the body. Many toxic metabolites are produced as side-products of the normal 
cellular metabolism. Those metabolites can then react with GSH via some enzymatic reaction 
or in some cases with GS● radicals formed from reactions with ROS. Those GS-X adducts 
are then excreted from the cell. Most glutathione S-conjugates are metabolized outside the 
cell to the corresponding N-acetyl cysteine S-conjugates and excreted through the urine and 
bile. γ-L-glutamate and glycine residues are usually recovered.38, 39 Both GSH and GSSG 
generated in the liver, circulate in the blood stream and are used to supply other organs. GSH 
is then used to detoxify injurious external agents from epithelial cells that contact with the 
exterior, such as intestine and lungs. Finally, this detoxification method is also applied in the 
case of external toxins, as in the case of some anticancer drugs. When complexes with similar 
reactivity as cisplatin enter the cell and hydrolyse, they can react with nucleophiles such as 
GSH. Adducts of GSH with the complexes (GS-X) are formed readily due to the high 
concentration of GSH in the cytosol and the function of some enzymes such as glutathione-s-
transferase. Then, GS-X adducts are transported to the outside of the cell. Cisplatin-resistant 
cells have increased the levels of GSH and enzymes that catalyse GS-X formation.40 
The role of GSH is not only as an antioxidant or detoxifying agent, but it is also 
involved in many other metabolic processes (such as storage and transport of nitric oxide, 
participation in the metabolism of estrogens, leukotrienes, and prostaglandins, the reduction 
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of ribonucleotides to deoxyribonucleotides, the maturation of iron-sulfur clusters of diverse 
proteins and it is involved in the operation of certain transcription factors).38 
Due to the importance of GSH in controlling high levels of oxidative stress, it is not 
surprising that it had become a possible target for cancer therapy. Furthermore, GS- adducts 
are not always excreted from the cell. On the other hand, depletion of GSH might enhance the 
cytotoxic activity of other anticancer drugs such as cisplatin.41  
In this section, reaction of GSH and GSSG with the complex [(p-cym)Ru(TsEn)Cl] (2) 
are studied as a model for the complexes of this type.  
 
5.2.2. Experimental 
 
5.2.2.1. Materials 
The ruthenium(II) complex [(p-cym)Ru(TsEn)Cl] (2) was synthesised as described in 
Chapter 3. Trifluoroacetic acid (TFA), glutathione reduced (GSH) and glutathione oxidized 
(GSSG) were obtained from Sigma-Aldrich. Potassium hydroxide, sodium chloride and 
perchloric acid were obtained from Fisher Scientific. Non-dried solvents were obtained from 
Fisher Scientific. The solvents used for HPLC and LC-MS were purchased from Fisher 
Scientific. D2O (99.9 % D) for NMR spectroscopy was purchased from Sigma-Aldrich.  
5.2.2.2. Interaction with GSH 
A stock solution of complex 2 (1.4 mM) in D2O was prepared and 300 µL added to a  
5 mm diameter NMR tubes containing 300 µL of a GSH solution (14 mM, ratio  
1:10 complex to GSH). The pH* of the reaction mixture was adjusted to 7.2 ± 0.1 and the 
reaction monitored by 1H NMR spectroscopy. 1H NMR spectra were recorded at 310 K 
during a period of 24 h on a Bruker AV III 600 spectrometer.  
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The experiment was repeated using a different concentrations of GSH, ratios 1:3, 1:2.5, 
1:2 and 1:1 complex:GSH. The pH* of the reaction mixture was also adjusted to 7.2 ± 0.1 
and the reaction monitored by 1H NMR spectroscopy. 1H NMR spectra were recorded at  
310 K during and at 24 h on a Bruker DRX 500 spectrometer. 
A NMR tube containing complex 2 and GSH in D2O (ratio 1:10) was also prepared 
under a nitrogen atmosphere (oxygen free). The pH* was adjusted to 7.2 ± 0.1 and the 
reaction monitored for a period of 24 h at 310 K on a Bruker AV III 600 spectrometer. 
5.2.2.3. Identification of species 
A reaction mixture of complex 2 with GSH in a molar ratio of 1 to 3 was prepared by 
adding 1 mL of solution of the complex (1.4 mM) and 1 mL of a solution GSH (2.1 mM), 
both solutions previously adjusted to pH 7.2 ± 0.1 using KOH and HClO4. The reactions were 
incubated at 310 K for 24 h. HPLC analysis on the reaction mixture was performed in order 
to adjust the gradient and separate all the product peaks HPLC experiment were performed in 
collaboration with Prof. Socorro P. Murdoch.  
The column used for HPLC and LC-MS was an Agilent ZORBAX Eclipse Plus C-18 
(250 x 4.6 mm, 5 µm pore size, PJS-44). The mobile phases were A: water (HPLC grade, 
Aldrich) containing 0.1 % trifluoroacetic acid, and B: acetonitrile (HPLC grade, Aldrich) 
containing 0.1% trifluoroacetic acid. Gradients in Table 5.7. The flow rate was 1 mL min-1, 
wavelength of detection 254 and 210 nm with the reference wavelength at 510 nm. 
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Table 5.7. HPLC and LC-MS gradients for the separation of the products from the reaction 
of complex 2 with GSH. Total run of 60 min. 
 
Time (min) % of B (acetonitrile, 0.1 % TFA) 
0 2 
10 12 
15 15 
20 20 
25 20 
30 50 
50 50 
60 2 
 
A reaction following the same procedure as that described above was carried out  
(1:3 mol equiv. complex:GSH). An aliquot of 0.5 mL was removed from the reaction mixture 
and frozen at times 0, 1, 4, 7 and 12 h. The samples were later analyzed by LC-MS. 
In order to obtain mass spectra with higher resolution, a freshly prepared sample of the 
reaction after incubation 12 h was analysed by LC-HRMS, using a Dionex Ultimate 3000 
with a VWD detector coupled to a Bruker MaXis UHR-ESI-TOF mass spectrometer.  
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5.2.3. Results 
5.2.3.1. Interaction with glutathione (GSH) 
A stock solution of complex 2 in D2O was added to a NMR tube containing a solution 
of GSH (ratio 1:10 complex:GSH) at pH* 7.2 ± 0.1. 1H NMR spectra were recorded at 310 K 
over 10 hours (Figure 5.12). The reaction was complete with 100 % conversion of the 
complex by the time the first NMR spectrum was recorded (< 10 min). A small shift of the 
resonances corresponding to the TsEn ligand (N-(2-aminoethyl)-4-toluensulfonamide) was 
observed (ca. 0.02 and 0.06 ppm), which correspond to free ligand. Two sets of peaks for the 
p-cym bound to Ru were observed, one of which corresponds to a non-symmetric product 
 (4 peaks corresponding to 4 protons of the p-cym unit) and a second one corresponding to a 
symmetric product (2 peaks corresponding to 4 protons of a p-cym unit). 5 % of free  
p-cymene can be observed (7.21 ppm). Finally a new multiplet at 3.15 ppm was observed. 
The integral of the multiplete was that of 1.75 – 2.5 protons per proton corresponding to the 
aromatic TsEn ligand. However, precise integration was not possible. 1H NMR spectrum over 
time (ca. 10 h) did not show any change. No formation of GSSG could be detected after 10 h 
reaction. 
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Figure 5.12. 1H NMR (600 MHz) spectrum of the reaction between complex 2 and 10 mol 
equiv. of GSH. The pH* was adjusted to 7.2 ± 0.1 and the spectra recorded at 310 K within 
10 min of mixing. The blue dots correspond to new peaks probably due to GS- in product 1 
or product 2. Unreacted GSH can be observed;  
A series of experiments using complex 2 and different concentrations of GSH  
(ratio 1:3, 1:2.5, 1:2 and 1:1) were carried out. The results are similar to those described 
above. 100 % of the GSH reacted with complex 2 in less than 10 min at 310 K, pH*  
7.2 ± 0.1. No further reaction was observed in 10 h after the first 1H NMR spectrum was 
recorded. 
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Figure 5.13. 1H NMR (500 MHz) spectra of the reaction between complex 2 and GSH. The 
pH* was adjusted to 7.2 ± 0.1 and the spectra recorded at 310 K within 10 min of mixing. 
The blue dots correspond to new peaks. Zoom of the peaks between 5 and 7 ppm is depicted 
in figure 5.14. In the first spectrum, 3 mol equiv. of GSH were used, peaks corresponding to 
free GSH are observed. In forth spectrum, 1 mol equiv. of GSH was used, Peaks 
corresponding to free GSH can not be observed, however, signals from the intact complex 
can be assigned.  
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Figure 5.14. 1H NMR (500 MHz) spectra, between 5 and 7 ppm, of the reaction between 
complex 2 and GSH. The pH* was adjusted to 7.2 ± 0.1 and the spectra recorded at 310 K 
within 10 min of mixing. In the first spectrum, 3 mol equiv. of GSH were used, peaks 
corresponding to two different products can be observed, one being symmetrical and another 
non-symmetrical. In the third spectrum, 1 mol equiv. of GSH was used, peaks corresponding 
to complex 2 can be observed in addition to some peaks corresponding to the different 
products from the reaction. 
A stock solution of complex 2 in D2O was added to a NMR tube containing a solution 
of GSH (ratio 1:10 complex:GSH) at pH* 7.2 ± 0.1. The reaction was prepared under 
nitrogen and the NMR tube filled with nitrogen before sealing. 1H NMR spectra were 
Chapter 5 
211 
 
recorded at 310 K over a period of 10 hours. 1H NMR spectra show the same results obtained 
previously for the reaction containing oxygen (air). 
5.2.3.2. Identification of species by LC-MS 
A reaction of complex 2 (0.4 mM) with 3 mol equiv. of GSH (1.2 mM) was carried out 
in H2O, pH adjusted to 7.2 ± 0.1. Samples were diluted to working concentrations with 
double distilled water. HPLC analysis was performed and the gradient optimised in order to 
separate the different species. At time < 10 min, six main peaks are observed. At time 12 h, 
three extra peaks appeared. Freshly prepared samples were then analysed by LC-MS using 
the gradient previously optimised (Figure 5.15).  
 
Figure 5.15. HPLC chromatogram, monitored at λ = 254 nm, for the reaction between 
complex 2 and 3 mol equiv. of GSH. The reaction was performed in H2O, 310 K and  
pH 7.2 ± 0.1. The sample was analysed at times <10 min, 1, 4, 7 and 12 h. See assignments in 
Table 5.8. 
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Figure 5.16.  HPLC  chromatogram, monitored at λ = 254 nm, of complex 2, GSH, free 
ligand (TsEnH) and the reaction mixture after incubating complex 2 with 3 mol equiv. GSH 
for 12 h at 310 K and pH 7.2. For assignments see Table 5.8. 
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Table 5.8. Assignment of the species detected by the LC-MS from the reaction of complex 
[(p-cym)Ru(TsEn)Cl] (2) and GSH (ratio 1:3, respectively). The reaction was performed in 
H2O, at 310 K and pH 7.2 ± 0.1. The wavelength of detection was λ = 254 nm  
(see Figure 5.15). The red boxes show the peaks that grow over time. 
Peak 
Retention 
time (min) 
Observed 
m/z 
Assignment 
Calc. m/z  
c1a 8.6 613.0 
 
308.0 
GSSG + 3 H+ 
m/z = 613.2 
GSH+ 2 H+ 
m/z = 308.1 
c2 16.5 693-694b [((p-cym)2Ru2(µ-GS)3]+4H+ 
m/z = 695.6 
c3 17.1 542.0 {(p-cym)Ru(GS)}+H+ 
m/z = 542.1 
c4 18.3 846-849b {(p-cym)Ru(GS)2}+3H+ 
m/z = 849.2 
c5a 22.4 215.4 [TsEnH] + H+ 
m/z = 215.1 
c6 23.8 475.3 Unknown  
c7 25.0 475.3 Unknown 
c8 28.5 475.3 Unknown 
c9a 32.2 449.0 [M-Cl]+ 
m/z = 449.1 
a
 peaks assigned by comparison with the controls. GSH, free ligand TsEnH and 
complex 2. b The resolution is too low and the peak is not clear. 
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Figure 5.17. Mass spectra of the species (A) c3 (m/z = 542.1) and (C) c9 (m/z = 449.1) 
detected at time = 12 h from the reaction of complex [(p-cym)Ru(TsEn)Cl] (2) and GSH 
(ratio 1:3, respectively). The reaction was performed in H2O at 310 K and pH 7.2 ± 0.1. The 
species are assigned to {[(p-cym)Ru(GS)]}+H+ and [(p-cym)Ru(TsEn)]+, respectively. 
Simulated spectra (B) and (D) are shown under the experimental data.  
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In order to obtain better resolution in the mass spectra for the peaks c2 and c4, and be 
able to assign the main product, LC-HRMS was performed. For this experiment, complex 2 
and 3 mol equiv. of GSH were incubated at 310 K and pH 7.2 ± 0.1 for 12 h. The column 
used was an Agilent Eclipse plus C18 (1.8 µm 2.1 x 100 mm), shorter than that used in the 
previous experiments. The retention time was now halved and some peaks overlapped with 
each other. 
 
 
Figure 5.18. (A) HPLC chromatogram at λ = 210 nm and (B) high resolution mass spectra 
of the reaction between complex 2 and GSH. The experiment was carried out in H2O, 310 K 
and pH 7.2 ± 0.1 and LC-HRMS recorded in a Dionex Ultimate 3000 with a VWD detector 
coupled to a Bruker MaXis UHR-ESI-TOF mass spectrometer. See assignments in Table 5.9. 
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Table 5.9. Assignment of the peaks in the  chromatogram obtained from LC-HRMS for the 
reaction of complex 2 and 3 mol equiv. of GSH in H2O, 310K and pH 7.2 ± 0.1. For 
chromatogram see Figure 5.18.  
Peak Retention 
time (min) 
Observed 
m/z 
Assignment 
Calc. m/z  
p1 2.4 308.0897 GSH 
m/z = 308.0911  
p2 4.7 613.1586  GSSG 
m/z = 613.1519 
p3 12.9 695.6315 
 
464.0904 
[(p-cym)2Ru2(µ-GS)3]2-+4H+ 
m/z = 695.6322 
[(p-cym)2Ru2(µ-GS)3]2-+5H+ 
m/z =  464.0905 
p4 13.3 215.0845 [TsEnH] + H+ 
m/z = 215.0849 
Chapter 5 
217 
 
   .
 
Figure 5.19. High resolution mass spectra, recorded on a Bruker MaXis UHR-ESI-TOF 
mass spectrometer, of the product p3 from the reaction between complex 2 and  
GSH in H2O, 310 K and pH 7.2 ± 0.1(see Figure 5.18). The peaks are assigned to  
(A) ([(p-cym)2Ru2(µ-GS)3] + 4H+)2+ and (C) ) ([(p-cym)2Ru2(µ-GS)3] + 5H+)3+. Simulated 
spectra (B) and (D) are shown under the experimental data.  
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5.2.4. Discussion 
Many platinum drugs such as cisplatin and carboplatin react with GSH to form GS-Pt 
adducts which are excreted from the cell.3 Other metallodrugs containing gold(I), 
bismuth(III), tellurium(IV) or rhenium(V) also display a high affinity for nuchleophilic S 
such as cysteine.42 In particular, ruthenium complexes have been shown to react with 
cysteine-containing proteins and peptides readily. RAPTA complexes, for example, have 
been shown to potentially inhibit glutathione-S-tranferase by binding to the cysteine in the 
active center,43 as well as other cysteine-containing proteins,42, 44 or peptides like 
glutathione.45 Other ruthenium complexes such as KP1019 are known to react with biological 
reductants such as glutathione. [(η6-arene)Ru(azpy)I]+ (azpy = N,N-dimethylphenyl- or 
hydroxyphenyl-azopyridine) complexes undergo activation by ligand reduction and appears 
to act as a catalyst to oxidise GSH.35, 46 [(p-cym)RuCl(o-pda)]+ (o-pda = o-phenylenediamine) 
undergoes ligand-based oxidation and hydrolysis. Interestingly, glutathione can reduce the 
complex which is oxidized readily by oxygen.47 [(p-cym)Ru(en)Cl]+ have been shown to bind 
to serum Cys34 of albumin and induce oxidation.13 Other ethylenediamine ruthenium 
derivates have been shown to oxidize glutathione to its sulfenato analogue then bind to 
DNA.15 Glutathione has also been shown to facilitate binding to N7 guanine in DNA for  
[(η6-arene)Ru(en)Cl]+ complexes after binding to the complex and being oxidised.16 In this 
section, the interaction of glutathione with complex 2 was studied. 
A first set of experiments using complex 2 and a large excess of GSH was followed by 
1H-NMR. All the spectral changes occurred within the first 10 min. A new peak (multiplet) at 
3.15 ppm which was identified as a new signal for the protons from cysteine (CH2) of bound 
glutathione (GS-). The resonances for the non-cysteine protons of bound GSH overlap with 
those from free GSH. The reaction between complex 2 and different concentrations of GSH 
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was followed by 1H NMR to be able to assign all the peaks of bound GSH when all GSH has 
reacted (Figure 5.13).  
Release of the TsEn ligand is evident from comparison of the 1H-NMR spectrum of the 
free ligand with that of the reaction mixture (Figure 5.13 and Figure 5.15).  
The peaks corresponding to the p-cym arene split into two different sets. Both p-cym 
types are bound to the ruthenium centre as can be seen by the chemical shift (5-6 ppm). 
Integration of the p-cym peaks and the new peak corresponding to the cysteine of the GSH 
adduct, gives a ratio 1:3.5 p-cym:GSH. 
Based on the NMR data, the complex undergoes ligand substitution, losing the TsEnH 
ligand, to form two different species containing GSH, however more analysis is needed to 
elucidate their nature. 
The reaction between complex 2 and GSH (ratio 1:3, pH 7.2 ± 0.1, 310 K) was 
analyzed by HPLC and LC-MS. HPLC chromatograms were recorded at times < 10 min, 1, 4, 
7 and 12 h. Six main peaks were observed at < 10 min (Figure 5.15). At times 1, 4, 7 and 12 
h, three additional peaks appeared and increased in intensity (Figure 5.15). 
The analysis of the chromatogram recorded at < 10 min indicates that the Ru(II) 
complex undergoes ligand substitution in the presence of GSH. A peak corresponding to the 
TsEnH ligand was observed with a retention time of 22.4 min. Mono-GSH adduct  
{(p-cym)Ru(GS)} (peak at 17.2 min, m/z = 542) and a di-GS dimer [((p-cym)Ru)2(µ-GS)3]2- 
(peak at 16.5 min, m/z = 695.6) are formed. (Figure 5.15, Figure 5.17, Table 5.8). The exact 
mass of the peak at 16.5 min (m/z 695.6322) was obtained by high resolution analysis in  
LC-HRMS. The peak at 28.5 min could not be identified, however, the isotopic pattern shows 
that it does not contain ruthenium. (Figure 5.18, Figure 5.19, Table 5.9) 
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The analysis of the  chromatogram recorded at time 12 h suggest that  
[((p-cym)Ru)2(µ-GS)2(GS)2]4- might be formed, slowly, over time (peak at 18.3 min,  
[((p-cym) Ru)2(µ-GS)2(GS)2] + 5H+ m/z = 849.2). However, the resolution of the mass 
spectrum was too poor for confirmation. Two new unidentified peaks which do not contain 
ruthenium appeared at 23.8 and 25.0 min.(Figure 5.15, Figure 5.17, Table 5.8) 
These results are significatively different from those obtained with the analogous 
ethylenediamine complexes [(η6-arene)Ru(en)Cl]+
 
at pH 7. Complex [(bip)Ru(en)Cl]+ 
(RM175) has been shown to react readily with GSH to form the GSH adduct 
[(bip)Ru(en)(GS)] which later is converted to [(bip)Ru(en)(GS(O)] by oxidation of the bound 
GSH in the presence of oxygen. The sulfenato complex can then react with DNA. When the 
reaction is performed under inert atmosphere, the oxidation of the GS- does not occur, 
however the GS- adduct is still the main product. 15 
Instead, the reaction of complex 2 with GSH resembles more that of complex RM175 
when at pH 3. In such a case, the formation of {(bip)Ru(GS)} and the Ru(II) dimer 
[((bip)Ru)2(µ-GS)3]2- are observed. However, in contrast with the reaction between RM175 
and GSH, no oxidation of the GS- in {(p-cym)Ru(GS)} to the sulfenato adduct  
[(p-cym)Ru(GS(O))]
 
were observed over a period of 12 h using complex 215, 48 
Based on the analysis by 1H NMR and LC-MS, the reaction of GSH with complex 2 at 
310 K and pH 7.2 ± 0.1 leads to the formation of {(p-cym)Ru(GS)} and a Ru(II) dimer with 
three GS- bound through a sulfur bridge [((p-cym)Ru)2(µ-GS)3]2-. {(p-cym)Ru(GS)} could 
arise from fragmentation of a ruthenium dimer containing only two GS-  
[((p-cym)Ru)2(µ-GS)2Cl2]2-. 
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Figure 5.20. Proposed structures for the products from reaction of complex 2 with GSH 
Recently, Süss-Fink et. al. has reported the synthesis and biological activity of a series 
of ruthenium dimers containing two or three thiolato bridges.  It was shown that complexes of 
the type [((p-cym)Ru)2(µ-SR)3]+ (SR = SPh, SC6H4-p-tBu, SC6H4-p-CH3) are highly 
cytotoxic toward human ovarian cancer cells, with IC50 values in the nanomolar range, 
among the most active arene ruthenium complexes evaluated.49-51 The neutral ruthenium 
dimers of the type [((p-cym)Ru)2(µ-SR)2Cl2] (R = CH2Ph, CH2C6H4-p-tBu) were found to be 
less cytotoxic than [((p-cym)Ru)2(µ-SR)3]+.52 These ruthenium dimers containing three 
thiolate bridges have been shown to catalyse the oxidation of GSH to GSSG, but such redox 
reactions does not seem to be involved in the mechanism of action since the Rh(III) and 
Ir(III) Cp* analogues show similar IC50 values but do not show any catalytic activity. 53 
Complex [((p-cym)Ru)2(µ-GS)3]2-, generated in situ through the reaction of complex 2 
with GSH, has a similar structure and characteristics as those described by Süss-Fink et al.,54 
suggesting that this complex could display some antiproliferative activity. 
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5.2.5. Conclusions 
The reaction of complex [(p-cym)Ru(TsEn)Cl] (2) with GSH at pH 7.2 ± 0.1 and 310 K 
was studied in this section. 1H NMR data show the formation of 2 different p-cym containing 
molecules, and the release of the TsEn ligand (TsEnH). LC-MS data, also shows the 
formation of TsEnH, in addition to two main Ru(II) products, [((p-cym)Ru)2(µ-GS)3]2- and 
{(p-cym)Ru(GS)}. No further spectral changes were observed by 1H NMR after the initial 
spectrum was recorded. However, the formation of a third Ru(II) species was observed by 
LC-MS over a period of 12 hours, but it could not be identified due to the low resolution of 
the mass spectrum. The reaction of complex 2 with GSH resembles that of RM175, 
[(bip)Ru(en)Cl]+, when at pH 3.15, 48. Interestingly, the formation of [((p-cym)Ru)2(µ-GS)3]2- 
was now achieved under biological relevant conditions suggesting that the ligand TsEn is 
more labil than ethylenediamine (en). 
Recently, Süss-Fink et. al. reported a series of complexes of the type  
[((p-cym)Ru)2(µ-SX)3]+ (SX = sulphur containing molecule) which display very high 
antiproliferative activities (0.12 - 1.7 µM). 53, 54 [((p-cym)Ru)2(µ-GS)3]2-, products of the 
reaction between GSH and complex 2, show similar structure to that described by Süss-Fink, 
and therefore, it is possible such dimmers play an important role in the low IC50 of complex 2 
(13.6 ± 0.6 µM).  
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6. Rhodium(III) half-sandwich complexes for the 
catalytic reduction of NAD+ 
 
6.1. Introduction 
Ruthenium(II) catalysts of the type [(η6-arene)Ru(XEn)Cl] where  
XEn = N-(2-aminoethyl)-4-Nitrobenzenesulfonamide (NbEn), N-(2-aminoethyl)-4-
(trifluoromethyl)benzenesulfonamide (TfEn), N-(2-aminoethyl)-4-toluenesulfonamide 
(TsEn), or N-(2-aminoethyl)methylenesulfonamide (MsEn), and η6-arene = p-cymene, 
biphenyl, hexamethylbenzene or benzene have been studied in Chapter 3 for the transfer 
hydrogenation reactions of NAD+ using sodium formate as a hydride source to obtain  
1,4-NADH. The biological use of those complexes was also investigated, showing that the 
complex can affect the ratio of NAD+ to NADH in a catalytic manner. This chapter will 
attempt to improve the catalytic activity of those complexes by changing the Ru(II) metal 
centre to Rh(III).  
In the field of transfer hydrogenation, half-sandwich Ru(II), Rh(III) and Ir(III) catalysts 
have been very successful.1-4 Within those, ruthenium complexes hold a prominent position 
partly explained by the tendency of the catalysts to be less reactive than rhodium or iridium, 
in many cases allowing higher regio- and chemo-selectivity. On the other hand, Rh-based 
catalysts have also been intensively studied,5,6,7,8 showing in many cases increased activities, 
yet, the high activity might correlate with a loss of chemo- and enantio-selectivity in some 
cases. Nevertheless, ultimately, their catalytic activity and enantio-selectivity depend on the 
choice of appropriate chiral ligands, the substrate, the hydride donor and the conditions of the 
reaction. 6, 9-17  
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The Rh(III)-based analogues of Noyori’s type catalysts [(Cp*)Rh(TsDPEN)Cl]  
(were TsDPEN = (1S,2S)-N-(p-toluensulfonyl)-1,2-diphenylethylenendiamine) have been 
reported to reduce imines with higher activity and enantio-selectivity than the ruthenium 
analogues. 14,18 In contrast, the catalytic activities of those complexes towards simple ketones 
have been shown to be lower than for Ru(II) complexes.19 On the other hand, better activity 
and enantio-selectivity was shown when reducing chlorinated ketones with the Rh(III) 
catalysts in comparison with the Ru(II) analogues.1,6,14 Interestingly, the use of 
[(Cp*)Rh(TsDPEN)Cl] gave rise to higher catalytic activities with good enantio-selectivity 
for the reduction of a wide range of ketones compared with the ruthenium analogues when 
used in aqueous media.1,20 
For the catalytic regeneration of NADH a library of Rh(III) complexes of the type 
[(Cp*)Rh(N,N′)Cl]+, where N,N′ is phenantroline, bypiridyne and derivates, has been 
synthesized by Stekhan and Štrĕpnička (Table 6.1).21-24 Those complexes were mainly 
synthesized in order to regenerate the cofactor NADH necessary for the enzymatic reduction 
of alcohols. Rh(III) complexes have shown, in general, higher turnover frequencies compared 
with their Ru(II) analogues and other ruthenium complexes (ca. 0.0053 to 10 h-1).21-23 The 
results in the literature show that higher activities can be achieved by using Rh(III) instead of 
Ru(II) complexes. 
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Table 6.1. Turnover frequencies of some of the Rh(III) catalysts synthesized by Stekhan and 
Štrĕpnička. (a) 5 M sodium formate, 0.38 mM NAD+, 0.025 mM complex, temp. 311 K, 
phosphate buffer pH 7. (b), 350 mM sodium formate, 8 mM NAD+, 0.008 mM complex, 
temp. 340 K, phosphate buffer pH 7. 21-24 
Compound TOF (h-1) 
[(Cp*)Rh(bipy)Cl]+ 77.5a 
[(Cp*)Rh(phen)Cl]+ 70.9a 
[(Cp*)Rh(4,4’-dimethylbipy)Cl]+ 76.4a 
[(Cp*)Rh(bipy)Cl]+ 875b 
[(Cp*)Rh(phen)Cl]+ 2000b 
[(Cp*)Rh(nitrophen)Cl]+ 1740b 
 
In this chapter, the synthesis of a series of organometallic rhodium (III) complexes of 
the type [(Cpx)Rh(N,N′)Cl] is described, where Cpx = pentamethylcyclopentadienyl (Cp*),  
1-phenyl-2,3,4,5-tetramethylcyclopentadienyl (CpxPh) or 1-biphenyl-2,3,4,5-
tetramethylcyclopentadienyl (CpxPhPh), and N,N′ = ethylenendiamine (en) or  
N-(2-aminoethyl)-4-(trifluoromethyl)benzenesulfonamide (TfEn) as bidentate ligands. The 
turnover frequences for the reduction of NAD+ under biological relevant conditions and using 
sodium formate as a hydride source were determined. The catalytic cycle was investigated 
and compared with their Ru(II) analogues and the [(Cp*)Rh(bipy)Cl] complex reported 
previously by Fish et al.25-29 
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6.2. Experimental 
6.2.1. Materials 
The Rh(III)-arene precursor dimers [(Cpx)RhCl2]2 where the Cpx is 
pentamethylcyclopentenyl (Cp*), 1-phenyl-2,3,4,5-tetramethylcyclopentenyl (CpxPh) or  
1-biphenyl-2,3,4,5-tetramethylcyclopentenyl (CpxPhPh) were prepared following literature 
methods,30 as was the ligand N-(2-aminoethyl)-4-(trifluoromethyl)benzenesulfonamide 
(TfEnH).31 Ethylenendiamine (en) was purchased from Sigma-Aldrich and freshly distilled 
prior to use. Magnesium sulphate, ammonium hexafluorophosphate, silver nitrate, potassium 
hydroxide, sodium chloride, perchloric acid and hydrochloric acid were obtained from Fisher 
Scientific. DMSO-d6, MeOD-d4, D2O, (CD3)2CO-d6 and CDCl3 for NMR spectroscopy were 
purchased from Sigma-Aldrich and Cambridge Isotope Labs Inc. Non-dried solvents used in 
syntheses were obtained from Fisher Scientific and Prolabo.  
6.2.2. Synthesis and characterisation of the complexes32 
 
[(Cp*)Rh(en)Cl]PF6 (17). [(Cp*)RhCl2]2 (51.3 mg, 83.0 µmol) was placed in a round-
bottom flask to which dichloromethane (50 mL) was added. Upon the addition of 
ethylenendiamine (9.88 mg, 0.16 mmol, 11 µl) the solution turned bright yellow. The 
solution was stirred under nitrogen overnight, after which the solvent was removed on the 
rotary evaporator to afford a light yellow powder. The crude product was redissolved in 
methanol and filtered. An excess of ammonium hexafluorophosphate (257.5 mg) was then 
added and the solution stored in the freezer. Bright yellow crystals were collected.  
Yield: 42.3 mg (78.3 %). 1H NMR (400 MHz, CDCl3): δH 5.91 (s, 2H), 3.05 (s, 2H),  
2.88 (s, 2H), 2.74 (s, 2H), 1.90 (s, 15H). Anal: Calc for C12H23ClF6N2PRh C: 27.91, H: 4.61, 
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N: 6.21; Found C: 28.11, H: 4.81, N: 5.95. ESI-MS: Calc for C12H23ClN2O2Rh  
(M)+ 333.0 m/z found 333.0 m/z.  
[(Cp*Ph)Rh(en)Cl]PF6 (18). Complex 18 was obtained following the method 
described above for complex 17 using the dimer [(CpxPh)RhCl2]2 (50.5 mg, 68.0 µmol). 
Recrystallisation from methanol resulted in bright yellow crystals. Yield: 31.7 mg  
(59.0 %).1H NMR (400 MHz, CDCl3): δH 7.49 (m, 5H), 5.59 (s, 2H), 3.11 (s, 2H),  
3.02 (s, 2H), 2.76 (s, 2H), 2.05 (s, 6H), 1.91 (s, 6H). Anal: Calc for C17H25ClF6N2PRh  
C: 37.76, H: 4.66, N: 5.18; Found C: 37.02, H: 4.67, N: 5.26. ESI-MS: Calc for 
C17H25ClN2Rh (M)+ 395.0 m/z found 395.0 m/z.  
[(CpxPhPh)Rh(en)Cl]PF6 (19). Complex 19 was obtained following the method 
described above for complex 17 using the dimer [(CpxPhPh)RhCl2]2 (51.6 mg, 57.6 µmol). 
Recrystallisation from methanol resulted in bright yellow crystals. Yield: 47.7 mg ( 54.2 %) 
1H NMR (400 MHz, CDCl3): δH 7.69 (d, 2H, J = 8.4 Hz), 7.60 (m, 4H), 5.49 (t, 2H, J = 7.5 
Hz), 7.41 (t, 1H, J = 7.5), 5.59 (s, 2H), 3.14 (s, 2H), 3.03 (s, 2H), 2.79 (s, 2H), 2.07 (s, 6H), 
1.97 (s, 6H). Anal: Calc for C23H29ClF6N2PRh C: 44.79, H: 4.74, N: 4.54; Found C: 43.98, H: 
4.65, N: 4.54. ESI-MS: Calc for C23H29ClN2Rh (M)+ 471.1 m/z, found 471.1 m/z. 
[(Cp*)Rh(TfEn)Cl] (20). [(Cp*)RhCl2]2 (49.7 mg, 80.4 µmol) and  N-(2-aminoethyl)-
4-(trifluoromethyl)benzenesulfonamide (TfEnH) (53.5 mg, 19.9 mmol) were dissolved in 
dichlormethane (25 mL). The reaction was then stirred under nitrogen atmosphere overnight. 
The solution was placed in a separating funnel and washed with brine, the organic layer 
separated and dried over MgSO4 and filtered. The solution was concentrated in vacuo and the 
product obtained recrystallised from methanol to afford an orange powder. Yield: 40.3 mg 
(46.4 %).1H NMR (400 MHz, CDCl3): δH 8.00 (d, 2H, J = 8.1 Hz), 7.54 (d, 2H, J = 8.1 Hz), 
3.19 (s, 2H), 2.60 (s, 3H), 1.71 (s, 15H). Anal: Calc for C19H25ClF3N2O2RhS C: 42.20,  
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H: 4.66, N: 5.18; Found C: 41.92, H: 4.36, N: 5.01. ESI-MS: Calc. for C19H25ClF3N2O2RhS 
(M-Cl)+ 505.0 m/z, found  505.0 m/z.  
 
6.2.3. Aqueous Solution Chemistry 
Aquation of the chlorido complexes 
Solutions of complexes 17-20 (1.4 mM, in D2O) were prepared and 1H NMR spectra 
recorded every 5 min for a period of 12 h. 1H NMR spectra were recorded at 310 K on a 
Bruker AV III 600 spectrometer (1H = 600 MHz) using 5 mm diameter NMR tubes. All data 
processing was carried out using Topspin 2.1. 1H NMR chemical shifts were internally 
referenced to TMS via 1,4-dioxane in D2O (δ = 3.75). 
An aqueous solution of the chlorido complex 17-20 (1.4 mM) was treated with silver 
nitrate (1 mol equiv.) and stirred overnight at room temperature. 1H NMR spectra were 
recorded after filtration of the samples through Celite to remove the silver chloride salt 
formed.  
Acidity of the Ru-H2O bond and pKa determination 
Changes in the chemical shifts of the methyl protons of the Cpx ligand in the aqua 
adducts for complexes 17-20 with the pH* (pH not corrected for deuterium) over a range 
from 2 to 12 were followed by 1H NMR spectroscopy. Solutions of KOH or HClO4 in D2O 
were used to adjust the pH*. 1H-NMR spectra were recorded at 298 K on a Bruker AV III 
600 spectrometer (1H = 600 MHz) using 5mm diameter tubes. The data were fitted to the 
Henderson–Hasselbalch equation using Origin 7.5.  
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6.2.4. Reduction of NAD+  
Complexes 17-20 were dissolved in D2O (1.4 mM, 4 mL) in a glass vial. Aqueous 
solutions of sodium formate (35 mM, 4 mL) and NAD+ in D2O (7 mM, 2 mL) were also 
prepared and incubated at 310 K. In a typical experiment, an aliquot of 200 µL from each 
solution were added to a 5 mm NMR tube. (Final concentrations for complexes  
17-19 = 0.44 mM, for NAD+ = 2.2 mM and for sodium formate = 11.02 mM; molar  
ratio 1:5:25). Experiments performed with complex 20 were performed at a lower 
concentration of NAD+ due to the lower catalytic activity, in that case 200 µL of the formate 
solution and complex solution were added to a 5 mm NMR tube containing 80 µL of NAD+ 
solution and 120 µL of D2O (Final concentrations for complex 20 = 0.44 mM, for  
NAD+ = 0.88 mM and for sodium formate = 11.02 mM; molar ratio 1:2:25). The pH* of the 
solution mixture was adjusted to 7.2 ± 0.1 bringing the total volume to 0.635 mL 1H NMR 
spectra were recorded at 310 K every 162 s until the completion of the reaction. 
6.2.5. Mechanistic studies 
A set of experiments were performed to elucidate the catalytic cycle of the complexes 
described above. All the experiments were performed with complex 17 (1.4 mM, D2O).  
6.2.5.1. Rate-limiting step 
Reduction of NAD+ using complex 17 and deutero-formate (25 mol equiv.) was 
followed by 1H NMR. The procedure for the kinetic experiment is described in section 6.2.4 
6.2.5.2. Dependence on NAD+ and formate concentrations 
The turnover frequencies of the reduction reaction of NAD+ using complexes 17 or 20 
and formate (25 mol equiv.) were calculated following the same procedure described in 
section 6.2.4. The reaction was studied using different concentrations of NAD+ (1, 2, 3, 4 and 
6 mol equiv.).  
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A second series of experiments using different concentrations of sodium formate  
(2, 5, 10, 25, 50, 100, 200 and 1000 mol equiv.) and a constant concentration of NAD+  
(2 mol equiv.) was also performed.  
6.2.5.3. Transfer hydrogenation reaction with 1,4-NADH as hydride source 
Oxidation of 1,4-NADH (400 µL, 1.4 mM) in D2O by complex 17-20 was studied by 
1H NMR. The pH* of the reaction mixture was adjusted to 7.2 ± 0.1 and the experiment 
performed at 310 K.  
6.2.5.4. pH dependence 
Optimum pH range for the catalytic process was studied in a series of experiments 
following the same procedure described in section 6.2.4. Each experiment was performed at a 
different pH* over a range from 6 to 10. The pH* of the reaction was adjusted using 
deuterated aqueous solutions of KOD and DClO4. 
6.2.6. Antiproliferactive activity 
The antiproliferative activity of complexes 17-20 was determined in A2780 ovarian 
cancer cell lines. IC50 values were calculated following the procedure described in Chapter 2. 
SRB assay was used to determine cell viability. IC50 values were determined as duplicates of 
triplicates in two independent set of experiments. 
Cell viability assays with complexes 17-20 in combination with sodium formate were 
carried out in A2780 ovarian cancer cells. These experiments were carried out as described in 
Chapter 2 with the following modifications: a fixed concentration of each Rh(III) complex 
equal to 150 µM
 
was used with co-administration of three different concentrations of sodium 
formate (0.5, 1 and 2 mM). 
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6.3. Results 
 
6.3.1. Synthesis and characterization 
Rh(III) complexes 17-20 were synthesised (Figure 6.1) using a similar procedure. 
Typically, the ligand (2 - 2.5 mol equiv.), was added to a dichloromethane solution of the 
rhodium dimer, [(Cpx)RhCl2]2 and the reaction mixture stirred under an N2 atmosphere. The 
details for individual reactions are described in the experimental section. All the synthesized 
complexes where characterized by elemental analysis (CHN), mass spectrometry (ESI-MS) 
and 1H NMR spectroscopy. 
 
Figure 6.1. Structures of the complexes studied in this work. 
6.3.2. Aqueous solution chemistry 
Aquation of complexes 17-20 was followed by 1H NMR over a period of 12 h. No 
apparent changes were observed by 1H NMR. Spectra were compared to that of the aqua 
adduct formed by reaction of the corresponding complex with silver nitrate (1 mol equiv.). 
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The rate of aquation of complexes 17-20 was too fast to be determined by 1H NMR, however 
the peaks were assigned to the aqua adducts of the complexes. 
Changes in the 1H NMR chemical shifts of the arene protons from the aqua adduct of 
complexes 17-20 were followed by changing the pH* ranging from 2 to 12. The data were 
fitted to the Henderson–Hasselbalch equation. pKa* values for complexes 17-20 are shown in 
table 6.1. (Figure 6.2). 
 
Figure 6.2. Dependence of the chemical shift of the protons in the arene rings of complexes 
17-20 on the pH*. The red lines represent computer fits to the  
Henderson-Hasselbalchequation.  
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Table 6.2. pKa* values for the aqua adducts of complexes 17-20 at 298 K. 
Compound pKa* 
[(Cp*)Rh(en)Cl] PF6 (17) 9.31 ± 0.06 
[(Cp*Ph)Rh(en)Cl] PF6 (18) 9.44 ± 0.08 
[(Cp*PhPh)Rh(en)Cl] PF6 (19) 9.40 ± 0.04 
 
6.3.3. Kinetics of transfer hydrogenation reactions 
Catalytic transfer hydrogenation to nicotinamide adenine dinucleotide (NAD+)  
in aqueous media using complexes 17-20 as catalyst and formate as hydride source  
(25 mol equiv.) was studied by 1H NMR at 310 K and pH* 7.2 ± 0.1. Spectra were recorded 
every 162 s until completion of the reaction. The turnover frequency (TOF) for the reactions 
was determined as described in the experimental section. 
Table 6.3.  Turnover frequencies for transfer hydrogenation reactions using catalysts 17-20. 
Complex Cpx NN′ ligand 
TOF (h-1) 
D2O 
Complex 17 Cp* en 7.50 ± 0.06 
Complex 18 CpxPh en 19.65 ± 0.01 
Complex 19 CpxPhPh en 24.19 ± 1.03 
Complex 20 Cp* TfEn 4.12 ± 0.01 
 
The turnover frequencies showed a marked dependence on the substituents in Cpx 
(Table 6.3), the TOF increasing in the order CpxPhPh > CpxPh > Cp*. [(CpxPhPh)Rh(en)Cl] 
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PF6 (19), with a TOF of 24.19 h-1, was the most active. The reaction was regioselective 
giving 1,4-NADH in 100 % yield when using complex 19, similar regioselectivity was 
achieved when performing the reaction with complex 17 and 18 (99 %). 
When comparing the ethylenendiamine complex with the complex containing the 
sulphonamide ligand, the catalytic activity decreases. A decrease in the regioselectivity of the 
reaction when using complex 20 was also observed with a 7.5 % of 1,6-NADH  produced.  
 
 
Figure 6.3. 1H NMR spectra after reduction of the NAD+ using catalyst 17-20 and formate as 
a hydride source. The experiment was performed in D2O at pH* 7.2 ± 0.1 and temperature 
310K. Green = Complex, Blue = 1,4-NADH and Red = 1,6-NADH. 
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6.3.4. Mechanistic studies 
Kinetic isotope experiments (KIE) were performed using complex 17 and deutero-
formate (25 mol equiv.) for the reduction of NAD+. The turnover frequency determined using 
deutero-formate was 2.32 ± 0.34h-1. The turnover frequency was 3.6 times lower than that 
obtained using formate (7.50 h-1) as the hydride source. 
Three experiments were performed using complex 17, sodium formate and NAD+ with 
ratio of 1:25:X, respectively, where X = 5, 7.5 and 10 mol equiv. Unchanged turnover 
frequency (7.50 h-1) was obtained when changing the concentration of NAD+. 
A second series of experiments with complex 17, sodium formate and NAD+ in the 
ratio 1:x:5, respectively, where x = 5, 10, 25, 50 or 100 mol equiv. of formate were 
performed. An important effect due to the concentration of formate can be observed  
(Figure 6.4). 
 
Figure 6.4.  Plot of the turnover number against time for the reduction of NAD+ by complex 
17 using formate as a hydride source (ratio 5:1:x, x= 5, 10, 25, 50 or 100 mol equiv. 
respectively. pH* 7.2, temperature 310 K, solvent D2O). Time is referenced to the mixing 
time.  
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Typical Michaelis-Menten behaviour is apparent from a plot of turnover frequency 
versus formate concentration (Figure 6.5).33 Thus, from the double-reciprocal (Figure 6.6)  
the Michaelis constant (KM = 54.16 mM) and the maximum turnover frequency  
(TOFmax = 41.49 h-1) were determined. 
 
 
Figure 6.5. Plot of the TOF against the formate concentration, for the reduction of NAD+ in 
the presence of different formate concentrations, catalyzed by complex  
[(Cp*)Rh(en)Cl]+ (17). 
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Figure 6.6. A plot of the reciprocal of the TOF against that of formate concentration,  
for the reduction of NAD+ in the presence of different mol equiv. of formate,  
catalyzed by complex 17. For a reaction following Michaelis-type kinetics,  
TOF-1= (KM /TOFmax)(1/[S])+(1/TOFmax) and KM and TOFmax can be obtained from the 
gradient and y intercept, respectively. 
Maximum TOF and Michaelis constant for complex [(Cp*)Rh(TsEn)Cl] (20) were 
calculated by performing a series of experiments with different concentrations of sodium 
formate (10, 25, 50, 100 or 500 mol equiv.). Similarly to the behaviour of complex 17, from 
the plot of TOF vs concentration of formate, a typical Michaelis-Menten behaviour was 
obtained. From the double-reciprocal (Figure 6.7) the Michaelis constant (KM = 108.37 mM) 
and the maximum turnover frequency (TOFmax = 37.24 h-1) were calculated. 
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Figure 6.7. Determination of maximum turnover frequency and Michaelis constant for the 
reduction of NAD+ using complex 20 and sodium formate (a) Plot of the TOF against the 
formate concentration, TOF = TOFmax [S]/(KM + [S]). (b) Plot of the reciprocal of the TOF 
against that of formate concentration, TOF-1= (KM/TOFmax)(1/[S])+(1/TOFmax). 
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The pH* dependence of the catalytic reaction (from pH* 4 to 10) was also investigated 
via a series of experiments using complex 17, sodium formate and NAD+ (ratio 1:25:2, 
respectively) in D2O. A dependence on pH* was observed. The highest TOF (7.5 h-1) was 
achieved at pH* 7.3, however the turnover frequencies between pH 6 - 8 are similar.  
A decrease in the catalytic activity was observed when the pH* is higher than 9 (Figure 6.8).  
 
Figure 6.8. Dependence of turnover frequency on the pH* for the reduction of NAD+ by 
complex 1 using formate as a hydride source (mol ratio 5:1:25, respectively, 310 K in D2O). 
Maximum turnover frequency achieved at pH 7.3 ± 0.1. 
6.3.5. Cancer cell growth inhibition 
The IC50 values for the Rh(III) complexes 17, 18, 19 and 20 against A2780 human 
ovarian cancer cells were determined and are listed in Table 6.4. The complexes were found 
to be inactive against A2780 up to a maximum concentration tested (> 100 µM). 
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Table 6.4. IC50 values for [(Cp*)Rh(en)Cl]+ (17), [(CpxPh)Rh(en)Cl]+(18), 
[(CpxPhPh)Rh(en)Cl]+ (19) and [(Cp*)Rh(TfEn)Cl] against A2780 human ovarian cancer 
cells 
Compound IC50 (µM) 
Complex 17 >100 
Complex 18 >100 
Complex 19 >100 
Complex 20 >100 
 
Cell survival experiments with complexes 17, 18, 19 and 20 upon addition of formate at 
concentrations of 0.5, 1 and 2 mM were determined (Figure 6.9). 
 
Figure 6.9. Cell survival of A2780 human ovarian cancer cells when treated with complex 
17, 18, 19 or 20 upon addition of sodium formate at 0.5, 1 or 2 mM concentrations 
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An increase of the antiproliferative activity of the four Rh(III) complexes upon addition 
of formate can be observed. The strongest effect was achieved with complex 
[(CpxPhPh)Rh(en)Cl]+ (19) with a decrease of cell survival of up to 15 %. 
 
6.4. Discussion 
6.4.1. Structures of the complexes 
The aim of this chapter was to improve the catalytic activity of the Ru(II) complexes 
studied for the reduction of NAD+ using sodium formate as a hydride source. For that 
purpose, Rh(III) complexes with the same structure to that of the ruthenium complexes  
[(η6-arene)Ru(XEn)Cl] were synthesised. However, the oxidation state Rh(III) cannot be 
stabilized by electron deficient η6-arenes, therefore the more electron rich 
pentamethylcyclopentadienyl (Cp*) was used. N-(2-aminoethyl)-4-
(trifluoromethyl)benzenesulfonamide (TfEn), the bidentate ligand which showed the highest 
catalytic activity for ruthenium complexes, was selected for the synthesis of complex 20.  
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Complex Metal R1 R2 Arene or Cp ring 
RM175 Ru H H biphenyl 
Complex 2 Ru 
 
- p-cymene 
Complex 3 Ru 
 
- p-cymene 
Complex 17 Rh H H Cp* 
Complex 18 Rh H H CpxPh 
Complex 19 Rh H H CpxPhPh 
Complex 20 Rh 
 
- Cp* 
Figure 6.10.  Ru(II) and Rh(III) complexes studied in this thesis for thre transfer 
hydrogenation reduction of NAD+ using sodium formate as a hydridesource.  
On the other hand, the analogous ethylenendiamine complex [(Cp*)Rh(en)Cl]+ 
(complex 17) was also synthesized as a model to compare with complex [(Cp*)Rh(TsEn)Cl] 
(20). However, complex 17 is more relevant with respect to this project due to higher TOF 
and increased region-selectivity.  
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The catalytic activity of complexes of the type [(Cpx)M(N,N′)X] can be tuned by 
changing the chelating ligand (N,N′) or the Cpx ring. Recently, a series of iridium complexes 
containing Cpx rings with aromatic rings as substituent has been reported.34-36 Those 
complexes have been shown to have good catalytic properties towards transfer 
hydrogenation.37 In order to improve the catalytic activity of [(Cp*)Rh(en)Cl]+ (17), 
complexes containing CpxPh (18) or CpxPhPh (19) have been synthesized. 
6.4.2. Hydrolysis of chlorido complexes and acidity of the aqua complexes 
Aquation of the complexes 17-20 in D2O (1.4 mM) was confirmed by comparing the  
1H NMR spectra of the D2O solution of the complexes and the solutions obtained after 
removal of the chloride by reaction with silver ions (AgNO3). Complexes 17-20 show fast 
hydrolysis at 310K, reaching equilibrium by the time the first 1H NMR was recorded  
(< 6 min). Furthermore, 100% conversion of the chlorido complex to the aqua adduct was 
achieved. Consequently the turnover frequency for the transfer hydrogenation is not affected 
by the use of the chlorido complex instead of the aqua adduct. 
pH* titrations of the complexes 17-19 were performed so that the nature of the 
complexes (aqua or hydroxo adduct) could be determined at pH 7.2. Similar to the ruthenium 
complexes described previously, the pKa* values determined for the Rh complexes 17-19 are 
between 9 and 10. As a result the complexes exist predominantly as aqua adducts at pH close 
to 7.4 (Table 6.2).  
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Table 6.5. Summary of the behaviour of ruthenium and rhodium complexes in aqueous 
media. 
Compound Hydrolysis rateb 
Extent of 
hydrolysisb 
pKa* 
[(bip)Ru(en)Cl]+ (RM175) Fast-moderate a 76.2 % a 7.71a 
[(Cp*)Rh(en)Cl]+ (17) Very fast 100 % 9.31 
[(Cp*Ph)Rh(en)Cl]+ (18) Very fast 100 % 9.44 
[(Cp*PhPh)Rh(en)Cl]+ (19) Very fast 100 % 9.40 
[(p-cym)Ru(TfEn)] (3) Very fast 100 % 9.71 
[(Cp*)Rh(TfEn)Cl] (20) Very fast 100 % ND 
a 
references 38 and 39, hydrolysis rate constant: 1.24·10-3 s-1; ND =  not determined; b 1.4 
mM, 310 K. 
6.4.3. Kinetics of transfer hydrogenation reactions 
The turnover frequency (TOF) for the reduction of NAD+ using complexes 17-19 and 
formate as a hydride source were determined at biological relevant conditions (310 K, pH* 
7.2 ± 0.1). A general tendency in which the more electron-withdrawing Cpx ring leads to 
higher catalytic activity (Table 6.6) was observed. Accordingly, the complex 
[(CpxPhPh)Rh(en)Cl]+ show the highest activity followed by complex [(CpxPh)Rh(en)Cl]+ 
and, in turn, all of them are more active than [(Cp*)Rh(en)Cl]+. In contrast with the results 
obtained with complexes [(η6-arene)Ru(XEn)Cl], the increase on the steric hindrance does 
not have a dramatic effect on the turnover frequency for the Rh(III) complexes.  
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An improvement of 7 to 24 x times was achieved when using Rh(III) complexes 17-19 
compared with [(hmb)Ru(en)Cl]+. (Table 6.6). 
Table 6.6. Summary of TOFs of Ru(II) and Rh(III) complexes for reduction of NAD+ using 
formate as a hydride source at 310 K and pH* 7.4. 
Complex TOF (h-1) 
[(hmb)Ru(en)Cl]+ 0.85a 
[(Cp*)Rh(en)Cl]+ (17)
 
7.50  
[(CpxPh)Rh(en)Cl]+ (18) 19.65  
[(CpxPhPh)Rh(en)Cl]+ (19) 24.19  
[(Cp*)Rh(TfEn)Cl]+ (20) 4.12 
[(bn)Ru(TfEn)Cl]+ (12) 6.62 
 a
 reference 33. 
When performing the catalytic reaction with complex 20, the turnover frequency  
(TOF = 4.12 h-1) determined was 2x times lower than that obtained for complex 
[(Cp*)Rh(en)Cl]+ (17) (TOF = 7.5 h-1). The use of the chelating ligand N-(2-aminoethyl)-4-
(trifluoromethyl)benzenesulfonamide (TfEn) instead of ethylenendiamine (en) has been 
shown to enhance the catalytic activity of Ru(II) compounds (Table 6.6). Nevertheless 
Rh(III) compounds exhibit the opposite effect.  
Comparing the catalytic activity of complex 20 with the ruthenium complexes  
[(η6-arene)Ru(TfEn)Cl], Rh(III) is similar to the Ru(II). This is not completely unexpected, as 
a decrease in the catalytic activity when using the rhodium analogues of Noyori’s catalysts 
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[(Cp*)Rh(TsDPEN)Cl] instead of the ruthenium catalyst for the transfer hydrogenation of 
some ketones has been reported.40 
Several other Ru, Rh and Ir complexes have previously been reported to catalyze the 
regioselective reduction of NAD+ to 1,4-NADH using formate as a hydride source. 21, 22, 41, 42 
The complexes used in this work show a low TOF when compared with other 
[(Cp*)Rh(N,N′)Cl] (N,N′ = ethylenendiamine, bipyridyl, phenantrolidyl or dipyridylamine) 
(ca. Up to 2000 h-1). 21, 22, 41 Nonetheless, the improvement of the catalytic activity compared 
with the ruthenium complexes described in Chapter 3 is remarkable. (Table 6.6) 
6.4.4. Mechanism of the catalytic reduction of NAD+ 
In this section, the catalytic cycle for the transfer hydrogenation reaction using the 
complex [(Cp*)Rh(en)Cl]+ (17) as a catalyst is investigated. For that purpose a series of four 
experiments were performed and the results are compared to those obtained for the same 
reaction using the complex [(p-cym)Ru(TsEn)Cl] (2). 
Reduction of NAD+ using sodium deutero-formate (DCOO-) and complex 1  
(ratio 5:25:1 NAD+:formate:complex) was studied, the turnover frequency determined was 
3.6 times smaller than that with obtained using protiated formate (HCOO-). The difference in 
the turnover frequency between the two reactions suggests that the rate-limiting step of the 
reaction is the hydride transfer. 
The factors that might influence the reaction rate were also investigated in a series of 
experiments where the concentration of the different reagents was varied. No significant 
alterations in the rate were observed (TOF= 7.50) when the NAD+ concentration was changed 
from 5 to 7.5 or 10 mol equiv. The unchanged turnover frequency implies that the reaction 
rate does not depend on the NAD+ concentration. However when the experiments were 
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performed with different concentrations of the hydride source (sodium formate) the reaction 
rate decreased, suggesting that formate is involved in the reaction rate (Figure 6.7).  
Plotting the turnover frequency against formate concentration, shows a typical 
Michaelis-Menten behaviour.33,26,43 The maximum turnover frequency calculated from the 
double reciprocal of TON vs formate concentration for complex 17 gave a TOFmax = 41.49  
h-1, about 28 x higher than that previously determined for the ethylenendiamine complex 
[(hmb)Ru(en)Cl]+ (TOFmax=1.46 h-1).33 In comparison with the complex  
[(p-cym)Ru(TsEn)Cl] (2) (TOFmax 6.9 h-1) the turnover frequency is about 6x times higher.  
A set of experiments using NAD+, sodium formate and complex 20 in a ratio 2:x:1  
(x = 10, 25, 50, 100 or 500 mol equiv.) were recorded, and the maximum turnover frequency 
(TOFmax = 37.2 h-1) and the Michaelis-Menten constant (KM = 108.4 mM) calculated. 
Table 6.7. Summary of TOFmax and KM values determined for the reduction of NAD+ using 
formate as a hydride source and Ru(II) or Rh(III) complexes. Temperature 310 K, pH* 7.4. 
Complexes TOFmax (h-1) KM (mM) 
[(hmb)Ru(en)Cl]+  1.5a  58a 
[(Cp*)Rh(en)Cl]+ (17) 41.5 41.5 
[(Cp*)Rh(TfEn)Cl]+ (20) 37.2 108.4 
[(p-cym)Ru(TsEn)Cl] (2) 6.9 42.1 
a
 reference 33. 
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The Michaelis constant for complex 20 (KM = 108.4 mM) indicates a weak affinity for 
formate compared to complexes [(Cp*)Rh(en)Cl]+ (KM = 41.5 mM), [(hmb)Ru(en)Cl]+  
(KM = 58 mM)33, and [(p-cym)Ru(TsEn)Cl] (42.1 mM). However, it has stronger affinity for 
formate than [(Cp*)Rh(bipy)H2O]2+ (KM 140 mM).43 On the other hand the maximum 
turnover frequency (TOFmax = 37.2 h-1) of the reaction indicated an increase in the catalytic 
activity compared to [(hmb)Ru(en)Cl]+ (TOFmax=1.46 h-1)33 or [(p-cym)Ru(TsEn)Cl] (6.9 h-1) 
but lower catalytic activity compared with the complex [(Cp*)Rh(en)Cl]+ (TOF= 41.5 h-1). 
The maximum turnover frequency of the Rh(III) complexes is higher than that from the 
Ru(II) analogues which might result in an improvement on the catalytic activity in cells due 
to the high concentrations of formate used (2 mM sodium formate in the media), however 
complex 20 shows a much lower affinity for formate which could indicate that the catalyst 
will be poisoned more readily. Overall, the use of Rh(III) based systems allowed us to 
increase the efficiency of the transfer hydrogenation reaction. 
Finally, the possibility of the reverse reaction, where 1,4-NADH is oxidized to NAD+ 
was studied.44 Experiments employing 1,4-NADH as the hydride source were attempted, 
however no formation of the hydride adduct or NAD+ could be detected after 10 h using  
0.4 mM complex, 0.8 mM 1,4-NADH at 310K and pH* 7.4.  
With the data obtained, the catalytic cycle proposed is the same than that for the 
ruthenium complex [(p-cym)Ru(TsEn)Cl]. 
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Figure 6.11. Proposed catalytic cycle for complexes of the type [(Cpx)Rh(en)Cl]+
 
based on 
that proposed in Chapter 3  
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The last experiment performed was to determine the optimum pH and the possibility of 
using those complexes under biological conditions. The maximum activity for complex 17 
was observed at pH* 7.3 (Figure 6.8). However the TOF obtained was very similar in a range 
of pH between 5 and 9. At higher pH* the concentration of OH- inhibits the reaction due to 
the formation of Rh(III)-OH. 
Table 6.8. Comparison the catalytic cycles of ruthenium and rhodium complexes. 
 
[(p-cym)Ru(TsEn)Cl]  
(2) 
[(Cp*)Rh(en)Cl]+ 
(17) 
Hydrolysis Fast Fast 
Rate-limiting step Hydride formation Hydride formation 
NAD+ concentration 
dependence No No 
Formate concentration 
dependence Yes Yes 
Optimum pH* 7.2 ± 0.1 7.3 ± 0.1 
Reaction with 1,4 NADH No No 
 
6.4.5. Cancer cell growth inhibition 
Rh(III) complexes 17, 18, 19 and 20 were found to be inactive against A2780 up to a 
maximum concentration tested (> 100 µM) (Table 6.4).  
Cell survival with complexes 17 - 20 upon addition of formate at concentrations of  
0.5, 1 and 2 mM was determined (Figure 6.9). The complexes show a decrease in cell 
survival upon addition of formate. Taking into consideration the high excess of formate 
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compared to the complexes, and the fact that higher concentrations of formate gave lower cell 
survival, it can be assumed that the complex reacts catalytically with formate. This behaviour 
was also observed in Chapter 4 when using Ru(II) complexes.  
As discussed previously, the catalytic activity of the complexes of the type 
[(Cpx)Rh(en)Cl] (Cpx = Cp*, CpxPh and CpxPhPh) depends strongly on the Cpx ring. The 
catalytic activity decreases in the order CpxPhPh > CpxPh > Cp*. However, this trend cannot 
be observed in cells. Complex [(CpxPh)Rh(en)Cl]+ (18) show the smaller improvement after 
addition of formate, followed by [(Cp*)Rh(en)Cl]+ and [(CpxPhPh)Rh(en)Cl]+.
 
Despite the higher catalytic activity of the Rh(II) complexes 17-20 compared with the 
Ru(II) complexes studied in Chapter 3 and 4, the improvement on the antiproliferative 
activity of the Rh(III) complexes is not as drastic as in the case of the Ru(II) analogues. The 
Rh(III) complexes are probably poisoned more easily than the Ru(II) due to the higher 
reactivity of the Rh metal centre. 
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6.5. Conclusions 
In this chapter, a series of water-soluble RhIII half-sandwich complexes of the type 
[(Cpx)Rh(N,N′)(Cl)], where N,N′ is ethylenendiamine (en) or N-(2-aminoethyl)-4-
(trifluoromethyl)benzenesulfonamide (TfEn), have been synthesized for the first time. These 
complexes are analogous of [(η6-arene)Ru(en)Cl]+, previously studied in our group, and  
[(η6-arene)Ru(TfEn)Cl], studied in Chapter 3. The change of the metal centre from Ru(II) to 
Rh(III) was carried out to test the hypothesis that a higher reaction rate might be achieved by 
using Cp*Rh(III) systems, rather than arene Ru(II) compounds.  
Here, It has been demonstrated that the Rh(III) complexes synthesized are capable of 
carrying out transfer hydrogenation reactions for the reduction of NAD+ using formate as a 
hydride donor and under physiological relevant conditions (310 K, pH* 7.4). However, 
reduction of NAD+ using complex 20 leads to a turnover frequency of 4.12 h-1, displaying no 
improvement compared to the Ru(II) arene analogues (6.62 h-1 for [(bn)Ru(TfEn)Cl]). On the 
other hand, turnover frequency values for complexes 17-19 (7.50, 19.65 and 24.19 h-1 
respectively) are up to two order of magnitude higher than those for [(hmb)Ru(en)Cl]+  
(0.85 h-1).  
The nature of the Cpx ring significantly influences the catalytic activity, 
[(CpxPhPh)Rh(en)Cl]+ (19) (TOF = 24.2 h-1) being the most active compound, while the 
activity decreases in the order [(CpxPhPh)Rh(en)Cl]+ > [(CpxPh)Rh(en)Cl]+ > 
[(Cp*)Rh(en)Cl]+.  
Mechanistic studies in those new systems were carried out in order to determine a 
plausible catalytic cycle. Fast hydrolysis of the complexes was observed by 1H NMR. pKa* 
values (ca. 9-10) indicate that the Rh(III) complexes remain in their aqua form instead of the 
hydroxo. The rate-limiting step was identified as the hydride formation. The reaction with 
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complex [(Cp*)Rh(en)(Cl)]+ (17) showed a dependence of the reaction rate on the formate 
concentration but not on NAD+ concentration. No reaction between complex 17-20 and  
1,4-NADH was detected after 10 h. Optimum pH* for the reaction with complex 17 was 
found to be (7.3 ± 0.1) which is close to physiological pH. Those results indicate a similar 
cycle to the one proposed for their Ru(II) arene analogues. 
The maximum turnover frequency of complexes 17 and 20 indicates (41.5 and 37.2 h-1, 
respectively) an important improvement on the catalytic activity at high concentrations of 
formate compared with that of the Ru(II) analogues (6.9 h-1), even for complex 
[(Cp*)Rh(TfEn)Cl] (20). This improvement on the maximum turnover frequency is expected 
to translate in a significant enhancement of the antiproliferative activity when the complexes 
are used in combination with high concentrations of formate.  
Cell survival experiments showed an increase on the antiproliferative activity of the 
Rh(III) complexes in combination with formate. However, the improvement on the activity of 
Rh(III) complexes with formate is much lower than in the case of Ru(II) complexes. Rh(III) 
metal centres, being more reactive than Ru(II) are more likely to be poisoned. Therefore, it is 
concluded that Ru(II) complexes containing XEn ligands (XEn = TsEn, TfEn, MsEn or 
NbEn) are more suitable for catalytic reactions in cells than the Rh(III) studied in this 
chapter.  
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7. Conclusions and future work 
The aim of the project was primarily concerned with the design of catalytic 
organometallic ruthenium/rhodium complexes with the ability to reduce nicotinamide 
adenine dinucleotide via transfer hydrogenation. These complexes can then be used to 
perform the catalytic reaction in cancer cells, aiming to deplete the levels of NAD+ thereby 
effecting the disruption of the homeostasis and eventual death of cancer cells. 
 
7.1. Conclusions 
 
7.1.1. Chapter 3: Ruthenium(II) arene complexes for the catalytic 
reduction of NAD+ 
For the purpose of this thesis, Noyori’s catalyst ([(η6-arene)Ru(TsDPEN)Cl], 
 Figure 7.1) was selected as a structural model for the design of effective catalysts for transfer 
hydrogenation reactions. The Noyori catalyst has been successfully used for transfer 
hydrogenation of different substrates, such as ketones, imines and C=C double bonds.1 
Furthermore, the catalyst was stable and highly active in aqueous media.2 However, the 
design of the original Noyori catalyst (Figure 7.1) was directed towards asymmetric catalysis 
in organic solvents.3 For that reason, the chelating ligand contains two chiral carbons with a 
phenyl substituent, which confers the catalyst with enantioselectivity. The high 
enantioselectivity of these catalysts due to the lipophylic phenyl groups, is, however in 
detriment of the solubility in water. Given that enantioselectivity is not a requirement in 
NAD+/NADH catalysis, avoiding chiral centres offers a plausible strategy for the design and 
synthesis of a more water soluble derivative of Noyori’s catalyst (Figure 7.1). Furthermore, 
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reduction of different substrates could be performed using sodium formate as the hydride 
source, which is non-toxic to cells up to relatively high concentrations (< 7 mM), and could 
be used in combination with the drug.2, 4 
 
Figure 7.1. Structures of Noyori’s catalyst and complex 2. 
A series of arene Ru(II) complexes of the type [(η6-arene)Ru(N,Nˈ)Cl] containing the 
modified Noyori’s chelating ligand (N,Nˈ) were synthesised. Catalytic reduction of NAD+ 
was then studied using spectroscopic methods, using the complexes and 25 mol equivalents 
of sodium formate as a hydride source. In order to perform the experiments with more 
relevant conditions to our final aim, the reduction of NAD+ was performed in water, adjusting 
the pH* to 7.4 and keeping the temperature at 310 K. Comparison of the TOF of the 
complexes with different arene but the same ligands show a defined trend where a decrease 
on the catalytic activity of the complexes follows the order bn > bip > p-cym > hmb. 
Comparison of the TOF using different chelating ligands was also performed with the trend 
TfEn > TsEn > MsEn where the ligand TfEn contains the most electron-withdrawing 
substituent group in the sulphonamide while MsEn contains the less electron-withdrawing 
group. Complex (12) [(bn)Ru(TfEn)Cl] was found to be the most active with a TOF of  
10.4 h-1.  
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The catalytic cycle of this type of complexes was studied using complex  
[(p-cym)Ru(TsEn)(Cl)] (2). The effects of the concentration of substrate and hydride source 
(sodium formate) on the reaction rate has been determined for complex 2. Isotopic effect 
studies implicates [(η6-arene)Ru(N,N’)(H)] formation as the rate-limiting step. The 
dependence of the reaction rate for complex  
[(p-cym)Ru(TsEn)] (2) on the solvent and pH* were also investigated. The complexes 
showed a strong effect in the catalytic activity due to different solvents. The optimum pH* 
was found at 7.6. 
7.1.2. Chapter 4: Performing transfer hydrogenation reactions in cancer 
cells 
The more soluble and active compounds were selected from the series of complexes 
synthesised (chapter 3) for in cellulo experiments with A2780 ovarian cancer cells. In an 
ideal situation, the catalysts would be non-cytotoxic or moderately cytotoxic, but, upon 
addition of the hydride source (formate) the complexes will be highly cytotoxic. The 
complexes tested, displayed moderate antiproliferative activity with IC50 values between  
11.4 and 21.2 µM. Still, upon addition of formate, the antiproliferative activity of the 
complexes was potentiated, achieving lower IC50 values. Cell survival experiments show that 
complexes [(p-cym)Ru(MsEn)Cl] (1) and [(p-cym)Ru(TsEn)Cl] (2) display the higher 
increase of the antiproliferative activity. An IC50 of 1 µM, comparable to the clinically used 
cisplatin (1.2 µM), was achieved with complex (2) upon addition of 2 mM formate. A control 
experiment with cells treated only with increasing concentrations of formate had no effect on 
cell survival, showing that the increase in the proliferative activity is not due to the formate 
alone but as a result of the reaction between formate and the complex. Cellular accumulation 
experiments proved that cells treated with formate and complex accumulate as much 
ruthenium as the cells treated only with the complex. , experiments using acetate instead of 
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formate were also carried out, showing that no potentiation can be achieved. Acetate is a 
carboxylate similar to formate but which does not have the capability to act as a hydride 
donor. These experiments suggest that transfer hydrogenation reactions in cells can be 
achieved. 
Determination of the NAD+ and NADH levels in cells was also carried out. A decrease 
on the concentration of NAD+ can be observed while the concentration of NADH increases. 
Interestingly, this trend changes after 12 hours of drug exposure, probably due to poisoning 
of the catalyst.  
7.1.3. Chapter 5: Interactions of half sandwich Ru(II) mono-sulfonamide 
complexes with DNA and GSH  
Chapter 5 was concerned with the study of the interactions between the Ru(II) 
complexes synthesized in Chapter 3 and DNA or GSH. DNA was studied as a possible target 
for the complexes since the analogues ethylenediamine compounds ([(bip)Ru(en)Cl]+ 
RM175) have been shown to target DNA.5, 6 However, and despite the structural similarities 
with their ethylenediamine analogues, complexes [(p-cym)Ru(TsEn)Cl] 2 and 
[(bip)Ru(TsEn)Cl] 8 display very weak affinity for CT-DNA. Binding kinetics experiments, 
melting temperature and circular and linear dichroism were used. Complexes 2 and 8 were 
shown to weakly interact with CT-DNA though groove binding, but no coordination or 
intercalation could be proven. 
 
GSH is a tripeptide that is found in cells at concentrations of up to 10 mM. Some of the 
more important functions of the GSH are as an antioxidant and as a detoxifying agent.7, 8 
GSH is known to react with some metal-based drugs such as cisplatin.9 The GS--M adducts 
are then excreted from the cells. The interaction between GSH and the Ru(II) complexes of 
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the type [(η6-arene)Ru(en)Cl]+ has also been studied. Interestingly, these en complexes were 
shown to react with GSH to form a GS- adduct, which later undergoes ligand based oxidation 
to form sulfenato-GS. Finally, the Ru(II) complex undergoes ligand substitution and binds 
DNA.6, 10 In this section of Chapter 5, It has been demonstrated that the complexes  
[(η6-arene)Ru(XEn)Cl] (X = Ms, Ts, Tf and Nb, see Chapter 3 for structures) react readily 
with GSH. However, instead of forming mono GS- adducts, the reaction generates a Ru dimer 
containing three GS- units. Ru(II) dimers containing three µ-SR bridges have been previously 
shown to display antiproliferative activity towards cancer cells.11-14 Therefore, there is a 
possibility that the in situ GS--Ru dimer is the active form of the complex, and is responsible 
for the moderate IC50 values obtained in Chapter 4. 
7.1.4. Chapter 6: Rhodium(III) half-sandwich complexes for the catalytic 
reduction of NAD+ 
 In Chapter 6, a series of Rh(III) complexes, containing either ethylenediamine or the 
modified Noyori’s chelating ligand, were synthesized and studied. The aim was to develop 
more active catalysts which, in combination with formate, could improve the antiproliferative 
activity of the complexes even more than was possible with Ru(II) complexes. The Rh(III) 
complexes were shown to reduce NAD+ catalytically in the presence of formate, achieving 
TOF up to 3.5 times higher than the Ru(II) analogues. The catalytic cycle and optimum 
conditions for these catalysts was also studied. Despite the increased catalytic activity 
achieved by using a CpxRh system, the compounds were shown to achieve lower potentiation 
when tested in cells. Possibly, this is because the Rh(III) complexes can react with GSH and 
other biomolecules more readily than the Ru(II) analogues. 
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7.2. Future work 
In this section, the following steps for the completion of this project and some new 
areas of investigation will be described.  
7.2.1. New ligands for increased solubility 
Increasing water solubility: it has been shown that complexes containing o-terphenyl as 
a η6-arene display very good catalytic activity, however the water solubility of the complexes 
is a major drawback. In order to improve the water solubility of theses complexes, new 
chelating ligands containing a functional group that may confer improved water solubility 
without a detrimental effect on the activity of the complexes could be synthesised (Figure 
7.2).15 
 
Figure 7.2.  General structure of the chelating ligand. X = sulfinc, hydroxyl, carboxilate or 
phosphonate. 
In fact the addition of some electron-withdrawing groups, such as sulfonic acid, may 
even help to improve the catalytic activity of the complexes. It has been shown in Chapter 3 
that more electron withdrawing groups correlate with more active complexes. 
7.2.2. Increasing the stability of the catalysts 
In order to improve the stability of the type of catalysts described in this thesis, a series 
of tethered complexes can be synthesised. Wills et al. have reported the synthesis and 
catalytic activity of a series of tethered Noyori’s type complexes which have displayed very 
good enantioselectivity, conversions and catalytic activity. 16-20 These types of complex 
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contain an η6-arene unit which is bound to the chelating Noyori-type ligand. The complexes 
benefit from increased stability towards ligand substitution of the chelating ligand  
(Figure 7.3). 
 
Figure 7.3. Tethered complexes. 
7.2.3. Controlling the hydrolysis and selectivity of the complexes 
The antitumor activity of many metal based drugs results from the activation through 
hydrolysis. The labile aqua adducts can bind or coordinate specific targets. However, the 
indiscriminate uptake of metallodrugs in cells leads to poor selectivity and severe toxicity. 
These drawbacks have motivated the synthesis of new metallodrugs which can be activated 
by light. 21-23 
The complexes synthesised in Chapter 3 have been shown to hydrolyse readily. In order 
to control the hydrolysis, a series of compounds containing pyridine type monodentate 
ligands could be synthesised. Using such ligands the hydrolysis of the compounds could be 
blocked. However upon light irradiation of the complexes, induce the monodentate ligand 
substitution.21 However, to be able to photoactivate the complexes, it might be necessary to 
work with conjugated chelating ligands. 21, 22, 24, 25 
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Figure 7.4. Series of compounds containing py or BODIPY as a monodentate ligand. 
Some Ru(II) half sandwich complexes containing pyridine as a monodentate ligand, 
have been previously shown to be activated by light irradiation. 21 However, In order to 
achieve deeper tissue penetration long wavelengths (λ 650-900 nm) of irradiation are more 
suitable than those necessary for the activation of pyridine containing complexes. For this 
reason a long wavelength absorbing chromophore (BODIPY) could be used as an optimum 
monodentate ligand.22 
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7.2.4. Cell studies 
Study the selectivity of the complexes towards cancerous cells. For that purpose, A set 
of experiments with MRC5 human fetal lung fibroblast cells could be performed using 
complex [(p-cym)Ru(TsEn)Cl] (2) in combination with formate. The antiproliferative activity 
of this type of complexes towards A2780c cisplatin resistant ovarian cancer cells could also 
be tested. 
7.2.5. Reactions with GSH 
In order to investigate whether the complexes discussed in this thesis react with GSH, 
to form an active Ru(II) dimer, a series of experiments in co-administration with L-BSO 
(Figure 7.5) could be carried out. L-Buthionine sulfoximine (L-BSO), is a small organic 
molecule that is able to inhibit the enzyme γ-glutamylcysteine synthetase. This enzyme is 
involved with the synthesis of GSH. As a consequence of treatment with L-BSO, a significant 
decrease on the intracellular levels of GSH can be observed. L-BSO can be administered in 
high doses, increasing ROS levels and inducing apoptosis.26 However, low doses of L-BSO 
have been used to reduce levels of GSH in cells and increase sensitivity of some metal based 
drugs that are detoxified by GSH. Interestingly, a reduction of GSH of up to 40 % has been 
shown to be safe with no apoptosis induced. 26-28 
 
Figure 7.5. L-Buthionine sulfoximine. 
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7.2.6. Reactions between Rh(III) complexes and GSH 
The possibility of Rh(III) catalysts being poison more readily than the Ru(II) analogues 
has been discussed previously in Chapter 6. However, no experimental evidence was 
provided. In order to confirm the hypothesis, reaction between GSH and the Rh(III) 
complexes could be carried out. 
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